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ABSTRACT 
Candida albicans infections are common and can be severe in the 
immunocompromised. However, there are a limited number of chemotherapeutic agents 
that can be used to treat these infections, resistance to these agents is rising and these 
agents may have side effects. Phytotherapy with garlic extracts has been reported to be 
a possible alternative form of treatment, however the reasons why some women do not 
respond to this therapy is unknown. It is possible that efficacy of garlic treatment is 
strain dependent. In vitro results of susceptibility to garlic may also be dependent on the 
testing milieu as it is known that serum influences whether C. albicans transitions to the 
more invasive hyphal form. 
 
C. albicans has several virulence genes that play an essential role in its pathogenicity. It 
has previously been reported that fresh garlic extract (FGE) down-regulates the SIR2 
gene in C. albicans ATCC 14053. Our study aimed to see if this observation was 
reproducible in the ATCC strain and to pilot investigations in two clinical strains from 
two patients with reported variable efficacy of using garlic for treatment of VVC.  
 
Since the report of garlic down-regulation in SIR2, an additional virulence gene ECE1 
(extent of cell elongation) has been shown to be important in one of the crucial steps to 
the commencement of infection (attachment) and results in the production of a 
cytotoxin called Candidalysin. Candidalysin has been demonstrated to be responsible 
for the immunopathogenesis of C. albicans vaginitis. These results suggest that ECE1 
is an essential virulence gene of C. albicans expressed during the invasion of host cells. 
 
 XX 
 
Garlic extract was used to test its effect on two genes (SIR2 and ECE1) using Real-time 
PCR. in the absence and presence of foetal bovine serum (FBS), which is known to 
enhance the switching of blastospores to the more invasive hyphal form. In addition, 
the isolates were investigated to see if differences in response to garlic therapy could be 
attributed to biofilm formation or fluconazole susceptibility. The isolates were not 
resistant to fluconazole and biofilm measurements indicated that the clinical isolates 
were similar to ATCC strain 14053 regarding biofilm formation (P < 0.05). Treatment 
of cells with FGE and pure allicin (the active ingredient of garlic) resulted in a decrease 
in SIR2 expression in all strains. In contrast, ECE1 expression was up-regulated in the 
ATCC strain 14053 and clinical isolate 1358 (isolate from patient unresponsive to 
garlic therapy) in the presence of FGE or pure allicin, while in clinical isolate 0861 
(isolate from the patient responsive to garlic therapy) there was down-regulation of 
ECE1. This variation in ECE1 expression among these isolates may indicate that 
treatment with garlic is strain dependent and may explain differing response of patients 
to garlic therapy. Further examination of the genetic background of these two isolates 
as well as examination of additional clinical isolates should be performed in further 
studies to support this association. 
 
To further investigate the pathogenic potential of ECE1, the gene was cloned, 
expressed and purified. For ECE1 cloning, RNA of C. albicans ATCC 14053 was 
extracted, cDNA synthesised and ECE1 amplified. ECE1 was transformed and 
expressed in an E. coli expression system to produce a recombinant ECE1 (rECE1) 
protein. Also, native proteins from C. albicans ATCC 14053 were extracted and 
analysed using SDS-PAGE and also confirmed by immunoblotting assay using rabbit 
anti-ECE1 polyclonal antibodies. An immunoblotting assay of rECE1 indicated the 
 XXI 
 
presence of a 32.51 kDa molecular weight protein that was in agreement with the size 
of native ECE1 protein that had been extracted from C. albicans ATCC strain 14053. 
Sequencing of ECE1 from C. albicans ATCC strain 14053 revealed high sequence 
homology with published ECE1 of other C. albicans isolates.  This study is the first 
study to show in full, a methodology for cloning of ECE1 protein with expression at 
high levels in an E. coli expression system.  
 
Inflammation is the primary symptom of local mucosal infection caused by C. albicans. 
Candidiasis also includes invasive candidiasis. As inflammation is the primary 
symptom suffered by patients with candidiasis, the inflammatory effects of rECE1 were 
investigated in cell culture assay by measuring interleukin production.  This work was 
to support the hypothesis that complementary medicines such as garlic have a 
biological effect in reducing the pro-inflammatory effects of C. albicans infections. The 
pro-inflammatory effect of rECE1 was investigated and demonstrated in a tissue culture 
assay using the macrophage cell line J774 and by ELISA measurement of three 
cytokines (TNF-alpha, IL-6 and IL-1 beta). Next, the role of ECE1 protein in 
participation in the morphological switch of yeast to hyphal form was investigated 
parallel with the investigation of the effect of FGE on the expression of ECE1 protein 
during the transformation process, in a cell culture system. A polyclonal ECE1-
antibody was developed through predictive sequence analysis and used to investigate in 
situ production of native ECE1 by confocal microscopy.  
 
Interestingly, we were unable to see any ECE1 associated fluorescence with 20 µg/ml 
of FGE, yet we were able to demonstrate a small amount of ECE1 production, even in 
the presence of 20 µg/ml of FGE, indicating that fluorescence was not as sensitive as 
 XXII 
 
immunoblotting for detection of proteins. The overall findings of the last part of this 
work support recent publications that ECE1 protein induces a pro-inflammatory 
response and that treatment with FGE inhibited the expression of the ECE1 protein. 
In summary, FGE showed a significant role in the inhibition of expression of one of the 
virulence genes (ECE1) that is responsible for the pathogenicity of C. albicans. The 
response to the FGE treatment was strain dependent however this work should be 
confirmed in further clinical trials of the efficacy of garlic.  Secondly, this thesis 
presents the full methodology for the cloning, expression and purification of the ECE1 
protein from C. albicans ATCC 14053 in an E. coli expression system. Thirdly, this 
study reported for the first time the ability of the rECE1 as a whole protein to produce 
pro-inflammatory effects in cell culture assay when tested in vitro. This thesis provides 
a model of prokaryotic expression of eukaryotic proteins that may help other 
researchers investigate essential virulence genes. The high level of protein expression 
was able to demonstrate subtle antimicrobial effects by immunoblotting that could not 
be seen through immunofluorescence. Finally, the investigation into published ECE1 
shows that there is a significant variation in the sequence of this gene in isolates 
examined. This finding supports the hypothesis that the efficacy of complementary 
medicine may be strain dependent and thus a personalised medicine approach may be 
needed to determine when garlic can be effectively used in the management of VVC. 
This finding should be investigated further in larger clinical trials. This finding also has 
broader implications as antibodies to ECE1 have previously been demonstrated in the 
serum of patients with invasive candidiasis, and thus complementary medicine such as 
garlic may have usefulness beyond the treatment of mucosal candidiasis.
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1.1 Introduction 
The microbiota of the human body consists of a wide range of organisms. Most 
abundant amongst these are bacteria, and their growth is kept in control by nutrient 
limitation. In turn, the presence of bacteria keeps the control of fungi such as yeast, in 
check. Many fungi are harmless members of the microbiota; however, imbalance and 
deficiencies in the microbiota and host immunity can allow fungi to cause human 
disease.  
 
Candida, Aspergillus and Cryptococcus are the most common genera of fungi causing 
invasive human fungal infections. Diseases caused by these fungi are reported to be on 
the increase in the past two decades (Khan, et al. 2010) and this increase is mostly 
associated with medical interventions that have prolonged patient survival. Growing 
populations of immunocompromised individuals are at risk of infection from 
opportunistic pathogens like Candida albicans which are present in the human body 
(Pappas 2010). Immunocompromised individuals, especially those infected with HIV 
exhibit significant morbidity associated with mucosal candidiasis (Klein, et al. 1984). 
 
Yeast infection of the human body may arise after antimicrobial treatment of bacterial 
infections (Sobel 1992; Spinillo, et al. 1995; Sobel 1999). Other features that also 
influence the occurrence of yeast infections include predisposing factors such as 
diabetes or other causes of compromised immune systems. Additionally, fungi are a 
common cause of vaginitis in women of reproductive age. 
 
The genus Candida belongs to the kingdom of fungi, and like all fungi, the contents of 
the cell are surrounded by a specialised cell wall and cell membrane. Yeast can be 
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distinguished from other fungi as they possess a relatively rigid layer of cell wall 
consisting of 1,3 β glucan, 1, 6 β glucan, chitin and mannan (Chaffin, et al. 1998). Also, 
ergosterol is the primary sterol component of the cell membrane instead of cholesterol 
found in other eukaryotic cells (Murray, et al. 2005). The species of yeast causing most 
invasive human infections is Candida albicans (Pfaller and Diekema 2007) 
 
C. albicans exists primarily in the unicellular form known as the yeast form. The cells 
are oval and small in size (approximately 2.5 µm wide) and they reproduce asexually 
by a budding process. C. albicans grows as creamy white, smooth colonies when 
cultured on Sabouraud's dextrose agar  (SDA) media (Mandell, et al. 2005; Bhavan, et 
al. 2010). On the other hand, moulds have some similarities with yeast as both are 
eukaryotic cells but differ from yeast as they exist predominately in the form of tubular 
structures with a multicellular shape known as the hyphal form. The growth of these 
hyphae in moulds occurs by an apical extension and branching of cells, which form 
filamentous colonies on agar medium (Mandell, et al. 2005; Murray, et al. 2005). A 
type of hyphal form is also produced by some yeast and in particular C. albicans. This 
filamentation process enables this species to cause disease by invading the epithelial 
layers and phagocytes (Lorenz, et al. 2004) and entering blood vessels. The hyphal 
form in C. albicans is thus suggested to be the pathogenic form and the critical factor in 
causing the clinical condition candidiasis; however, both the budding and hyphal forms 
of C. albicans are detected at the site of infection (Odds 1988c).  
 
C. albicans is the species causing most cases of mucosal candidiasis. This dimorphic 
fungus lives as a commensal organism in the gastrointestinal tract and the lower part of 
the female genital tract. C. albicans is part of the resident microbiota of skin surfaces 
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and is found in up to 25% of individuals averaging at 15% in the vagina and reaching 
70% (mean 50%) in the oral mucosa (Sobel 1988; Hauman, et al. 1993).  
 
Candidiasis can cause significant morbidity due to skin irritation and mortality in the 
immunocompromised following bloodstream invasion. Infections of the 
immunocompromised pose a significant challenge to treatment as there are limited 
antifungal agents in use. Additionally, some Candida spp. like C. glabrata exhibit 
significant resistance to antifungal drugs (Bennett, et al. 2004). Anti-fungal therapy of 
mucocutaneous candidiasis may cause unwanted side effects such as increases in 
hepatic enzymes, nausea, mild burning or irritation and headache (Laudenbach and 
Epstein 2009) and more severe complications of using conventional antifungal 
treatment such as birth-defects have been reported (Mølgaard-Nielsen, et al. 2013). The 
combined occurrences of resistance and side-effects have led many sufferers to 
question whether there are alternative forms of treatment especially in the case of 
superficial candidiasis. 
 
1.2 Mucocutaneous candidiasis  
As mentioned in the introduction, C. albicans is part of the gastrointestinal tract (GIT) 
and genitourinary tract microbiota, and less frequently the skin. It is an opportunistic 
pathogen especially in hosts with depleted immune systems such as HIV patients, 
patients undergoing cancer chemotherapy and neonates due to their undeveloped 
immune system. As previously mentioned, mucocutaneous candidiasis can occur 
following treatment with antibiotics, which can eliminate the competitive microflora 
(Berman and Sudbery 2002).  
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In healthy individuals, the overgrowth of commensal C. albicans results in a localised 
infection in non-sterile areas such as the mouth, oesophagus, colon, etc. rather than as a 
life-threatening illness (van Burik and Magee 2001), however the commensalism 
mechanism of C. albicans is still unclear (Kumamoto 2011; Gow and Hube 2012). This 
overgrowth leads to skin infections (superficial mycosis) as well as mucosal infection 
such as thrush and vulvovaginitis (Shareck and Belhumeur 2011). Vaginal, 
oropharyngeal, and oesophageal candidiasis have been shown to be the most common 
forms of mucosal candidiasis (Odds 1988a).  
 
To avoid being carried away from the body through food or body fluids and to establish 
its colonisation, C. albicans has developed an ability to attach to host cells (Soltesz, et 
al. 2015). In spite of the vital role played by the immune system (innate and adaptive) 
including humoral responses against C. albicans infection (Fidel 2002), C. albicans can 
survive host immune and non-immune defenses at mucosal surfaces (Soltesz, et al. 
2015). Even when a host has natural immunity, local conditions can predispose C. 
albicans to cause skin and mucosal inflammation. 
 
Superficial skin and mucous membranes of the mouth, pharynx, oesophagus and 
gastrointestinal tract and the vulvovaginal mucous membranes are all potential sites for 
candidiasis (Laudenbach and Epstein 2009). Because of the heat and humidity in the 
skin folds under the breasts, gluteus and the bending creases between the fingers, toes, 
armpits and groin, these surface sites are considered favourable environments for the 
hyphal form of C. albicans to grow, invade and cause infection (Lopez-Martinez 2010). 
The clinical presentation of infected skin appears as an erythematous rash in infants, the 
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elderly and adult patients who are obese. This rash causes a skin eruption resulting in 
secretions, itching and burning (Ruhnke 2002). 
 
The terms used to describe infection of the mucous membrane of the digestive tract and 
the vagina are linked to the location of the infection. Infection of the gastrointestinal 
tract is often referred to as thrush (especially the oropharynx). Oropharyngeal infection 
in HIV patients is easily diagnosed due to visible colony-forming units adherent to the 
mucosa (pseudomembranes). A red colour (erythema) of the mucosa results from the 
stimulation of inflammatory mediators and direct invasion by yeast as they use mucosal 
nutrients. Similarly, yeast can grow at the corner of the mouth resulting in inflammation 
called angular cheilitis (van Burik and Magee 2001).  
 
1.2.1 Significance of candidiasis of the GI tract 
Candidiasis has many forms includes cutaneous candidiasis, genital candidiasis, 
oesophageal candidiasis, mucocutaneous candidiasis and oropharyngeal candidiasis 
where the last two are the most common forms of mucocutaneous candidiasis (Soltesz, 
et al. 2015). 
  
Thrush and erythematous oropharyngeal candidiasis (OPC) are mainly diagnosed in 
patients with HIV disease, as well as in patients with denture stomatitis. The essential  
sequelae that result from oesophageal candidiasis are difficulty in swallowing 
(dysphagia) and severe pain during the swallowing process (odynophagia) (Ruhnke 
2002).  
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Infections caused by C. albicans in the stomach, small and large intestines are known 
as gastrointestinal (GI) candidiasis (Fidel 2007). Although GI candidiasis is rare 
compared to OPC and vulvovaginal candidiasis (VVC), it plays an essential and critical 
role as a source of disseminated disease in individuals with depleted immune systems 
(Mathews and Witek-Janusek 2002).  
 
C. albicans may disseminate to other areas of the body by gaining access to the 
bloodstream after breakdown occurs in the mucosal lining of the digestive tract. This 
relocation can result from oncological chemotherapy, radiation, trauma and ulcers 
caused by viral infection in individuals who suffer from health problems (van Burik and 
Magee 2001).   
 
1.2.2 Genital mucocutaneous candidiasis  
Candida species are part of the microbiota of the vagina and their growth is kept in 
check by competition from bacterial members of the microbiota (in particular 
lactobacilli) and local immune responses (Ferrer 2000). A definition of VVC as chosen 
by Goncalves et al. (2016) is vaginal inflammation in the presence of Candida sp. and 
in the absence of other infectious agents (Goncalves, et al. 2016). Goncalves et al. 
(2016) provide a review of VVC that lists definitions for uncomplicated VVC (fewer 
than four episodes per year with mild to moderate severity and in the absence of risk 
factors such as pregnancy, diabetes and immunosuppression) and complicated VVC 
(including episodes caused by non-C. albicans Candida spp., or presence of the risk 
factors such as those previously mentioned or severe cases). Recurrent VVC (RVVC) is 
characterised by four of more episodes of VVC per year. 
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According to Sobel (1985), bacterial vaginosis is the most common complaint that 
women present to their GP’s regarding vaginal health and results from a dysbiosis of 
the vaginal ecosystem. Vulvovaginal candidiasis (VVC) is the second most common 
presenting complaint regarding vaginal health and negatively affects physical and 
emotional health, sexuality and relationships (Sobel 1985; Chapple, et al. 2000). This 
disease remains a concern for global health for its important role and direct impact on 
the quality of life of women infected (Achkar and Fries 2010). The estimated cost of 
diagnosis and treatment of VVC along with the loss of productivity was estimated at 
1.8 billion (US $) in the USA in 1995 and was projected to reach 3.1 billion US $ by 
2014 (Foxman, et al. 2000), although no recent cost estimates have been published. 
Although vulvovaginal candidiasis is an acute inflammatory disease of the female 
genitalia, candidiasis cases have also been recorded in male genitalia but less than in 
women (Sobel 1992).  
 
C. albicans is the most prevalent species causing VVC candidiasis and causes up to 85% 
of cases, while, in diabetic women, C. tropicalis followed by C. glabrata are more 
common (Murina, et al. 2011). VVC is considered one of the most common fungal 
diseases among women of all ages and approximately 75% of women have been 
affected at least once during their life (Sobel 2011). 
 
The most significant clinical signs of VVC are vaginal discharge, severe itching, 
dyspareunia and an erythematous vulva (Ruhnke 2002). Pregnancy, use of oral 
contraceptives, uncontrolled diabetes mellitus and prolonged use of broad-spectrum 
antibiotics are reported as predisposing factors leading to VVC (Sobel, et al. 1998). 
Numerous studies have indicated that the symptoms of VVC and the level of 
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colonisation of Candida spp. are increased in the second half of the menstrual cycle 
(Odds, et al. 1987; Nelson 1997; Eckert, et al. 1998; Eschenbach, et al. 2000; Engberts, 
et al. 2007). The symptoms of VVC were shown to be milder when there were small 
numbers of C. albicans in the vagina (Odds, et al. 1987; Odds, et al. 1988; Sobel and 
Chaim 1996; Bauters, et al. 2002). More precisely, 100 CFU/ml of C. albicans or less 
was in most cases related to the absence of symptoms (Odds, et al. 1988; Sobel and 
Chaim 1996).  
The treatment of VVC with antifungal drugs is usually more uncomplicated than 
treatment of other infections of the genitourinary tract except when strains of the 
causative yeast are resistant (Bauters, et al. 2002; Moreira and Paula 2006). Removal or 
control of the predisposing factors leading to VVC may result in a full recovery with no 
further recurrence. On the other hand, recurrent vulvovaginal candidiasis (RVVC) can 
be more problematic from a clinical point of view and is defined as reoccurrence four 
or more times per year (Sobel, et al. 2004). Also, there is an absence of an effective and 
efficient treatment for RVVC (Sobel, et al. 2004). Despite the long-term use of 
antifungals to treat RVVC, full recovery does not occur, but rather a prolonging of the 
asymptomatic period between symptomatic episodes (Sobel, et al. 2004). The 
percentage of women with VVC that have RVVC ranges between 7% to 8% (Foxman, 
et al. 2013) and is higher than that previously reported by Mardh et al. (2004) who 
estimated it at 1% to 2%. RVVC causes stress and discomfort to women, especially in 
their reproductive years. It has profound effects on their quality of life, affecting work 
and their social life. As a result of RVVC, some women use a large number of 
alternative treatments which are often not as useful as antifungal drugs and also may 
have undesirable effects (Mardh, et al. 2004). To evaluate how some of these 
Chapter 1 – Introduction and Literature Review 
 
10 
 
alternative treatments may work, an understanding of the pathogenesis of candidiasis 
will be examined in the following sections. 
 
1.3 Pathogenesis of mucocutaneous candidiasis 
Colonisation of the vagina is endogenous via the lower gastrointestinal tract. Sobel 
(2016) explains that colonisation persistence is poorly understood but is enhanced by 
the presence of an oestrogen rich environment following puberty and this persistence 
declines in the post-menopausal years. It is not known what triggers an overgrowth of 
Candida in healthy women or why tolerance to Candida is altered leading to an 
inflammatory response. Similarly, for RVVC in otherwise health women, it is thought 
that the increased rate of colonisation is due to poorly understood genetic, biological or 
behavioural factors in the host  (Sobel 2016). To understand whether strain variation 
plays a part in RVVC, the following section will look at C. albicans virulence factors. 
 
The virulence factors of C. albicans include those critical to induce disease, for instance, 
the ability of C. albicans to live and grow at 37°C and its ability to adapt and live at the 
physiological pH of the various mucosae (Calderone and Fonzi 2001).  
 
Most fungi live as saprophytic organisms growing on non-animal sources or residing as 
commensal organisms on or inside the human or animal body. On mucosal surfaces, 
yeast does not cause harmful effects but cause symptomatic infection when transformed 
from the yeast form into a hyphae form. This transformation in the structure of yeast 
cells is a complicated process, and its role in pathogenicity is thought to be more 
complicated and less understood in fungi than the pathogenic mechanisms described in 
bacteria (van Burik and Magee 2001).  
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Unlike the yeast form that remains present on surface membranes, the hyphal form 
enables the cell to penetrate and reach deep into the lower layers of tissues. A 
histological examination of the lingual tissue obtained from a patient diagnosed with 
oral candidiasis has confirmed the existence of hyphal cells only in deeper layers 
whereas both yeast cells and hyphae cells were shown within the vacuolated regions of 
lingual tissue (Kumamoto and Vinces 2005; Hileman, et al. 2006). Jacobsen et al. 
(2012) have also reported hyphal cells at the sites of infection to be more prominent 
than yeast cells. This propensity for the yeast cells of C. albicans to convert to hyphal 
forms can be demonstrated in vitro by incubating in the presence of serum (Figure 1.1). 
These observations suggest that the hyphal form was more involved in pathogenesis 
and caused the reported damage (Calcagno, et al. 2003). 
 
 
Figure 1.1 SEM of Candida albicans showing blastopores (round) and filamentous
pseudo-hyphal extensions.  Vader1941 
(https://en.wikipedia.org/wiki/File:SEM_of_C_albicans.tif) (public domain). 
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Hydrolytic enzymes (secreted aspartic proteinases (SAPs) and phospholipases) secreted 
by C. albicans have been shown to play a significant role in the pathogenesis process 
through the destruction of proteins involved in cell membrane construction 
(Kantarcioglu and Yucel 2002; Marcos-Arias, et al. 2011). Phospholipase B has been 
shown to aid in the dissemination of C. albicans from the bloodstream and 
gastrointestinal tract to different body tissues (Ghannoum 2000; Mukherjee, et al. 2001; 
Dolan, et al. 2004). These hydrolytic enzymes have been hypothesised to degrade the 
cell membrane of host cells or impair the immune system through degradation of the 
molecules of the host surface to promote the adhesion process (Kantarcioglu and Yucel 
2002; Marcos-Arias, et al. 2011).  
 
Recently a new cytolytic peptide (Candidalysin) produced by C. albicans was reported 
by Moyes et al. (2016). Verma et al. (2017) described the road to the discovery of 
Candidalysin by defining that a mutated form of C. albicans, reported to be lacking in 
the ability to transfer from the yeast to the hyphal form, showed a marked weakness in 
the proliferation of TCR αβ+cells and the expression of interleukin (IL) 17a. This 
mutant was found to be defective in the production of protein from the gene ECE1. 
Replacement of a functional copy of this gene restored the ability of the strain to 
damage epithelial cells as well as stimulate the production of inflammatory cytokines 
(Verma, et al. 2017). Verma et al. (2017) went on to report that the synergism of 
Candidalysin with IL-17 triggered the expression of IL-1α/β and other cytokines thus 
producing the inflammation seen in mucosal candidiasis. 
 
The degree of disease that occurs in humans is due to the presence of the pathogen in 
the host and microbial virulence factors in concert with host factors that may mediate 
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the ease in which virulence factors are expressed. Responses to therapy for VVC can 
vary, and to design alternative therapeutic strategies, the next section will examine host 
factors in more detail. 
 
1.3.1 Host factors in VVC 
To successfully manage VVC infection and to develop a successful strategy for control 
of the infection, it is essential to understand and know the role of the host as a 
participant of the disease process by shedding light on the immunological and 
epidemiological conditions of RVVC (Patel, et al. 2004). 
 
It has been assumed that the recurrence of infection in RVVC is due to host factors and 
a weak response to treatment, in addition to the presence of C. albicans at the site of 
infection (Sobel 1988; Fidel and Sobel 1996). What is not known is whether there are 
any specific characteristics of the strain of C. albicans involved in RVVC. 
 
Meech et al. (1985) reported no correlation between the clinical symptoms of VVC and 
the number of C. albicans in the vagina (Meech, et al. 1985). Witkin et al. (1988) said 
that some women had C. albicans counts of more than 10,000 cells/ml and no clinical 
symptoms, while other women had C. albicans counts less than 100 cells/ml and 
suffered intense symptoms. This finding indicates that some women may be more 
sensitive to C. albicans antigens or its products even when the number of cells was 
under the level of detectable culture (Witkin, et al. 1988; Witkin, et al. 1991). Another 
possible explanation for different symptoms may be strain variation as some isolates 
might be more pro-inflammatory than others (Hazen 1989). In general, the immune 
status of the host, the degree of the tissue damage, the inoculum size of the attacking 
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pathogen and its ability to reproduce within the tissues are the most critical factors 
needed to determine the severity of the disease and thus treatment planning (Khan, et al. 
2010). The following section will explore traits of Candida spp. that may show strain 
variation. 
 
1.3.2 C. albicans biofilms (adherence) 
Myckatyn et al. (2016) provide a modern definition of biofilms associated with 
infection as “composed of an aggregate or microcolony of microbial cells adherent to a 
living or nonliving surface embedded in an extracellular polymeric matrix” (Myckatyn, 
et al. 2016). In the case of C. albicans, this would be composed of dense layers 
consisting of yeast cells, hyphal cells and pseudohyphal cells immersed in a matrix of 
exopolymeric material (Ramage, et al. 2005).  
 
Biofilm formation has traditionally been seen as a response to an interaction with the 
surrounding environment (Lynch 1994) that leads to the growth of biofilms on the 
surfaces of medical devices implanted inside the body such as intravascular catheters 
(Edwards, et al. 1978). In most cases of VVC however, the biofilm should be 
considered as a biotic biofilm as there is no implanted device and instead plaques of 
growth occur on vaginal mucosal surfaces. Biotic biofilms are an important virulence 
mechanism for yeast as the surface plaque of growth contains an extracellular matrix 
that makes the yeast more resistant to antifungal treatment (Costa-Orlandi, et al. 2017). 
 
Biofilm formation is considered one of the effective strategies used by C. albicans to 
enable resistance to antifungal treatments. Biofilm formation has been reported in 
different sites in the body after a course of antifungal therapy (Lehrer and Cline 1969; 
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Chandra, et al. 2001; Douglas 2003). Developed biofilm has been demonstrated in 
patients diagnosed with denture stomatitis (Yamamoto, et al. 1994). Images obtained 
from scanning electron microscopy (SEM) showed that yeast cells are present in the 
first layers of the biofilm, while hyphal cells and matrix are found in the later stages of 
construction of the structure (Baillie and Douglas 1998; Ramage, et al. 2001; Ramage, 
et al. 2009). 
 
Thrush (mucosal candidiasis) is considered one of the most significant clinical 
complications resulting from biofilm formation by C. albicans. Failure of some medical 
devices that are implanted in the human body (such as catheters, artificial limbs, and 
struts) have been attributed to the growth of yeast biofilm (Kojic and Darouiche 2004). 
The biotic biofilm on mucosal surfaces can often be visualised as a white adherent mass 
and is called a plaque. When this plaque is gently scraped from the mucosal surface, an 
erythematous area remains which is probably indicative of the activity of invasive 
pseudohyphae and other inflammatory extracellular substances (Tsui, et al. 2016). Tsui 
et al. (2016) explain that the hyphal wall protein (Hwp1) is one of the major adherence 
proteins produced by C. albicans and is found predominantly in hyphal cells. This, 
together with the many published images showing the large number of hyphae present 
in plaques would suggest that the two major strategies used by C. albicans to cause 
infection, biofilm and hyphal formation that are highly correlated. 
 
In order to prevent yeast biofilm formation, research is currently focused on genetic 
factors of C. albicans (Rodriguez-Suarez, et al. 2007; Xu, et al. 2007; Jiang, et al. 2008) 
that may influence strain formation of biofilm (Selmecki, et al. 2006; Whiteway and 
Bachewich 2007; Tuch, et al. 2008). More recently, Zhong et al. (2017) while 
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investigating the antimicrobial properties of a plant toxin sanguinarine (SAN), showed 
its significant effect against the biofilm formation caused by C. albicans. SAN was able 
to decrease the cellular surface hydrophobicity and interrupt the process of 
transformation from the yeast form to hyphal form which is needed for biofilm 
formation. Also, SAN was shown to have a down-regulation effect on some putative C. 
albicans virulence genes (ALS3, HWP1 and ECE1) which are related to the adherence 
process (the first stage in biofilm formation) (Zhong, et al. 2017).  
 
A recent paper has disputed the role of biofilm in VVC. Swidsinski and colleagues 
(2019) aimed to verify the role of biofilm in VVC. In this study, biopsy samples from 
35 women with clinically, microscopically and culture-proven VVC were compared to 
25 biopsy samples from healthy women and from 30 women with active bacterial 
vaginosis (Swidsinski, et al. 2019). This study is the first of its kind to directly visualise 
Candida in biopsy samples from VVC. The study failed to demonstrate the elements 
that constitute the classic definition of biofilm when Candida was present. Further 
studies will be required to examine whether this also applies to other species of 
Candida causing VVC. 
 
1.3.3 C. albicans transformation (morphogenesis and phenotypic switching) 
In response to specific environmental conditions, C. albicans is capable of undergoing 
morphological changes such as growing in budding form (blastospore) or various 
filamentous structures ranging from pseudohyphae to true hyphae (Odds and Kerridge 
1985; Scherer and Magee 1990). This transformation of morphological form is termed 
morphogenesis. 
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Morphogenesis is the process where there is a transition or shift from a single-phase 
cell (yeast form) to a phase where multiple cells are in a filamentous form (true hyphae 
and pseudohyphae). This process can occur in reverse where hyphae and pseudohyphae 
convert to the yeast form. Among Candida species, only C. albicans and C. 
dubliniensis can transition between these two forms and so are called polymorphic 
(Odds, et al. 1988). 
 
The ability to transfer from the yeast form to the hyphal form is one of the most 
researched areas concerning the relationship between this transformation and the 
disease caused by the infection of C. albicans. Both forms have an essential role and 
direct involvement at the different stages of infection and the development of disease 
stages including adhesion, invasion, damage, spread, immune evasion and host 
response (Jacobsen, et al. 2012). 
 
Phenotypic switching (Figure 1.2) is believed to be the crucial primary virulence factor 
of C. albicans. To understand the complexity of this process, researchers have shed 
light on the genetic control and the effects on pathogenicity that occurs as a result of 
this switching (Brown and Gow 1999; Whiteway and Oberholzer 2004). Phenotypic 
switching can also be seen through change s in the colonial morphology of C. albicans 
(Soll 1992; Soll, et al. 1993).  
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Figure 1.2 C. albicans growth on agar demonstrating switching phenomenon.
Outer smooth colony indicative of blastospore growth, central wrinkled colony indicating 
filamentous growth. Garnhami, Candida albicans mixed colony, CC BY-SA 4.0, (public 
domain), https://commons.wikimedia.org/wiki/File: Candida_albicans_mixed_colony.jpg 
 
White–opaque transition and 3153A-type switching are two examples of 
phenotypic switching that have been described in C. albicans (Silva, et al. 2012). 
This ability to switch (the white–opaque transition) distinguishes C. albicans from 
other Candida spp. (Cutler 1991; Lo, et al. 1997). The terms opaque and white are 
used to describe the the cells and colonies of C. albicans resulting when C. 
albicans cells transform from a round shape to an oval form and then to the linear 
shape that gives the appearance of a filamentous form (Soll, et al. 1993). The 
discovery of opaque cells explains the process of mating that occurs for C. albicans 
(Miller and Johnson 2002). The first description of white–opaque transition was 
made by Slutsky et al. (1987) when they noticed that the cells of WO-1 strain was 
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able to switch reversibly from a hemispherical, white creamy colony (white phase) 
to flat, grey colonies (opaque phase) under certain conditions (Slutsky, et al. 1987). 
The difference between white colonies and opaque colonies strongly reflects the 
difference in the form of individual cells of both colonies. While the white cells are 
relatively circular in comparison with those of the yeast Saccharomyces cerevisiae, 
the cells isolated from the opaque colonies are usually rectangular and have a rough 
surface (Soll, et al. 1993).  
 
The phenotypic switching in the 3153A-type was first described in the standard 
laboratory culture of 3153A-type (Slutsky, et al. 1985), whereas this switching has 
also been noticed in other laboratory clinical strains (Pomes, et al. 1985; Soll 1992). 
It has been demonstrated that phenotypic switching spontaneously occurs when C. 
albicans is under stress and this switching is pleiotropic and reversible (Chaffin, et 
al. 1998; Lan, et al. 2002). 
 
Phenotypic switching has been reported in C. albicans isolates derived from VVC 
during treatment relapses (Soll, et al. 1989). In other species of Candida, the 
relationship between pathogenesis and phenotypic switching is unclear and less 
well understood (Lachke, et al. 2000; Lachke, et al. 2002). High frequencies of 
phenotypic switching have been observed in isolates of C. albicans strains driven 
from systemic infection and vaginitis which supports the role of phenotypic 
switching in disease progression (Kvaal, et al. 1999). 
 
In the same way, certain types of Candida spp. such as C. albicans and C. 
dubliniensis can produce growth in the form of filaments such as true hyphae or 
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pseudohyphae (Silva, et al. 2012). The difference between true hyphae and 
pseudohyphae is related to how these forms are shaped. Pseudohyphae are formed 
from the yeast or other hyphal cells by budding, where the new growth remains 
connected to the mother cell with the elongation of the cell. It produces a threadlike 
shape with a contraction between the daughter cell and the mother cell (Silva, et al. 
2012). There is no real wall separating the cells in these pseudohyphal cells. 
Compared to pseudohyphal cells, the initial growth of the true hyphae starts as a 
germ tube or projection from the yeast cell. This protrusion extends as a branching 
component with a clear separation wall called the septa dividing the hyphae into 
new fungal units (Silva, et al. 2012).  
 
C. albicans and C. dubliniensis can exist in many forms because of their capability 
to form true hyphae and/or pseudohyphae as well as their competence to produce 
germ tubes, making it easy to identify these species and treat compared to other 
Candida spp. (Calderone 2002).  
On the other hand, C. glabrata is not polymorphic and grows only in the form of 
blastoconidia (yeast). In the past, this species was included in the genus Torulopsis 
as it was thought not able to produce pseudohyphae. In 1978 the ability to form 
pseudohyphae was demonstrated and thus no longer considered a decisive factor in 
the classification of C. albicans. Torulopsis glabrata has now been renamed as a 
Candida spp. due to its association with human disease (Fidel, et al. 1999).  
 
C. parapsilosis can produce pseudohyphae that are large and twisting, and it cannot 
produce true hyphae (Larone 2002; Trofa, et al. 2008). C. tropicalis, when 
germinated in differentiate media (corn meal Tween 80 agar and at 25°C after 72 h) 
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is capable of producing oval blastospores and pseudohyphae, as well as true hyphae 
according to some reports (Calderone 2002; Larone 2002; Okawa and Goto 2006). 
 
1.4 Can switching be down-regulated? 
The transition from the yeast form to the hyphal form happens in conjunction with 
significant changes occurring within the cell, such as a change in the polarity of the 
cell and cell cycle as well as the biosynthesis of the cell wall (Zheng, et al. 2004b; 
Zheng, et al. 2007). External signals probably trigger this switch. 
 
It has been demonstrated that the level of immunoglobulin A protein in serum and 
saliva (Biswas, et al. 2007), nutritional status, environmental temperature, and 
catalysts such as serum, L-protein and N-acetyl glucosamine (Biswas, et al. 2007), 
as well as the acidic environment and the non-aerobic environment (Fan, et al. 
2013) have a clear effect on the transformation phenomenon of C. albicans and its 
transition from the yeast to the hyphal phase. This transition from spore to germ 
tube and mycelium was found to be controlled by proteins expressed from specific 
genes; these genes have been shown to be active at the switching stage (yeast to 
hyphae) and contribute in the adhesion process, which is the first stage of the 
pathogenesis. It has been shown that the more transformations from the yeast phase 
to hyphal phase, the more dangerous the infection (Fan, et al. 2013). 
 
Researchers have identified many important transcriptional factors in C. albicans 
phase-to-phase (budding yeast to hyphal growth form) transistion such as Cph2, 
tec1 (Lane, et al. 2001) and czf1 (Brown Jr, et al. 1999). Many genes have been 
identified as important for this switching; these genes are known as hyphae specific 
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genes (HSGs) and include HGC1, UME6, EED1, HWP1, ECE1, ALS3, RBT1 and 
RBT. These genes have been shown to be the first genes for regulating all the 
pathways of the transformation. It was found that efgl is responsible for regulating 
the signalling of the passage of adenylate cyclase protein and that cphl, nfgl, and 
nrgl-mediated inhibitory pathways are responsible for regulating the pathway of 
mitogen-activated protein kinase (MAPK), riml01 was shown to be responsible for 
a pH response pathway (Huichun S 2010). Table 1.1 shows a summary of 
important genes that have been found to have a direct relationship to the 
phenotypic transformation process. 
 
Table 1.1 Genes involved in virulence and cellular processes of C. albicans 
Name of the gene Abbrevi
-ation  
Function Features References 
Hyphal G cyclin 1 HGC1  Gene for shape (Zheng, et al. 2004a; Carlisle and Kadosh 
2010; Huichun S 2010; Fan, et al. 2013) 
global negative 
regulatory gene 
UME6 Hyphal 
formation 
Gene for structure 
and pathogenicity 
(Carlisle and Kadosh 2010; Wilson and 
Hube 2010; Moran 2012) 
Agglutinin-like 
sequence 
ALS1 Adhesion Gene for 
pathogenicity 
(Hoyer 2001; Kamai, et al. 2002; Wilson 
and Hube 2010; Murciano, et al. 2012) 
Agglutinin-like 
sequence 
ALS3 Adhesion Gene for 
pathogenicity 
(Hoyer, et al. 1998; Phan, et al. 2007; 
Cleary, et al. 2011; Fan, et al. 2013) 
Hyphal wall 
protein1 
HWP1 Adhesion Gene for shape 
and pathogenicity 
(Staab, et al. 1999; Alonso-Monge, et al. 
2010) 
Secreted aspartyl 
proteinases 1 
SAP1 Phenotypic 
switching 
Gene for 
pathogenicity 
(Hube, et al. 1998) 
Secreted aspartyl 
proteinases 3 
SAP3 Phenotypic 
switching 
Gene for 
pathogenicity 
(Schaller, et al. 1999) 
 WH11 Phenotypic 
switching 
 (Srikantha, et al. 1997) 
transcription factor CPH1 Hyphal 
formation 
Gene for shape 
and signal 
transduction 
(Lo, et al. 1997; Nobile, Solis, et al. 2008) 
transcription factor EFG1 Hyphal 
formation 
Gene for shape 
and signal 
transduction 
(Nobile, Solis, et al. 2008; Alonso-Monge, 
et al. 2010) 
 INT1 Hyphal 
formation  
 (Kinneberg, et al. 1999) 
Extent of cell 
elongation 
ECE1 Hyphal 
formation 
Gene for shape 
and pathogenicity 
(Nobile, Solis, et al. 2008; Alonso-Monge, 
et al. 2010; Wilson and Hube 2010) 
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1.4.1 Genes associated with adherence and switching 
The description of the regulatory networks that control gene expression is complex 
but essential to understanding why genes are expressed and the changes that can 
result in altered gene expression. Evolution in these networks can give rise to the 
emergence of new cellular phenotypes (Homann, et al. 2009) that may create new 
treatment challenges. 
 
 The genome of C. albicans is comprised of eight chromosomes consisting of 
around 14 million bp of nuclear DNA and about 40 thousand bp as mitochondrial 
DNA (Odds, et al. 2004). Approximately 6,400 open reading frames (ORFs) have 
been demonstrated within these eight chromosomes (Odds, et al. 2004). Some 
genes are regularly expressed such as the ribosomal genes, while the expression of 
some other genes such as hyphae-specific genes (HSGs) are regulated by the 
particular state of metabolism, stress, and food consumption (Mi X 2010). Also, 
transcriptional factors Bcr1, Efg1, Wor1, Tup1 and Flo8 are reported to be a 
necessity for regulating the expression of the HSGs in the adhesion and 
morphogenesis processes and to determine the virulence of C. albicans (Braun, et 
al. 2000; Tebarth, et al. 2003; Cao, et al. 2006; Noble, et al. 2017).  
 
It has been suggested that bcr1 is a positive regulator gene for the adherence 
process and important for the expression of several cell wall proteins. The hyphal 
developmental activator (Tec1) is responsible for the accumulation of bcr1 RNA, 
and a considerable number of hyphal specific genes have been confirmed to be 
under the regulation of the bcr1 gene (Nobile and Mitchell 2005). Although, it is 
believed that Bcr1 acts downstream of Tec1 to activate the acquisition of hyphal 
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adherence properties, it is not required for the morphogenesis process (Nobile, et al. 
2006). Tup1 is a transcriptional repressor gene and has been demonstrated to show 
a negative effect on hyphal formation in C. albicans (Braun, et al. 2000). Both 
transcription factors Efg1 and Wor1 have been shown to have a vital role in 
controlling the morphological plasticity of C. albicans (Noble, et al. 2017). 
 
In order to examine the relative contribution of each of the primary adherence and 
hyphae-specific genes listed in Table 1.1 for pathogenesis, it will be necessary to 
explore some of these genes and their transcriptional regulators in more detail. 
 
1.4.1.1 HGC1 and UME6  
Hyphal G cyclin 1 gene (HGC1) encodes a protein that regulates the growth of 
mycelia. Expression of this protein is related to the growth and elongation of 
hyphae. HGC1 plays a significant role in the polarity of growth (Zheng, et al. 
2004b) and the inhibition of cell division from hyphae. The morphogenesis 
processes has been reported to be significantly reduced in a HGC1 mutated strain 
(Fan, et al. 2013). 
 
Expression of HGC1 has only been demonstrated in mycelium and this specific 
gene is considered as one of the best examples of the non-cell cycle-regulated 
genes. The protein encoded by this gene has been shown to be under the regulation 
of mycelium inducing signals (Wang, et al. 2007). The mycelium grows longer 
when the conditions that meet its formation are available (Fan, et al. 2013). 
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Recently, HGC1 was identified as one of the essential genes for the Candida 
morphogenesis process that is stimulated by hyphae-inducing signals (Zheng, et al. 
2004b). Expression of the HGC1 protein was shown to be at a high-level during 
hyphae formation and no expression was demonstrated in the yeast stage. This 
finding was further supported by demonstrating that in the absence of HGC1 
protein, the growth and the extension of the hyphae were stopped. These findings 
support that HGC1 is one of the essential hyphae genes (Huichun S 2010). More 
studies investigating the relationship between HGC1 and other cell cycle genes 
may help further the understanding of the process of mycelial formation during 
polarised cellular growth (Carlisle and Kadosh 2010). 
 
Many studies have reported that the expression of HGC1 protein declined in strains 
that have a mutation in the global negative regulatory gene (UME6), indicating that 
UME6 plays a significant role in the regulation of HGC1 protein expression (Fan, 
et al. 2013). UME6 is a filament-specific regulator and plays a vital role in the 
formation and elongation of hyphae and the virulence of C. albicans (Carlisle and 
Kadosh 2010). Research has shown that C. albicans strains with a mutation in 
UME6 are no longer able to form hyphae in appropriate conditions such as 37°C, 
pH neutral to alkaline, the presence of serum, nutrient deficiency and N-
acetylglucosamine (Zeidler, et al. 2009). Interestingly the expression of UME6 was 
not detected until 15 minutes after hyphal induction compared to the expression of 
HGC1 which was detected 5 minutes after hyphal induction (Carlisle, et al. 2009). 
 
 
 
Chapter 1 – Introduction and Literature Review 
 
26 
 
1.4.1.2 ALS3 
A significant amount of cell wall proteins are expressed during the adhesion 
process (Fan, et al. 2013). Among these proteins are the agglutinin-like (Als) 
family. The large cell-surface glycoproteins of C. albicans that are implicated in 
the process of adhesion to host surfaces are encoded by the ALS gene family, also, 
these genes are detected in other Candida species isolated from clinical samples. 
 
ALS3 is one of the ALS family that are important in the formation of adhesion and 
hyphal cell wall proteins (Klotz, et al. 2007). The expression of the ALS3 protein, 
encoded by Als3 gene, is controlled by transcription factors Efg1, Tec1 and Bcr1, 
and is inhibited by Tup1 and Nrg1. Also, Cph1 (Fan, et al. 2013) plays a significant 
role in the stimulation process of ALS3. C. albicans strains that do not have ALS3 
protein are unable to form a biofilm, however these strains can form standard 
mycelium (Cleary, et al. 2011). 
 
1.4.1.3 HWP1 
Hyphal wall protein 1 gene (HWP1) is one of the hyphae-specific genes necessary 
for hyphal formation (Tsuchimori, et al. 2000). The HWP1 gene encodes a 
mannose protein, and this protein has been shown to be one of the principal 
constituents of the cell wall and possesses significant antigenicity. It is thought to 
be essential for the proper growth of mycelium (Tsuchimori, et al. 2000). HWP1 
has been shown to be a vital adhesion factor for growth regulation (Tsuchimori, et 
al. 2000). In a mouse model of kidney infection, the ability of a C. albicans HWP1 
mutant strain to induce infection in host cells was still remarkable but produced 
less harm. These cells were attacked and engulfed by host cells quickly which 
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diminished their adherence to epithelial cells (Tsuchimori, et al. 2000). On the 
other hand, HWP1 was required for proper biofilm formation where in vitro and in 
vivo studies using a HWP1 mutated C. albicans strain showed production of 
incomplete biofilm (Nobile, Schneider, et al. 2008; Fan, et al. 2013). 
 
1.4.1.4 ECE1 
ECE1 (extent of cell elongation) is one of the HSGs that encodes a cell wall protein 
(Miwa, et al. 2004). A gnotobiotic pig model of oral candidiasis found that ECE1 
protein accumulated significantly during infection (White, et al. 2007). Later a 
significant decrease in tissue damage and neutrophil recruitment was demonstrated 
in an ECE1 knockout strain infection using a zebrafish swimbladder model of the 
mucosal disease. Together, this was thought to indicate the importance of ECE1 as 
a critical virulence factor in the mucosal infection caused by C. albicans (Moyes, et 
al. 2016).  
 
Sequencing of the ECE1 protein showed that this protein consists of seven lysine 
and arginine motifs (KR). These KR motifs undergo cleavage by the Kex2p 
enzyme, (Golgi-located protease that cleaves proteins after lysine-arginine) that 
results in eight peptides (Moyes, et al. 2016). Moyes et al. (2016) reported for the 
first time that one of these eight peptides (Ece1-III62–92K) was able to elicit direct 
tissue damage; this toxic peptide was named Candidalysin. Richardson et al. (2017) 
recently demonstrated that Candidalysin toxin was responsible for the 
immunopathogenesis of C. albicans vaginitis. These results suggest that ECE1 is 
an essential virulence gene of C. albicans expressed during the invasion of host 
cells. 
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Richardson et al. (2017) also noted that there was a strong correlation between the 
severity of damage and the pathogenesis caused by some of the strains of C. 
albicans and between the degrees of expression of ECE1 Candidalysin. They also 
suggested that a synchronisation of the presence of hyphae with the presence of 
Candidalysin is believed to play an essential and vital role in causing the full 
infection of candidiasis. 
 
1.4.2 Current evidence for inhibitors of switching/adherence 
As mentioned previously, phenotypic switching of C. albicans is a phenomenon in 
which C. albicans can switch from the budding form into the more invasive hyphal 
form and this is thought to occur in response to specific environmental conditions. 
Although clinical strains isolated from patients with candidiasis have shown high 
levels of switching, it is not understood what effect anti-fungal treatment has on the 
switching process.  
 
Studies have demonstrated that the phenotypic switching process in commensal 
strains of C. albicans was significantly less than that in clinical strains isolated 
from infected patients with candidiasis (Hellstein, et al. 1993). The virulence of 
opaque cells in causing mucocutaneous candidiasis in a mouse model was more 
than that of white cells in the same infection model. Interestingly, the virulence of 
white cells in causing systemic candidiasis in a mouse model was more than that of 
opaque cells in the same infection model (Kvaal, et al. 1997; Kvaal, et al. 1999). 
This observation further supports that the virulence of C. albicans is closely linked 
to the process of phenotypic switching (Lan, et al. 2002).  
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The following sections look at anti-fungal treatment to evaluate whether there is a 
role for alternative treatment strategies and whether these strategies may influence 
phenotypic switching. 
 
1.5 Current treatment strategies 
Fungal and human cells are both eukaryotic cells and share some similar chemical 
and cellular structures that make it difficult to find drugs that directly target fungal 
cells without any toxicity to human cells. The types of side effects experienced by 
patients treated for VVC vary from mild to severe (Achkar and Fries 2010). 
 
Topical treatment of vaginal C. albicans infection using azoles and polyenes 
formulated as creams, vaginal tablets, aerosol sprays, lotions and coated tampons 
are all considered valid treatment strategies (Odds 1988b). Kinghorn, et al (1992) 
states that there is no evidence that the choice of treatment or the type of 
formulation has any significant effect on the clinical outcome of therapy (Kinghorn, 
et al. 1992). Due to the emergence of AIDS, the use of systemic azoles for the 
treatment of oral candidiasis increased dramatically in the 1980s (Tooley 1989). In 
the United States, the introduction of systemic azoles for the treatment of oral 
candidiasis was delayed in comparison to Europe due to considerations for side 
effects and toxicity (Sobel, et al. 1995). Successful therapy relies on sufficient 
contact time between the oral mucosa and the topical antifungal agents (2 minutes) 
and continued treatment for at least 2 to 3 days after the disappearance of clinical 
symptoms (Patton, et al. 2001). The period of treatment ranges from 7 to 14 days, 
and lack of absorption through the digestive system is one of the advantages of 
topical mucosal therapies when used in standard doses (Patton, et al. 2001). 
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A high dose of oral or vaginal antifungal followed by a long-term treatment 
protocol (weekly or monthly) is recommended currently to secure a complete cure 
for RVVC (Sobel, et al. 2004). But in 50% of women who were previously 
infected with VVC, the use of long-term treatment did not prevent the return of the 
infection after cessation of therapy for a few months (Sobel, et al. 2004). Also, 
there are many side effects reported by some women after and during treatment 
such as gastrointestinal disorders and headaches (Sobel, et al. 2004). 
 
The Infectious Disease Society of America has released guidelines (Pappas, et al. 
2016) for the treatment of VVC and in uncomplicated infection states that no one 
topical agent is superior. Table 1.2 combines the recommendations for treatment of 
RVVC from these guidelines with those reported by Sobel (2016). Unfortunately, 
in the case of RVVC, by its nature it indicates that current recommended therapies 
may still fail to prevent recurrences and Sobel (2016) states that cure rates after 
long-term therapy are not available. 
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Table 1.2 Treatment recommendations for VVC and RVVC (Sobel 2016; Pappas et al. 2010)
Causative agent Antifungal Administration               Uses 
Induction/Maintenance 
Mode of action 
C. albicans,  
C. tropicalis, 
C. parapsilosis  
 
  . Fluconazole  
  . Itraconazole 
  . Clotrimazole 1% 
  . Clotrimazole 2% 
  . Miconazole 2% 
  . Miconazole 4% 
  . Tioconazole 6.5% 
  . Terconazole 0.4% 
  . Terconazole 0.8% 
  . Butoconazole 2% 
Systemic (oral) 
Systemic (oral) 
Topical (vaginal cream) 
Topical (vaginal cream) 
Topical (vaginal cream) 
Topical (vaginal cream) 
Topical (vaginal ointment) 
Topical (vaginal cream) 
Topical (vaginal cream) 
Topical (vaginal suppository) 
150 mg q 72 h for 3 doses/ 150 mg q w for 6 m 
200 mg bid x3 d/ 100-200 mg/d for 6 mo 
7 nights/ Miconazole 1200 vs once w for 6 m 
3 nights/ Mic 1200 vs once w for 6 m 
7 nights/ Mic 1200 vs once w for 6 m 
3 nights/ Mic 1200 vs once w for 6 m 
1 nigh t/ Mic 1200 vs once w for 6 m 
7 nights/ Mic 1200 vs once w for 6 m 
3 nights/ Mic 1200 vs once w for 6 m 
1 dose / Mic 1200 vs once w for 6 m 
 
Inhibits ergosterol 
biosynthesis 
     
C. glabrata Boric acid 
 
Nystatin 
Topical (vaginal 
suppository/capsule) 
Topical (vaginal suppository) 
600 mg daily for 14 d/? 
 
100,000-U suppository per vagina for 14 d/ same dose 
Binds to ergosterol and 
disrupts fungal cell 
membrane 
     
C. krusei All the above 
except fluconazole 
   
     
Azole-resistant 
Candida species 
Boric acid 
 
Nystatin 
Amphotericin B  
 
Flucytosine 
 
Combination 
amphotericin 
B/flucytosine 
Topical (vaginal 
suppository/capsule) 
Topical (vaginal suppository) 
Topical (vaginal cream 
/suppository) 
Topical (vaginal cream) 
Topical (vaginal cream 
/suppository) 
600 mg daily for 14 d/? 
 
100,000-U suppository per vagina for 14 d/ same dose 
 
5-10% nightly for 14 d 
 
17% per vagina, nightly for 14 d 
Binds to ergosterol and 
disrupts fungal cell 
membrane 
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1.5.1 Antifungal targets  
Four main types of antifungal agents are currently used for the treatment of Candida 
infections (azoles, polyenes, echinocandins and fluorinated pyrimidine analogues, e.g., 
flucytosine). The mode of action of these antifungals includes targeting of the fungal 
cell wall or components of the plasma membrane (ergosterol) as well as protein or 
DNA synthesis (Odds, et al. 2003). 
 
In the last 20 years, researchers have focused on the cell wall and plasma membrane of 
the yeast cell as targets for the development of new antifungal agents, and more 
precisely on preventing the disruption by these agents which would affect the same cell 
configuration (Odds, et al. 2003). Novel antifungals that are derivatives of the group 
mentioned above have been developed and are currently used to treat candidiasis. 
Among these antifungals three (posaconazole, ravuconazole, and voriconazole) belong 
to the azoles group. A further three belong to echinocandins group (anidulafungin, 
caspofungin and micafungin), and these drugs are considered upgraded versions of 
cilofungin that was discontinued in 1980. 
 
1.5.2 Limitations to the use of antifungal drugs  
Fluconazole is a preferred antifungal for treatment of oral infection due to its high 
secretion level in saliva (Force and Nahata 1995). The growth of C. albicans, C. 
parapsilosis and C. tropicalis is inhibited by fluconazole, while, C. glabrata and C. 
krusei, appear resistant to fluconazole (Marr, et al. 2000; Redding, et al. 2003; Bennett, 
et al. 2004). Compared to C. albicans, nearly half of C. glabrata strains isolated from 
cases of RVVC showed increased resistance to treatment with fluconazole (Bauters, et 
al. 2002; Holland, et al. 2003; Richter, et al. 2005). The MIC (Minimum Inhibitory 
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Concentration) of fluconazole is higher compared to that of itraconazole, voriconazole 
and posaconazole for most types of Candida spp. (Pfaller and Diekema 2007).  
 
Local burning has been observed after treatment with topical azoles and 
ciclopiroxolamine in 1-10% of cases, despite the feature of high tolerance that 
characterises these antifungal agents (Mendling 1988; Mendling, et al. 2004). Also, 5% 
of gynaecological patients treated with oral imidazole ketoconazole have experienced 
some side effects such as a headache and nonviral hepatitis reported at a rate of 1 in 
500,000 to 1,000,000 as a result of treatment with this antifungal (Cauwenberg 1984). 
The use of these antifungals is not recommended during pregnancy (Mendling and 
Brasch 2012). 
 
The side effects and the low efficacy of these antifungal agents (Odds, et al. 2003; 
Looi, et al. 2005) in addition to the emergence of drug-resistant Candida spp. (C. 
albicans and C. glabrata) (Boschman, et al. 1998) makes the need to discover and 
develop new antifungal agents from plant or microbial sources a priority for 
pharmaceutical research.  
 
An emerging threat to the future success of treatment is the evolution of resistance. In 
2005, Richter et al. published the MICs of 420 isolates of C. albicans causing VVC. 
All isolates were found to have MICs less than the resistant breakpoint for fluconazole 
(< 8 ug/ml), with 91% having an MIC of less than 0.25 ug/ml and 100% having an MIC 
of less than or equal to 4 ug/ml. Although more recent reports of susceptibility of VVC 
isolates are scant, an interesting trend was reported by researchers in China who found 
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that the numbers of VVC C. albicans isolates found to be resistant to fluconazole had 
increased from 2006 to 2013 (Wang, et al. 2016). 
 
The most important limitation to current treatment strategies from the point of view of 
sufferers of RVVC is that we currently do not have treatments guaranteed to prevent 
recurrence of infection. Novel approaches are required, and the following section looks 
at current alternative approaches and the rationale for investigating some of these 
alternative approaches from a species molecular perspective. 
 
1.5.3 Alternative approaches to the treatment of VVC  
Since VVC may arise following disruption of the normal microflora, restoring the 
microbiological pressure on C. albicans has been shown to be an efficient way to treat 
VVC. Wilson et al. (2010) reported that lactobacilli could be used to restore microflora 
and prevent infection. However, in a previous study reported by Pirotta et al. (2004) to 
assess oral and vaginal treatment using Lactobacillus in a group of 278 non-pregnant 
women in Melbourne (Australia) suffering from VVC after antibiotic treatment, it was 
found that this method of therapy was ineffective (Pirotta, et al. 2004). Despite the 
absence of any evidence that explains the impact of Lactobacillus in the treatment of 
VVC, Pirotta et al. (2004) stated that this approach still has widespread use following 
microbial treatment. 
 
It is possible that resident microbiota may play a role in regulating switching in 
Candida spp. Wang et al. (2017) showed that the cell-free supernatant (CFS) from 
Lactobacillus crispatus had a significant antimicrobial effect (> 60% reduction of 
growth of C. albicans), and this CFS showed a substantial impact on the suppression of 
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yeast-hyphae transition of C. albicans when cultured in specific media used to induce 
growth of hyphae. Also, this CFS from L. crispatus showed a down-regulation effect on 
the expression of some particular hyphal genes such as ALS3, HWP1 and ECE1 (Wang, 
et al. 2017). 
 
1.5.4 Management of recurrent vulvovaginal candidiasis (RVVC) 
Many factors can lead to RVVC. Efforts to limit predisposing factors may help such as 
a limited refined sugar intake as was shown in a small group of women suffering from 
RVVC (Spinillo, et al. 1999). Sobel (1985) states that the diagnosis and the 
identification of Candida spp. is one of the most important factors that can lead to 
successful treatment and cure. He reports that treatment should continue regardless of 
whether the patient has received topical or systemic therapy until a negative culture is 
obtained or the patient is asymptomatic. Inadequate treatment strategies can lead to 
recurrence of the infection within three months in 50% of patients (Sobel 1985). 
Unfortunately, this heavy reliance of anti-fungal therapy to control RVVC may not be 
acceptable to patients, especially if they perceive there are side effects to this chemical 
treatment. 
 
An interesting relationship is observed among recurrent VVC sufferers, that being 
atopy and allergy (Neves, et al. 2005). Persistent allergic rhinitis and also familial 
allergies occur at high rates in patients with VVC, which support the hypothesis of the 
role of hypersensitivity as a significant risk factor in RVVC (Moraes 1998). It has been 
suggested that local vaginal hyperglycemia may be associated with prolongation of the 
period of VVC as well as the recurrence of this infection and this prolongation of the 
presence of C. albicans may be an allergy factor (Neves, et al. 2005). A few studies 
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reported encouraging results of suppression of RVVC through the subcutaneous 
injection of C. albicans antigen (Rosedale and Browne 1979; Rigg, et al. 1990; Moraes, 
et al. 2000). Women with inadequate response to treatment with azole agents have been 
recommended to try this approach for prevention of VVC and to reduce the episodes of 
RVVC (Rigg, et al. 1990). 
 
1.5.5 Garlic treatment 
Alternative treatment strategies that have been trialled include probiotics (Falagas, et al. 
2006) and alternative complementary therapies reviewed by Watson et al. (2012) and 
Van Kessel et al. (2003). The review performed by Watson et al. (2012) let to a study 
investigating the use of garlic in RVVC (Watson, et al. 2014). 
 
Garlic is a traditional herbal plant that has been used throughout history as a cure for 
many diseases (Kelly, et al. 2005; Zhang, et al. 2008). Garlic contains a precursor 
compound (Allin) which is converted immediately after the crushing of garlic cloves 
into the active form (allicin) by alliinase enzyme (Ankri and Mirelman 1999). Allicin is 
a sulphur compound (Figure 1.3) and has shown high efficacy and activity against 
many diseases including fungal infection (Yamada and Azuma 1977). An in vitro study 
using fresh garlic extract against planktonic Candida spp., demonstrated that the effect 
of fresh garlic extract was attributed to the action of allicin (Ghannoum 1988). Allicin 
has been shown to reduce serum levels of cholesterol and lipid, also helped to lower 
intraocular pressure, in addition to putative anti-cancer and antimicrobial properties 
(Miron, et al. 2000; Rabinkov, et al. 2000). 
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Figure 1.3 Generation of allicin in a garlic clove following crushing of the clove.  
 
Garlic extract has also been reported to produce other antifungal compounds such as 
allitridium (diallyl trisulfide) and ajoene which seems to have in general more antiviral 
activity than allicin (Tatarintsev, et al. 1992). Allitridium has been investigated in 
Chinese garlic and showed efficacy in the treatment of cryptococcosis when used 
intravenously (Davis, et al. 1990; Davis, et al. 2003). The therapeutic effect of this 
product has been demonstrated to cure infections caused by different species of C. 
albicans and Aspergillus as well as bacteria such as methicillin-resistant 
Staphylococcus aureus (Tsao and Yin 2001). Ajoene has been shown to be useful as an 
antifungal agent when used topically. The successful intravenous administration of 
ajoene has been reported in dogs (Apitz-Castro, et al. 1988). Also a single intravenous 
dose of ajoene (10 to 25 mg/kg) or repeated treatments at 2 to 3 h intervals indicated a 
complete inhibition of platelet aggregation in a Baboon platelet aggregation assay 
(Teranishi, et al. 2003). 
 
The potential effect of allicin as an anti-fungal has been reported in an in vitro study 
conducted by Khodavandi et al. (2010). This research showed a synergistic effect of 
allicin and azoles when used for some Candida species, including C. albicans, C. 
glabrata and C. tropicalis. While this synergy was not notable in the majority of 
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Candida spp. investigated (Khodavandi, et al. 2010), further in vivo investigations are 
needed to confirm these findings. 
 
The mechanism of action of garlic in inhibiting the growth of C. albicans is not known. 
It is thought that inhibition of hyphae formation (Lemar, et al. 2002; Low, et al. 2008; 
Yousuf, et al. 2011) and prevention of the synthesis of proteins, as well as the 
inhibition of synthesis of nucleic acids, may be due to garlic’s obstructive effect on 
lipid synthesis in yeast which enables the fungicidal effect of garlic on yeast (Adetumbi, 
et al. 1986).  
 
Taking garlic by oral or intravenous route has been shown to lead to a significant 
reduction in Candida spp. colony forming units (CFU) according to the findings of two 
animal studies using high concentrations of garlic (Prasad and Sharma 1980; PP 1990). 
 
As a result of the inability of traditional treatments to fully cure VVC or reduce the 
recurrence of infection or due to the unwanted side effects of these drugs, many women 
are resorting to complementary and alternative therapies to reduce the incidence of this 
disease (Van Kessel, et al. 2003; Falagas, et al. 2006). Garlic is one of these treatment 
options that have shown encouraging results in this field (Sandhu, et al. 1980; 
Bahadoran, et al. 2010). Garlic has been used throughout history to treat many diseases 
(Kelly, et al. 2005; Zhang, et al. 2008). A recent study on the effect of garlic on C. 
albicans vaginitis found that in some patients, the symptoms suffered were modified by 
taking oral garlic (Watson, et al. 2014). 
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1.6 Research objectives 
As detailed in the literature review, VVC and RVVC are significant and common 
infections blighting the lives of women around the world. Current anti-fungal strategies 
are failing a number of these women and inappropriate use of anti-fungals may lead to 
increasing resistance of strains. 
 
C. albicans can reside as a harmless commensal on human mucosa. It is not entirely 
understood why morphogenesis occurs in some women to render this harmless 
commensal a bothersome pest. Previous work in our laboratory (Watson, et al. 2014)  
showed that although overall, garlic could not be found to reduce C. albicans counts in 
all women; some women, did obtain symptomatic relief. The current study thus will 
examine two of these clinical strains, one carried by a woman who obtained 
symptomatic relief with garlic and the other from a woman without symptomatic relief. 
To date no other study has examined the reason for such a finding and has assumed that 
host factors are responsible for the varying clinical outcome. This study looks more 
closely at two clinical isolates from patients experiencing differing responses to garlic 
therapy strains to see if there is evidence that strain characteristics rather than host 
factors play a part in the clinical outcomes of alternative treatment strategies. 
This study has three broad aims: 
1: To confirm the previous reported findings that Allium sativum (garlic) affects the 
morphogenesis process and gene expression level of SIR2 gene and further to determine 
its impact on the newly recognised important ECE1. 
2: To investigate the role of ECE1 protein in the adhesion and morphogenesis of C. 
albicans in cell culture.  
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3: To confirm the reported findings that ECE1 protein has a pro-inflammatory role and 
to investigate whether garlic can down-regulate these reported pro-inflammatory effects.
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2.1 Introduction  
Some virulence factors thought to be responsible for the pathogenicity of C. albicans 
are expressed when a suitable environment to cause disease exists. These factors 
include that accountable for attachment of C. albicans to the site of infection (adhesion) 
and are called host recognition molecules and the morphogenesis process which is a 
reversible transformation between the unicellular form (yeast) and the pathogenic 
filamentous form (hyphae). Treatment with anti-fungal agents, however, is directed 
towards killing the yeast rather than interfering with its growth cycle. 
 
Unfortunately, the over-prescription of some antifungal agents (azole drugs) and the 
easy access to over-the-counter (OTC) antifungal drugs (Sihvo, et al. 2000) have 
contributed to increasing resistance to these drugs (Vandeputte, et al. 2012). This 
resistance has been reported and confirmed in Aspergillus, and C. albicans as 
standardised susceptibility testing and associated breakpoints have been developed 
(Arendrup, et al. 2012; Hope, et al. 2013). 
 
This emerging resistance concern raises the question of whether there are alternative 
ways to treat C. albicans infection. Research has focused on looking for other drugs 
and molecules that can control candidiasis with fewer side effects. Allicin (derived 
from garlic) is one of these substances showing a potent antifungal and anti-bacterial 
action in both in vivo and in-vitro studies. Allicin is the primary active components of 
freshly crushed garlic generated from the precursor compound (alliin) by alliinase 
enzyme (Ankri and Mirelman 1999).  
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The treatment of infection by Candida spp. may produce undesirable side-effects in 
humans. This concern has generated interest amongst healthcare professionals and their 
patients in the use of alternative medicines to treat candidiasis. A recent study on the 
effect of garlic on C. albicans vaginitis found that in some patients, the symptoms 
suffered were modified by taking oral garlic (Watson, et al. 2014).  
 
Many genes have been investigated to assess their role in promoting the switch from 
the yeast form to filamentous form in Candida spp. The SIR2 gene is one of these 
morphologic control genes. This gene was shown to be down-regulated by garlic in the 
reference strain C. albicans ATCC 14053 (Low, et al. 2008). However, other clinical 
isolates were not investigated in this study.  
 
ECE1 produces a protein that is thought by some reports to correlate with cell 
elongation (Birse, et al. 1993; Fan, et al. 2013). The ability of garlic to affect the 
transcription of this gene has not been reported. The ECE1 expression has been 
reported to occur 30 minutes after the yeast form is induced to form hyphae but was not 
detected when C. albicans was grown as a budding yeast cell (Birse, et al. 1993). Also, 
this gene has been reported to be highly expressed during the invasion of host tissue 
and during epithelial infection (Thewes, et al. 2007; Rohm, et al. 2013). Although 
ECE1 is highly expressed by cells that are growing in the hyphal form (filamentous 
cells lacking constrictions at their septa), its function remained unclear and was poorly 
understood (Birse, et al. 1993; Nantel, et al. 2002; Nobile, et al. 2006) until recent 
reports emerged in the last two years (Moyes, et al. 2016; Richardson, et al. 2017). 
Although it is now thought to lead to the production of a toxic peptide, its role in the 
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cell cycle remains uncertain; an intriguing possibility is that early ECE1 protein 
production may promote surface exposure of adhesions.  
 
Biological substances such as saliva, human serum, urine and  foetal bovine serum 
(FBS) have been used in vitro in order to closely mimic in vivo conditions and to 
promote the transition of yeast form to hyphal form (Cannon and Chaffin 1999; Thein, 
et al. 2007; Silva, et al. 2009; Kucharíková, et al. 2015). FBS and human serum have 
been shown to have an inhibitory effect on the formation of biofilm in some bacteria 
such as Staphylococcus aureus (Reichart, et al. 1995) and Pseudomonas aeruginosa 
(Lehrer and Cline 1969). It is unknown what effects FBS has on Candida biofilm. 
Wild-type C. albicans cells have been reported to have improved survival and growth 
when grown in the presence of FBS (Yamamoto, et al. 1994; Sanglard, et al. 2003).  
 
Biofilm formation is considered one of the effective strategies used by C. albicans to 
enable resistance to antifungal treatments. Biofilm formation may be a significant 
source of spread of infection to other areas of the body. It has significant clinical 
implications due to the increased resistance of antifungal drugs to these biofilms, their 
ability to resist host immune defenses and their ability to cause organ transplant failure 
(Kojic and Darouiche 2004; Ramage, et al. 2005) and through mediating the yeasts 
ability to colonise many biomaterials. 
 
This part of the study aims to answer thes following research questions 
1- Are there C. albicans strain differences that could explain the differing symptoms 
suffered by patients and are there strain variations in the genes reported to be putative 
virulence factors? 
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2- Does garlic affect the expression of putative virulence genes? 
3- Does allicin down-regulate the ECE1 gene? 
 
2.2 Materials and Methods 
2.2.1 Strains, media and inoculum preparation 
C. albicans ATCC 14053 (Thermo Fisher, Scoresby, Vic, Australia) and two C. 
albicans clinical isolates 0861 and 1358 (Watson, et al. 2014) were tested. These 
strains were chosen as 0861 was isolated from a patient that reported relief from taking 
garlic as a complementary medicine while 1358 was isolated from a patient that did not 
report any change in the typical candidiasis symptoms that were being experienced 
during her treatment for an acute episode of RVVC. The isolates were first subcultured 
on sabouraud dextrose agar (SDA, BBL, Becton Dickinson and Company, Cockeysville, 
MD, USA) and incubated for 24 h at 37°C and passaged at least twice to ensure purity 
and viability. Stock inoculum suspensions of the Candida spp. were prepared by 
picking five colonies from 24 h cultures grown on SDA at 37°C and suspended in 5 ml 
of sterile saline (0.85%) v/v NaCl. Cell density was adjusted with a spectrophotometer 
(Eppendorf, UK), at 530 nm wavelength to achieve a turbidity equivalent of a 0.5 
McFarland standard. Each sample was maintained in 20% (v/v) sterile glycerol stocks 
and subcultured on yeast-nitrogen base (YNB) with amino acids (Difco Laboratories, 
Detroit, Michigan, USA) at 35–37°C for 24–48 h to ensure viability and purity before 
testing. 
 
2.2.2 Antifungal agents  
Garlic extract was prepared freshly before each test according to Lemar et al. (2002). 
Total weight of 10 g of fresh garlic was ground in 10 ml of distilled water to prepare a 
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stock solution. In keeping with the work of previous investigators, this stock solution 
was called fresh garlic extract (FGE) and given a concentration value that related to the 
initial concentration of garlic in water. Hence, this stock solution was said to have a 
concentration of 1 gm/ml. This stock solution was diluted to give a working solution of 
20 µg/ml, 60 µg/ml and 100 µg/ml. The solution could stand for 30 min at room 
temperature to enable the alliin amino acid in fresh garlic to convert to allicin by the 
alliinase enzyme and then centrifuged at 4500 x g for 10 min. The supernatant fluid was 
then passed through a sterile 0.22 µm filter (Millipore, UK). Commercial allicin (purity > 
98%, Catalog No. A4440, Sapphire Bioscience, Redfern, NSW, Australia) was 
dissolved according to the supplier recommendation at 1 mg/ml in 
methanol/water/formic acid (60:40:0.1) then stored at -80ºC until use. A 5 mg/ml stock 
solution of fluconazole was prepared (Sigma Aldrich, Castile Hill, NSW, Australia) by 
dissolving in dimethyl sulfoxide (DMSO) and stored frozen at -80ºC until use.  
 
2.2.3 Broth microdilution method for determination of MIC 
Microdilution broth susceptibility testing was performed in triplicate according to the 
CLSI M27,4th ed. standard for determination of MIC (CLSI 2017). The in-vitro efficacy 
of FGE and fluconazole was measured against C. albicans ATCC 14053 and two 
clinical isolates (0861 and 1358). The lowest concentrations of the antifungals that 
could inhibit 50% and 90% of C. albicans growth (MIC50 and MIC90, respectively) 
compared with an untreated growth control were determined as described by 
Khodavandi, et al. (2010). In brief, serial dilutions of 100 µl of antifungal agents 
(prepared in RPMI 1640 medium with 0.2% glucose buffered to pH 7.0 with 0.165 M 
morpholino phosphinyl sulfate) were tested by adding 100 µl of inoculum containing 
between 5 x102 and 2.5 x103 yeast cells/ml in a 96-well microplate (Brand 781660, 
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Wertheim, Germany). The assays were incubated for 24 h at 35°C and the absorbance 
measured at 530 nm from two independent experiments using three replicates 
(FLUOstar Omega microplate reader, BMG LABTECH. Mornington, Victoria, 
Australia).  
 
2.2.4 Investigation of the effect of FGE on biofilm formation of C. albicans in 
presence and absence of 3% FBS 
A biofilm assay was run to determine the effect of FGE on biofilm formation of the two 
C. albicans clinical isolates 0861 and 1358 and ATCC14053 in the presence and 
absence of foetal bovine serum (3% FBS), as low concentrations of FBS still able to 
induce the enhancement of biofilm development without a negative impact on firm 
biofilm attachment (Kipanga and Luyten 2017). 
 
2.2.4.1 Formation of biofilm  
C. albicans ATCC 14053 strain and the two clinical isolates (0861 and 1358) were 
induced to form biofilm according to the protocol of Braga et al. (2008) with slight 
modifications. In brief, the yeast strains were grown on SDA agar at 37°C for 24 h, and 
then ten colonies of each strain were inoculated into 5 ml of YNB broth and incubated 
at 37°C for 24 h. A suspension of each strain containing 1x106 cells/ml of C. albicans 
[in standard RPMI 1640 medium (with 0.2% glucose and buffered to pH 7.0) with 
MOPS (0.165 M)] was added to 100 µl of FGE at concentrations of 0, 20, 60 and 100 
µg/ml using a tissue culture plate of 96 wells (Greiner Bio-One GmbH, Frickenhausen, 
Germany), and incubated at 37°C for at least 90 min (with no shaking) to complete the 
adhesion of yeast cells (beginning phase of biofilm formation). Subsequently, the 
mixture was incubated at 37°C for 24 h (growth phase) with gentle shaking (Chandra, 
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et al. 2008; Pierce, et al. 2008). Parallel to this process, the same isolates (ATCC strain 
and clinical isolates) were treated with the same concentrations of FGE (0, 20, 60 and 
100 µg/ml) in the presence of 3% FBS. The assay was carried out in triplicate and 
repeated on different days under the same conditions. The effect of antifungal agents on 
biofilm produced by C. albicans was quantified using 2,3-bis (2-methoxy-4-nitro-5 
sulfophenyl)-5-[(phenylamino) carbonyl]- 2H-tetrazolium hydroxide (XTT) 
colorimetric and crystal violet (CV) assays. 
 
2.2.4.2 XTT assay 
In the biofilm quantification protocol using XTT assay, 4 mg XTT (Sapphire 
Bioscience, Australia) in 10 ml prewarmed phosphate buffered saline (PBS) (10 mM 
phosphate buffer, 2.7 mM potassium chloride, 137 mM sodium chloride, pH 7.4) was 
dissolved and supplemented by 100 µl menadione stock solution, which contained 55 
mg menadione (Sapphire Bioscience, Australia) in 100 ml acetone. One hundred µl of 
the XTT/menadione solution was added to all wells and incubated in the dark at 37°C 
for 5 h. The contents of the wells were transferred to Eppendorf tubes and centrifuged 
at 13,000 rpm for 4 min. One hundred µl of supernatant from each well was transferred 
to a new microplate wells (Peeters, et al. 2008) and the absorbance measured at 490 nm 
using a FLUOstar Omega microplate reader.  
 
2.2.4.3 Crystal violet (CV) assay to quantify biofilm assay 
One hundred µl of 99% methanol was added to each well for 15 min to fix the biofilm. 
The supernatants were then removed, and the microplates air-dried. 100 µl of CV 
solution, 1:50 from the stock solution (Sigma Aldrich) were added to wells and then 
incubated at room temperature for 20 min. The plates were then washed with tap water. 
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One hundred and fifty µl of 33% acetic acid (Sigma Aldrich) was added to the wells 
(Peeters, et al. 2008) and the absorbance measured at 600 nm using a FLUOstar Omega 
microplate reader.  
 
2.2.5 Investigation of the effect of FGE and pure allicin on C. albicans gene 
expression of ECE1 and SIR2 
A suspension of C. albicans ATCC 14053 and clinical isolates 0861 and 1358 
containing 1 x 106 cells/ml in RPMI 1640 (with L-glutamine) were incubated in freshly 
prepared garlic extract at final concentrations of 20, 60 and 100 µg/ml and with pure 
allicin at final concentrations of 10 and 60 μg/ml, and then incubated at 37°C for 24 h 
with brief shaking. The three concentrations of FGE were chosen about Low et al. 
(2008) who showed that 20 and 60 µg/ml of garlic extract was able to reduce the 
growth of C. albicans but was not enough to be fungicidal and that 20 µg/ml of garlic 
extract suppressed hyphal production with very few small germ tubes visible even after 
24 h of incubation. In contrast, 100 µg/ml of garlic extract was able to produce a 
prominent zone of inhibition in a disc diffusion susceptibility assay and resulted in 
severe suppression of growth and very few viable cells.  
 
2.2.5.1 RNA extraction and cDNA formation 
Total RNA was extracted from a broth culture of C. albicans ATCC 14053 and clinical 
isolates using the RNeasy mini kit (Qiagen, Germany) with a slight modification for 
yeast. According to the manufacturer’s operating instructions for yeast cells, 2 ml of 
sorbitol lysis buffer (1 M sorbitol and 0.1 M EDTA pH 7.4) was added to 5-10 ml of 
broth culture of each treated sample. Then 50 U of lyticase (ICN Chemicals, USA), and 
10 μl of β-Mercaptoethanol were added to the mixture to lyse the yeast cell wall and 
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generate spheroplasts. The RNA solution obtained was then purified with Turbo DNA-
free kit (Ambion Life Technologies, Carlsbad, CA, USA) to remove residual DNA. The 
RNA concentration and quality were measured for purity estimation using a 
POLARstar Omega. The ratios of readings of A260/A280 and A260/A230 for all 
samples were above 2.0 in nuclease-free water. Single-stranded cDNA was synthesised 
from approximately one μg of the resulting RNA using a QuantiTect Reverse 
Transcription Kit (QIAGEN, Australia). The reverse transcription reactions were 
performed in triplicate. 
 
2.2.5.2 Designing and preparation of the primers  
All primers used in this study were designed for specific mRNA regions (on different 
exons and/or crossing over an intron) and intended for gene expression real-time PCR 
analysis using Clone Manager suite of analysis tools (Scientific and Educational 
Software; Cary, NC) (Table 2.1). β-actin was chosen as the housekeeping gene. A 
negative control without QuantiTect reverse transcriptase was included for each sample 
to ensure that the PCR products originated from cDNA. 
 
2.2.5.3 Reverse transcription PCR and relative real-time PCR 
C. albicans SIR2 and ECE1 were amplified from the synthesised cDNA. Relative 
quantification of mRNA transcription was performed in a 72-well Rotor-Gene Q series 
5 plex (QIAGEN) Real-Time centrifugal Cycler (Corbett Research, Mortlake, NSW, 
and Australia). The PCR parameters were as follows: initial denaturing at 95°C for 2 
min to activate the Platinum Taq DNA polymerase followed by 40 cycles of 5 s at 95°C, 
30 s at 60°C, with fluorescence gain for SYBR green set at 8. The Rotor-Gene software 
generated a melting curve analysis following the end of the final cycle for each sample, 
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by continuously monitoring the SYBRgreen fluorescence throughout the temperature 
ramp from 45 to 95°C in 1° increments and 5 s hold at each degree. A single melt peak 
observed for each sample was used to validate that only a single product was present. A 
PCR run was considered valid when the no template control (NTC) and QuantiTect 
reverse transcriptase was negative. 
 
Table 2.1 Primer sequences used in real-time PCR transcriptional assay 
Primer Full name Orientation Sequence (5′-3′) 
Product length 
(bp) 
Region Reference 
ECE1 Forward GTTGCTAATGCCGTCGTC 98 397-494 This study 
 Reverse TCTGGAACGCCATCTCTC   This study 
SIR2 Forward TGGACCTGCAACTGGAAC 205 532-537 This study 
 Reverse CCTGCACCAGTAACTACC   This study 
ACT Forward TCCAACTGGGACGATATG 219 183-402 This study 
 Reverse GGTGGTTCTACCAGAAGAG   This study 
 
2.2.6 Investigation of the effect of FBS on the expression of ECE1 gene on the 
biofilm of C. albicans strains 
Biofilm was induced for the three isolates of C. albicans for RNA extraction according 
to the protocol of Cury and Koo (2007) with slight modifications (Cury and Koo 2007). 
Briefly, C. albicans ATCC 14053 and the two clinical isolates (0861 and 1358) were 
grown on SDA at 37°C for 24 h. Ten colonies of each strain were inoculated into 5 ml 
of YNB broth media and incubated at 37°C for 24 h. A suspension containing 1 X 106 
cells/ml of each C. albicans isolate [in standard RPMI 1640 medium (with 0.2% 
glucose and buffered to pH 7.0) with MOPS (0.165 M)] were added to the 6 wells of a 
tissue culture plate and incubated at 37°C for at least 90 min (with no shaking) to 
complete the adhesion of yeast cells (the beginning phase of biofilm formation). 
Subsequently, the mixture was incubated at 37°C for 96 h (growth phase) with gentle 
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shaking, and the YNB broth media was replenished daily (Chandra, et al. 2008; Pierce, 
et al. 2008). The cells were washed in ice-cold sterile PBS in the tissue culture plate 
and then removed from the plate surfaces with a sterile scraper. The cells were 
centrifuged for 20 min at 4°C and 10000 rpm and the supernatant were discarded, and 
the pellets were lysed with 2 ml of sorbitol lysis buffer and continue with RNA 
extraction as in section (2.2.5.1). Alternatively, the same strains were incubated with 3% 
FBS to extract RNA from C. albicans cells treated and untreated with FBS.  
2.2.6.1 Reverse transcription PCR and relative real-time PCR 
C. albicans ECE1 along with the β-actin was amplified from the synthesised cDNA. 
Additionally, negative control without QuantiTect reverse transcriptase was included 
for each sample to ensure that the PCR products originated from cDNA, PCR 
parameters and melting curve analysis were as stated above. 
 
2.2.6.2 A Validation Experiment to Determine ΔΔ CT Calculation  
An active validation test was run as the input of cDNA was ~100 ng/µl, three replicates 
were run for each standard curve point, the target (SIR2 and ECE1) genes and the 
endogenous control reactions (β-actin) gene ran in separate wells (singleplex reactions) 
and the concentrations of primers were at the levels of 900 nM for each primer. The 
ΔΔC
T 
calculation was valid in this assay as the efficiency of the target amplification 
(SIR2 and ECE1), and the efficiency (E) of the reference amplification (β-actin) were 
approximately equal. 
 
2.2.7 Statistical analyses 
Two-way ANOVA was carried out for quantitative statistical analysis of inhibitory 
effects of FGE on biofilm formation on strains in the presence or absence of 3% FBS. 
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To calculate the fold-differences in SIR2 and ECE1 between samples, the Comparative 
CT Method (ΔΔCT Method) was used for Data Analysis. Mean CT values and standard 
deviations are used in the ΔΔCT calculations. An independent T-test was used to 
compare ECE1 expression in two biofilm-associated FBS treated groups. Results were 
considered significant at P ≤ 0.05 and each sample CT mean was calculated, and 
standard deviations were calculated for each mean CT value. The statistical analyses 
were performed using GraphPad Prism Version 6.01. 
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2.3 Results 
2.3.1 Minimum Inhibitory Concentration Determination (MIC) 
The MIC50 and MIC90 of FGE for all isolates (ATCC, 0861 and 1358) were 0.05 mg/ml 
and 0.4 mg/ml, respectively, and the MIC50 and MIC90 of fluconazole were 2 µg/ml and 
4 µg/ml for the ATCC strain, and 0.2 µg/ml and 2.0 µg/ml for clinical isolates 0861 and 
1358, respectively (Table 2.2). All the isolates were sensitive to fluconazole as 
extrapolated from the result. 
 
Table 2.2 MIC 50 and 90 of isolates as determined by broth microdilution assay 
Isolates٭  Fresh garlic extract  Fluconazole 
  MIC50 / MIC90 (mg/ml)  MIC50 / MIC90 (µg/ml) 
C. albicans ATCC 14053  0.05/0.4  2/4 
C. albicans isolate 0861   0.05/0.4  0.2/2 
C. albicans isolate 1358  0.05/0.4  0.2/2 
٭Strains with numbers only without the ATCC prefix are clinical isolates from local hospitals. 
 
2.3.2 Investigation of the effect of different concentrations of FGE on biofilm 
formation of C. albicans with and without 3% fetal bovine serum (FBS) 
The inhibitory effect of fresh garlic extract on the growth of C. albicans ATCC 14053 
and clinical isolates was demonstrated over a range of fresh garlic extract 
concentrations. Khodavandi et al. (2010) reported that the MIC of allicin and 
fluconazole were 0.1 µg/ml and 2.0 µg/ml respectively for C. albicans ATCC 14053 
and 0.1 mg/ml and 2.0 µg/ml for FGE and fluconazole respectively. In the following 
sections, the effect of FGE on biofilm formation and on the presence and absence of 
FBS in a biofilm assay has been tested. 
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2.3.2.1 Measuring the viability of biofilms cells using XTT assay 
In vitro biofilm formation by C. albicans, the kinetics of adherence and subsequent 
biofilm formation by C. albicans ATCC strain 14053 and clinical isolates 861 and 1358 
on the surface of polystyrene wells over 24 h, as determined by the colorimetric XTT-
reduction assay when treated with different concentrations of FGE and in presence and 
absense of FBS, are illustrated in Figure 2.1 and 2.2.  
 
In Figure 2.1 it can seen that there was no significant reduction in biofilm with 20 
µg/ml of FGE in the presence and absence of 3% FBS comparing to the untreated 
control in ATCC strain and clinical isolate 135, while, in the clinical isolate 861 there 
was a significant reduction in biofilm formation (P < 0.001) in the presence and 
absence of FBS. In contrast, treatment with 60 and 100 µg/ml of FGE in the presence 
and absence of 3% FBS showed significant reductions (P < 0.0001) in biofilm 
compared to untreated controls for all isolates. 
 
 
Chapter 2 – The effect of fresh garlic extract 
 
 
56 
 
 
Figure 2.1 Biofilm formation in wells of microtiter plates as determined by the 
colorimetric XTT reduction assay of C. albicans ATCC 14053 (A) and clinical isolates 
0861 and 1358 (B and C) respectively. (*) means a significant reduction of biofilm 
formation compared to untreated control at levels range between P < 0.05 to P < 
0.0001. Data showing the level of biofilm formation with standard error from three 
independent experiments run in triplicate. 
 
To more directly compare the effect of FBS, the data is also shown in Figure 2.2. 
Treatment of the ATCC strain and clinical isolates 861 and 1358 with three different 
concentrations of FGE 20, 60 and 100µg/ml FGE in the presence of 3% FBS showed 
no significant reduction or increas in biofilm formation compared to growth without 
FBS. For isolate 0861, the effect of FBS was not significant at 60 µg/ml of FGE but 
reached significance at 100 µg/ml. 
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Figure 2.2 Biofilm growth of C. albicans ATCC 14053 and clinical isolates 0861 and 
1358 at different concentrations of FGE in the presence and absence of 3% FBS. 
 
2.3.2.2 Quantification of biofilm biomass using crystal violet (CV) assay 
Using CV biofilm assay to quantify the biofilm mass showed similar results comparing 
to XTT assay. In Figure 2.3 it can seen that there was no significant reduction in biofilm 
with 20 µg/ml of FGE in the presence and absence of 3% FBS comparing to the 
untreated control except in the clinical isolate 1358 where there was a significant 
increase in biofilm formation (P = 0.0006) in the absence of FBS, the difference between 
biofilm formation under the stress of garlic at 0 and 20 ug/ml could be explained by 
experimental error, however this was not seen in the presence of FBS. In contrast, 
treatment with 60 and 100 µg/ml of FGE in the presence and absence of 3% FBS 
showed significant reductions (P < 0.001) in biofilm compared to untreated controls for 
all isolates. 
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Figure 2.3 Biofilm formation in wells of microtiter plates as determined by the 
colorimetric CV biofilm assay of C. albicans ATCC 14053 (A) and clinical isolates 
0861 and 1358 (B and C) respectively. (*) means a significant reduction of biofilm 
formation compared to untreated control at levels range between P < 0.05 to P < 
0.0001. Data showing the level of biofilm formation with standard error from three 
independent experiments run in triplicate. 
To more directly compare the effect of FBS, the data is also shown in Figure 2.4. 
Treatment of the ATCC strain with 60 µg/ml FGE in the presence of 3% FBS showed a 
significant reduction (P < 0.05) in biofilm formation compared to growth without FBS. 
For isolate 0861, the effect of FBS was not significant at 60 µg/ml of FGE but reached 
significance at 100 µg/ml. In contrast, clinical isolate 1358 increased its biofilm 
formation significantly in the presence of FBS and without exposure to garlic, however, 
this was not significant at 20 µg/ml of garlic. At 60 µg/ml, this isolate had a substantial 
increase in biofilm in the presence of FBS (P < 0.001). 
Chapter 2 – The effect of fresh garlic extract 
 
 
59 
 
 
Figure 2.4 Biofilm growth of C. albicans ATCC 14053 and clinical isolates
0861 and 1358 at different concentrations of FGE in the presence and absence of 3% 
FBS. 
 
2.3.3 Investigation of the effect of FGE and pure allicin on C. albicans gene 
expression of ECE1 and SIR2 
A quantitative relative real-time PCR assay for measuring the expression of SIR2 gene 
and ECE1 of C. albicans ATCC 14053 and clinical isolates 0861 and 1358 was 
performed on a Rotor-Gene Q Real-Time PCR Cycler in a 72-well optical plate format 
including primers for the β-actin (housekeeping gene) amplified under the same 
conditions to normalise the expression of both genes as shown in Figures A.1 (A), A.2 
(A) and A.3 (A) for β-actin, SIR2 and ECE1 respectively (Appendix A). In this 
experiment, the effect of FGE was compared to a commercially sourced preparation of 
pure allicin. 
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Specificity of RT-PCR products was documented with high-resolution gel 
electrophoresis and resulted in a single product with the desired length (β-actin, 219 bp; 
SIR2, 205 bp; and ECE1, 98 bp). Also, a rotorgene melting curve analysis was 
performed which resulted in a single product-specific melting temperature as follows: 
β-actin, 82.5C; SIR2, 80.2C; and ECE1, 83.3C. No primer-dimers were generated 
during the applied 40 real-time PCR amplification cycles as shown in Figures A.1 (B), 
A.2 (B) and A.3 (B) for β-actin, SIR2 and ECE1 respectively (Appendix A). 
 
2.3.3.1 Real-time PCR Amplification Efficiency  
Accurate estimation of PCR efficiency depends on a variety of reagent, experimental 
set-up, sample quality, and analysis factors. PCR amplification efficiency is the rate at 
which a PCR amplicon is generated commonly expressed as a percentage value. If a 
PCR amplicon doubles in quantity during the geometric phase of its PCR amplification, 
then the PCR assay has 100% efficiency. The slope of a standard curve is commonly 
used to estimate the PCR amplification efficiency of a real-time PCR reaction. A real-
time PCR standard curve is graphically represented as a semi-log regression line plot of 
CT value vs. log of input nucleic acid. A standard curve slope of –3.32 indicates a PCR 
results with 100% efficiency. Slopes more negative than –3.32 indicate reactions that 
are less than 100% efficient, and the slopes more positive than –3.32 indicate sample 
quality or pipetting problems. A 100% efficient reaction will yield a 10-fold increase in 
PCR amplicon every 3.32 cycles during the exponential phase of amplification (log2 10 
= 3.3219). In the present study, the PCR efficiency was 97%, 100% and 101% for β-
actin, SIR2 and ECE1 as shown in Figures A.1 (C), A.2 (C) and A.3 (C) (Appendix A). 
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2.3.3.2 The Comparative C
T 
Method (ΔΔ C
T 
Method)  
The comparative CT method used in this assay also referred to as the ΔΔCT method, is 
like the relative standard curve method, except it uses arithmetic formulas to achieve 
the result of relative quantitation. The ΔΔCT method for relative quantitation was used 
as the PCR efficiencies between the target (SIR2 and ECE1), and endogenous control 
(β-actin) are relatively equivalent. Rotor-Gene Q software for relative quantitation 
calculation and analysis were used for data analysis. The software performs all the 
calculations, and final fold change determinations were presented in Table A.1 and 
Table A.2 (Appendix A). 
 
2.3.3.3 Relative quantitative RT-PCR of SIR2 and ECE1 
C. albicans ATCC 14053 and clinical isolates 0861 and 1358 were subjected to 
different concentrations of FGE and pure allicin. RNA was then harvested after 24 h of 
incubation. The extracted RNA was then reverse transcribed to cDNA and subjected to 
RT-PCR using SIR2 and ECE1 specific primers. The relative quantification of SIR2 and 
ECE1 expression ratio normalised to β-actin indicated that both genes tested had 
significant differences in gene expression between the antifungal exposed cells and the 
untreated control. Figure 2.5 (A, B and C) shows a reduction in SIR2 expression in cells 
exposed to FGE compared with cells that had not been treated with FGE and pure 
allicin. The SIR2 mRNA as shown in Table A.1 (Appendix A) was down-regulated by 
both FGE and allicin. At 20 µg/ml and 60 µg/ml FGE there were significant reductions 
of SIR2 expression; however, this was not as significant at 100 µg/ml. This difference is 
because the growth of cells is severely reduced at 100 µg/ml of FGE. The results of 
allicin confirm that the effect of 10 µg/ml of allicin is like 60 µg/ml of FGE. 
Interestingly 60 ug/ml of allicin has an even more significant effect than 10 µg/ml, 
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while, not showing the effect seen by 100 µg/ml of FGE. The clinically resistant isolate 
1358 behaved similarly in SIR2 expression except for perhaps activity of the gene was 
still noticeable at 100 µg/ml. 
 
 
Figure 2.5 Relative quantitation of SIR2 expressions normalised to housekeeping 
gene (β-actin) in C. albicans ATCC 14053 (A), clinical isolate 0861 (B) and 1358 (C) 
after 24 h of treatment with different concentrations of FGE and pure allicin. (*) means 
significant reduction of gene expression to untreated control at levels range between P 
< 0.05 and P < 0.0001. Data are showing the ratio of gene expression with standard 
error from three independent experiments performed in triplicate. 
 
The behaviour of each isolate to one another is more easily seen in Figure 2.6. The 
reduction in SIR2 expression at 20 µg/ml FGE was most marked in the clinically 
responsive isolate 0861. The clinically resistant isolate 1358 was significantly less 
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affected in SIR2 expression to clinical isolate 0861 (P < 0.0001). At 60 µg/ml FGE, 
isolate 0861 was significantly different to the ATCC strain (P < 0.05) however isolate 
1358 was not significantly different. Results at 100 µg/ml should be interpreted with 
caution as growth is severely affected by this level of FGE and the levels of overall 
expression are very low.  
 
 
Figure 2.6 Relative quantitation of SIR2 expression normalised to the housekeeping 
gene (β-actin) in C. albicans ATCC 14053 and clinical isolates 0861 and 1358 after 24 
h of treatment with different concentrations of FGE and pure allicin by RT-PCR. 
Untreated samples of the three isolates were used as a reference to show the differences 
among strains. Data are showing the ratio of gene expression with standard error from 
three independent experiments performed in triplicate. 
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In contrast, the behaviour of ECE1 expression was markedly different to the SIR2 gene. 
The results are shown in Figure 2.7 (A, B and C). There is an increase in ECE1 
expression in cells exposed to FGE compared to non-exposed cells. FGE has an up-
regulation effect on the ECE1. On the other hand, the normalised ECE1 expression 
level for cells incubated with pure allicin showed a complete reduction in expression of 
ECE1.The full results of ECE1 expression are shown in Table A.2 (Appendix A). 
 
 
Figure 2.7 Relative quantitation of ECE1 expression normalised to β-actin 
in C. albicans ATCC 14053 (A) and clinical isolate 0861 (B) and 1358 (C) after 24 h of 
treatment with different concentrations of FGE and pure allicin. (*) means significant 
reduction of gene expression to untreated control at levels ranging between P < 0.05 to 
P < 0.0001. Data showing the ratio of gene expression with standard error from three 
independent experiments amplified in triplicate.  
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The behaviour of each isolate is directly compared in Figure 2.8. Down-regulation of 
ECE1 in the clinically responsive isolate 0861 was a markedly different response to the 
upregulation of the gene seen in the clinically unresponsive isolate 1358. 
 
 
Figure 2.8 Relative quantitation of ECE1 expression normalised to β-actin 
in C. albicans ATCC 14053 and clinical isolate 0861 and 1358 24 h after treatment 
with different concentrations of FGE and pure allicin measured by RT-PCR. (*) means 
a significant change in gene expression between clinical isolates and the ATCC strain at 
levels ranging between P < 0.05 to P < 0.0001. Data show the ratio of gene expression 
with standard error from three independent experiments amplified in triplicate 
 
2.3.4 Investigation of the effect of FBS on ECE1 expression of C. albicans strains 
biofilm  
A quantitative relative real-time PCR assay for measuring the expression of ECE1 of C. 
albicans ATCC 14053 and clinical isolates 0861 and 1358 when treated with 3% FBS 
was performed on a Rotor-Gene Real-Time PCR Cycler in a 72-well optical plate 
format including primers for the β-actin amplified under the same conditions to 
normalise the expression of both genes as shown in Figures A.4 (A) and Figure A.5 (A) 
for β-actin and ECE1 respectively (Appendix A).  
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2.3.4.1 Confirmation of primer specificity 
Specificity of RT-PCR was documented with a rotorgene melting curve analysis which 
resulted in single product-specific melting temperatures (Figure A.4 (B) and Figure A.5 
(B) for β-actin and ECE1, respectively (Appendix A)). Table A.3 (Appendix A) 
presents data from an experiment where the expression levels of a target gene (ECE1) 
and endogenous control (β-actin) are evaluated. The levels of these amplicons in ATCC 
14053 and clinical isolates 0861 and 1358 were compared to an untreated ATCC 14053 
strain as a calibrator sample. The validation was performed as described in 2.3.3. 
 
Also, the PCR efficiency was 92% and 98% for β-actin and ECE1 as shown in Figures 
A.4 (C) and A.5 (C) for β-actin and ECE1, respectively (Appendix A). 
 
2.3.4.2 The Comparative CT Method (ΔΔCT Method) 
A validation experiment previously demonstrated that the efficiency of the target 
amplification and the effectiveness of the reference (endogenous control gene) 
amplification are approximately equal. Therefore, the ΔΔCT method was used to 
calculate the fold differences in the expression of ECE1 between strains 
 
The ECE1 mRNA in the presence of FBS as shown in Table A.4 (Appendix A) and 
graphed in Figure 2.9 was significantly different. In the clinically responsive 0861 
strain, FBS reversed the down-regulation of ECE1 compared to the ATCC strain being 
upregulated.  There was a significant difference in gene expression between the two 
clinical isolates.  
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Figure 2.9 Relative quantitation of ECE1 expression normalised to β-actin 
gene in C. albicans ATCC 14053 and clinical isolates 0861 and 1358 after 24 h of 
treatment with 3% FBS. Untreated ATCC 14053 strain wase used as a reference strain 
to show the differences among strains. (*) means a significant change in regulation of 
ECE1 expression 
 
The effect of FBS on the strains is more easily seen in Figure 2.10. If only the ATCC 
strain had been used, then it would not have been thought necessary to include FBS in 
the cultural milieu. The presence of FBS has a significant impact on how the strains 
perform.  
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Figure 2.10 Relative quantitation of ECE1 expression normalised to β-actin 
in C. albicans ATCC 14053 and clinical isolates 0861 and 1358 after 24 h of treatment 
with 3% FBS. 
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2.4 Discussion 
Garlic (Allium sativum) has been used throughout history as an herbal medicine. 
Previous studies performed in vitro have established the role of allicin as an antifungal 
agent against Candida spp., Trichophyton and Aspergillus (Yamada and Azuma 1977). 
The antifungal activity of allicin has also been reported in a mouse model of systemic 
aspergillosis (Shadkchan, et al. 2004).  
 
The endpoint MIC was determined to see if the clinical isolates had differing profiles in 
susceptibility testing to the ATCC strain 14053. The results of MIC testing showed that 
this could not explain the differing responses to garlic therapy experienced by the two 
patients selected from the study performed by Watson et al. (2014). Only two clinical 
isolates were used in this study as the main goal of this study was not the difference in 
the response to the treatment with FGE rather than how the FGE can affect on the 
expression of some genes related to the transformation process. In addition, as only two 
clinical isolates were used in this experiment the results generated need to be viewed 
with caution and further confirmation is required in a much larger collection of isolates. 
Also, a biofilm assay was performed to see if the clinical isolates behaved differently in 
terms of their biofilm production that may have been a cause for their differing 
susceptibility to garlic therapy. In the absence and in the presence of FBS, where we 
hypothesised that serum would enable isolates to behave more like they were in the 
human body, no significant difference in biofilm could be demonstrated. These results 
indicate that biofilm production was not the cause of the different clinical responses in 
our two selected patients. 
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Ghannoum (1988) and Lemar et al. (2002) reported differing MIC of aqueous garlic 
extract and FGE at lower levels of 2.0 mg/ml and 10 mg/ml respectively. In contrast, 
the MIC of 100 mg/ml was considered fungicidal in a disc diffusion assay for ATCC 
strain 14053 as reported by Low et al. (2008). In this study, fluconazole has been 
selected as the standard anti-C. albicans drug for comparison with fresh garlic extract. 
In our study, we observed that 0.05-0.4 mg/mL of FGE was able to produce a 
fungicidal effect in the MIC assay for ATCC strain 14053 as well as for the clinical 
isolates 0861 and 1358 tested in this study. The observed MICs of FGE and fluconazole 
against C. albicans fell within the ranges of 0.05-0.4 mg/mL and 0.2-4 µg/mL, 
respectively (Table 2.2), which is similar to findings from previous reports (Ankri and 
Mirelman 1999; Khodavandi, et al. 2010). All the isolates in our study were thus 
deemed sensitive to fluconazole, and drug resistance was not seen. Khodavandi et al. 
(2010) reported that the MIC of allicin and fluconazole were 0.1 µg/ml and 2.0 µg/ml 
respectively for C. albicans ATCC 14053 which we also found for our ATCC 14053 
culture thus validating our susceptibility method. 
 
The colonisation of C. albicans on the surfaces of various body tissues is considered as 
the primary step in the start of infection. Moreover, biofilm formation is also 
considered as a mechanism used by Candida spp. to resist antifungal treatment as 
biofilm can be a barrier against these antifungals (Calderone and Fonzi 2001). In the 
present study, the clinical isolates 0861 and 1358 were compared to the control strain 
ATCC 14053 regarding their biofilm formation when treated with different 
concentration of FGE in the presence and absence of 3% of FBS.  
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We were, however, able to describe for the first time that isolates do behave differently 
to exposure to garlic regarding biofilm production. If garlic can be considered a threat 
to the yeast cell, some strains may respond differently when stressed by garlic. This 
difference was observed with our two isolates. The clinically responsive strain 
produced less biofilm when treated by both FGE and allicin. In contrast, the clinically 
unresponsive strain 1358 was significantly able to increase its defence mechanisms by 
upregulating the production of biofilm in the presence of the inhibitory signals 
produced by garlic, and this was further amplified in the presence of FBS. This is the 
first time that this has been described in the scientific literature. Previous literature has 
only described reduction in biofilm as reported in ATCC strain 14053 when treated 
with allicin (Khodavandi, et al. 2011). The concentration of the FGE required to 
produce a lowering of biofilm in the current study against C. albicans ATCC 14053 and 
clinical isolates 0861 and 1358 was lower than that reported by Khodavandi et al. 
(2011).  
 
SIR2 has been identified as one of the C. albicans genes that play a significant role in 
phenotypic switching in C. albicans (Perez-Martin, et al. 1999). The down-regulation 
of this gene in ATCC strains 14053 was reported by Khodavandi, et al., 2011 and Low, 
et al., 2008. The work of the present study confirms the significant inhibition of SIR2 
gene expression by FGE in C. albicans ATCC 14053 as well as clinical isolates 0861 
and 1358 when treated with more than 20 µg/ml FGE and more than 10 µg/ml of pure 
allicin. Thus, these results could not explain why the response to garlic therapy may 
have been different in the two patients we selected to study. On the other hand, ECE1 
which previously had been suggested to have a role in the adhesion process and 
transformation from yeast form to hyphal form, showed a significant reduction in 
Chapter 2 – The effect of fresh garlic extract 
 
 
72 
 
expression in clinical isolate 0861 when treated with FGE and allicin, but up-regulation 
in ATCC strain 14053 and the clinically unresponsive to garlic treatment strain 1358 
when treated with sub-inhibitory concentrations of FGE. This confirms our hypothesis 
that strain variation may explain different clinical responses to garlic therapy for VVC. 
This study also importantly confirms that the testing milieu may affect the expression 
levels of genes. We investigated the expression of ECE1 in induced biofilms in the 
presence and absence of FBS. A serum substrate was selected in the belief that this 
would mimic actual body conditions on mucosal surfaces. Our results confirm that 
serum should be incorporated into the testing medium to reflect changes that may not 
be measurable without its presence. 
 
In conclusion, our results demonstrated that FGE inhibits C. albicans biofilms and 
confirms the results reported by Low et al. (2008) and Khodavandi et al. (2011) for 
SIR2 expression. The present study presents for the first time that the expression of 
ECE1 showed variable differences between strains and that this differing expression 
could potentially explain the failure of garlic to control symptoms in a patient suffering 
from VVC. ECE1 expression was reduced in all strains exposed to allicin at the levels 
tested. These hopeful results indicate that allicin may have a role beyond its inhibitory 
growth effects and have the additional action of reducing the expression of important 
virulence genes when present at sub growth inhibitory concentrations and thus could be 
a potential additive to the arsenal against C. albicans infections in humans.
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3.1 Introduction 
In a recent study published by Moyes et al. (2016) that looked at the importance of 
ECE1 protein and its role in the stimulation of the immune system, it was shown that 
ECE1 protein was indeed important in the inflammatory process. To further understand 
its role in the disease process, isolation of this protein is required. 
 
The first identification of ECE1 was conducted by Birse et al. (1993) by differential 
hybridisation screening of a C. albicans cDNA library using probes derived from 
populations of yeast cells or hyphae to investigate its association with cell elongation of 
the dimorphic pathogen C. albicans.  
 
In a study published in 2005, Elguezabal et al. demonstrated that the expression of the 
recombinant hemagglutinin influenza virus (HA)-tagged Ece1p could be obtained using 
an E. coli expression system (M15 carrying the lac repressor-producing pUHA1 
plasmid) by induction of IPTG. In this experiment, a recombinant  ECE1 (rECE1) 
protein produced in an E. coli expression system was used to detect antibodies in the 
serum of patients with invasive candidiasis using immunoblotting and ELISA assays 
(Elguezabal, et al. 2005). E. coli expression systems are convenient and more 
convenient to work with than yeast expression systems, however, can be problematic as 
they also produce endotoxin that is a potent inflammatory mediator. 
 
E. coli BL21 strain and E. coli BL21 (DE3) strains are both deficient in Lon protease 
(cytoplasm) and OmpT protease (outer membrane). These isolates are preferred 
systems for yielding intact full-length recombinant proteins in microbial expression 
systems (Studier and Moffatt 1986). The BL21 and BL21 (DE3) strains are used in 
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many strategies for the production of recombinant protein (Sandini, et al. 1999; Laín, et 
al. 2007).  
 
Ordinarily, the T7 bacteriophage promoter is used for the expression of recombinant 
proteins in E. coli and induced by IPTG. High levels of expression are achieved with 
this option (Laín, et al. 2008). BL21 (DE3) contains the λDE3 lysogen that carries the 
gene for T7 RNA polymerase under control of the lacUV5. BL21(DE3) is suitable for 
expression from promoters recognised by the E. coli RNA polymerase or a T7 or T7-lac 
promoter (Studier and Moffatt 1986).  
 
The aim of this Chapter was to produce purified rECE1 in order to test the performance 
of anti-ECE1 antibodies in future experiments designed to visualise if garlic could 
downregulate expression of ECE1 in cell culture experiments. Thus, high expression 
levels would be desirable to measure subtle effects of alternative therapies. As an 
additional challenge, we needed to see if modern purification techniques could remove 
contaminating endotoxin from such an expression system. 
 
In this chapter, experiments are detailed regarding the cloning of the ECE1 and 
transformation into E. coli DH5 alpha for gene propagation. The aim was to express 
and purify ECE1 protein to answer the following research questions:  
1- Is ECE1 a secreted protein in E. coli DH5? 
2- Can ECE1 be inserted into an expression vector? 
3- Can this expression vector be expressed in E. coli specific for protein 
production (BL21 (DE3) pLysS)?  
4- Can downregulation of ECE1 be visualised in real-time using cell culture and 
garlic extract? 
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3.2 Materials and Methods 
3.2.1 Organisms, media and growth conditions 
A list of organisms and plasmids used in this chapter are presented in Table 3.1. C. 
albicans ATCC 14053 is a blood culture isolate from a patient with disseminated 
candidiasis and used as the DNA template for cloning ECE1 and subsequent expression 
of His-tagged fusion proteins in E. coli. The isolate was subcultured on SDA and 
incubated for 24 h at 37°C and passaged at least twice to ensure purity and viability. 
Then 10 colonies were inoculated into 5 ml of yeast-nitrogen base broth (YNB) and 
incubated at 37°C for 24 h for RNA extraction and cDNA synthesis. E. coli TOP10F´ 
(Invitrogen, Mulgrave, VIC, Australia) was used for blue/white screening and 
sequencing and was grown first after transformation on SOC media consisting of 2% 
tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM 
MgSO4 and 20 mM dextrose (Invitrogen, Mulgrave, VIC, Australia). Transformed 
cells were plated onto Miller’s Luria-Bertani (LB) broth base agar consisting of 0.5% 
(w/v) yeast extract, 1% (w/v) tryptone, 1% (w/v) sodium chloride and 1% agar (Cell 
Biosciences Pty Ltd, West Heidelberg, VIC, Australia). E. coli DH5α was used for the 
construction of recombinant ECE1 protein clones. E. coli BL21 (DE3) pLysS was 
specifically designed for expression of genes regulated by the T7 promoter (Table 3.2). 
E. coli BL21 (DE3) pLysS was grown at 37°C with shaking in LB broth. When 
required, ampicillin and chloramphenicol were added to a final concentration of 50 
µg/mL and 34 µg/mL respectively. RPMI 1640 (with L-glutamine) (Sigma Aldrich) 
was used for inducing hyphal growth and for protein extraction purposes from C. 
albicans. The plasmids pCR
®
2.1 and pRSET-B were used for the mRNA and cDNA 
cloning of ECE1. 
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Table 3.1 Microorganisms used throughout this study 
Yeast strain Genotype/Description Source/Reference 
C. albicans (ATCC 
14053) 
LYS2, LYS5, vura3: imm434/vura3: imm434 Thermo Fisher 
Bacterial strain Genotype/Description Source/Reference 
E. coli (TOP10F´) This strains over expresses the Lac repressor (lacIq 
gene). This strain contains the F episome and can be 
used for single-strand rescue of plasmid DNA 
containing an f1 origin.  
F´ lacIq Tn10 (TetR) mcrA ∆(mrr-hsdRMS-mcrBC) 
Φ80lacZ∆M15 ∆lacΧ74 recA1 araD139 ∆(ara-
leu)7697 galU galK rpsL (StrR) endA1 nupG  
Invitrogen Australia P/L 
   
E. coli (DH5α) FP /endA1 hsdR17(rk-mk-) supE44 thi-1 recA1 gyrA 
(Nalr) reIA1 D(lacZYA-argF) U169 
deoR [F80dlacD(lacZ)M15] 
ATCC 
   
E. coli Bl21 (DE3) 
pLysS 
BL21 (DE3) pLysS is specifically designed for 
expression of genes regulated by the T7 promoter. F, 
ompT, hsdSB(rB3rB), dcm, gal, (DE3), pLsS, Cmr 
Novagen 
 
 
Table 3.2 Plasmids used throughout this study 
Plasmid Description/Genotype Diagram Source/Reference 
pCR®2.1 3.9 kbp PCR cloning plasmid, 
AmpR, KmR, lacZ, 3’ T-
overhang 
 Invitrogen, USA 
pRSETB ampr  Invitrogen 
 
3.2.2 Molecular techniques 
3.2.2.1 RNA extraction and purification 
Total RNA was extracted from a broth culture of C. albicans ATCC 14053 using the 
RNeasy mini kit (Qiagen, Germany) with a slight modification for yeast. According to 
the manufacturer’s operating instructions for yeast cells, 2 ml of sorbitol lysis buffer (1 
M sorbitol and 0.1 M EDTA pH 7.4) was added to 5-10 ml of ATCC strain 14053 broth 
culture. Then 50 units of lyticase (ICN Chemicals, USA), and 10 μl of β-
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Mercaptoethanol (Sigma Aldrich) were added to the mixture to lyse the yeast cell wall 
and generate spheroplasts. The RNA solution obtained was then purified with Turbo 
DNA-free kit (Ambion Life Technologies, Carlsbad, CA, USA) to remove residual 
DNA according to the manufacturer’s instructions. Briefly, 0.1 volumes 10X TURBO 
DNase Buffer and 1 µl TURBO DNase were added to the RNA solution and gently 
mixed. The solution was then incubated at 37°C for 25 min to allow degradation of 
DNA. Following incubation, 0.1 volume of resuspended DNase Inactivation Reagent 
was added to the mixture and mixed well. This mixture was then incubated for 5 min at 
room temperature with occasional mixing. After incubation, this mixture was 
centrifuged at 12,000 x g for 1.5 min. The supernatant containing RNA was then 
transferred to a new tube.  
 
3.2.2.2 Measurement of RNA concentration and quality by POLARstar Omega 
The RNA concentration and quality were measured for purity estimation using a 
POLARstar Omega (BMG LABTECH Pty. Ltd. VIC. Australia). The absorbance at 
wavelengths 260 nm (nucleic acid) was compared to wavelengths at 280 nm (protein) 
and 230 nm (organics) to determine protein or biological contamination. The ratios of 
readings of A260/A280 and A260/A230 for all samples were above 2.0 in nuclease-free 
water.  
 
3.2.2.3 Complementary DNA (cDNA) synthesis  
Extracted RNA was then converted to cDNA using a QuantiTect Reverse Transcription 
Kit (QIAGEN, Australia) according to manufacturer’s instructions. Briefly, 2 µl of 
gDNA Wipeout Buffer 7X was added to 12 µl template RNA (< 1µg/µl) and then 
incubated for 2 min at 42°C. The RNA was immediately placed on ice, and 6 µl 
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reverse-transcription master mix were added and incubated for 15 min at 42°C. The 
mixture was then further incubated for 3 min at 93°C to inactivate the reverse 
transcriptase. 
 
3.2.2.4 Prediction of signal peptides and transmembrane domain for ECE1 protein 
It is usual that most secretory proteins are initially synthesised in the cytoplasm as 
precursors containing 15-30 residues of extra peptide extensions at the beginning of 
their sequence (N-terminus). These so-called signal peptides play a significant role in 
the translocation of newly synthesised proteins across the membrane of the 
endoplasmic reticulum (ER) in eukaryotic cells (Tsuchiya, et al. 2003). To improve the 
expression level of recombinant protein expressed in E. coli, signal peptides are 
excluded from designed recombinant genes. Therefore, the ECE1 protein sequence of 
C. albicans SC5314 was subjected to SignalP 4.1 Server (predicts the presence and 
location of signal peptide cleavage sites in amino acid sequences from different 
organisms) – CBS (Centre for Biological Sequence analysis) analysis to identify any 
signal sequences. 
 
3.2.2.5 Design and preparation of the primers 
The primers to amplify the complete gene coding for ECE1 protein were designed 
manually as well as designing the orientation of the genes within pCR 2.1 and pRSET-
B vectors by SE Central (Clone Manager) software (Table. 3.3). Specifically, the first 
17 bases (after excluding the signal peptide) and the last 21 bases corresponded to the 
forward and reverse primers were used, respectively. The primers were manufactured 
by GeneWorks Custom Oligo Service (Thebarton, SA, Australia). The primers were 
supplied in a dried form, so 100 µmol stock solutions were prepared as shown below: 
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1) For-Fila (forward primer), 58.4 nmol/tube, Concentration= Mass/Volume 
 
𝑉𝑜𝑙𝑢𝑚𝑒 =
58.4 𝑋 103
100 
 = 584 µl of mQ water was added to reconstitute. 
 
2) Rev-Fila (reverse primer), 52.4 nmol/tube Concentration= Mass/volume 
 
𝑉𝑜𝑙𝑢𝑚𝑒 =
52.4 𝑋 103
100 
 = 524 µl of mQ water was added to reconstitute. 
To prepare 10 µmol working solutions, the stock solutions were diluted 1:10 (50 µl of 
each vial mixed with 450 µl of mQ water) and were stored at -20°C. 
 
Table 3.3 Primer sequences used to amplify the complete ECE1 coding for ECE1 
protein 
Primer Full 
name 
Orientation Sequence (5′-3′) 
Product 
length (bp) 
Region Reference 
ECE1 Forward 5’GCCATCATCCACCATGC3’ 758 55- 812 This study 
 Reverse 5’TTAAGCTTTTCCGAAATATTCTTC3’   This study 
 
3.2.2.6 Production of PCR Products and gel purification 
To produce an adequate and good quality of PCR product for optimal ligation 
efficiencies with the topo 2.1 vector, a conventional PCR was performed to amplify 
ECE1 in a PCR thermal cycler machine (G-Storm, Australia). The total reaction 
mixture volume was 50 µl and consisted of 10 µl of 5x MyTaq™ Reaction Buffer 
(Bioline, Alexandria, Australia), 1 µl (1.0 µM) of each primer and 1.0 µl (100 ng/µl) 
cDNA and 0.20 µl (2 U) Platinum Taq DNA polymerase (recommended to ensure the 
presence of 3’ A-overhangs on the PCR product). The PCR parameters were as follows: 
initial denaturing at 95°C for 2 min to activate the Platinum Taq DNA polymerase 
followed by 40 cycles of 15 s at 95°C, 30 s at 57°C and 60 s at 72°C and a final 
extension of 7 min at 72°C.  
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3.2.2.7 Purification of DNA from PCR amplification 
To obtain a purified PCR product for optimal ligation process with topo pCR 2.1 vector 
and to confirm that the right size of ECE1 had been amplified, 50 µl of PCR product 
was run on 1.5% agarose gel using 1× TAE electrophoresis buffer, at a voltage of 100 
V for 60 min. Gels were stained with ethidium bromide (3 µg/ml) before destaining in 
running tap water. The DNA product was visualised with an UV illuminator and 
photographed using a Biorad Geldoc imaging system running Quantity One Software. 
The size of the ECE1 band was compared to the 100 bp DNA ladder (Promega, 
Alexandria, Australia), of which 20 µl was loaded in the first well, then the ECE1 band 
was purified using Isolate II PCR and Gel Kit (Bioline) according to manufacturer’s 
instructions. Briefly, the gel slice was excised using a clean scalpel and dissolved in 
200 µl binding buffer and incubated at 50°C for 10 min. The sample was vortexed 
briefly every 3 min until the gel slice was completely dissolved. To bind DNA, the 
dissolved mixture was loaded to a column provided in the kit and centrifuged for the 30 
s at 11,000 x g and the flow-through discarded. The silica layer was washed with 700 µl 
CW buffer provided by the kit and centrifuged for the 30s at 11,000 x g. The 
centrifugation was repeated to dry the silica membrane and to remove residual ethanol 
and the column was transferred to a new 1.5 Eppendorf tube. The resulting DNA was 
eluted in 30 µl of elution buffer. 
 
3.2.3 First stage of cloning 
3.2.3.1 Cloning of ECE1 into pCR®2.1 vector 
To ligate ECE1 into the pCR2.1 vector (Figure 3.1), the PCR reaction to amplify the 
target gene was repeated to obtain a fresh product using the optimal annealing 
temperature (57°C). Then, the ligation constituents shown in Table 3.4 were mixed and 
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incubated for 5 min at room temperature. Subsequently, 2 µl of the ligation product was 
transformed into chemically competent TOP10F’ E. coli strain supplied by the kit and 
then the transformed cells were plated on LB agar containing 50 µg/ml of ampicillin, 
40 µg/ml X-gal, and 0.1 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) for 
blue/white colony selection. 
 
  Table 3.4 Cloning conditions of ECE1 into the pCR2.1 vector 
Components Volume 
Fresh PCR product 1.5 µl 
Salt Solution 1µl 
Nuclease-free water Add to total volume 5 µl 
TOPO® pCR2.1 vector 1 µl 
Total volume 6 µl 
 
3.2.3.2 Chemical (heat shock) transformation 
Chemically competent TOP10F’ E. coli cells were obtained from Invitrogen (Thermo 
Fisher) and stored at -80ºC. The cells were thawed on ice for 15 min, mixed with up to 
10 µL of a DNA (ligation product) and incubated on ice for a further 30 min. The cells 
were then heat shocked in a 42ºC water bath for exactly 90 s, followed by cooling on 
ice for 2 min. The SOC broth was added to a final volume of 1 mL and the cells 
incubated, shaking at 37ºC for 1 h. Aliquots of 100, 200 and 300 µL (to ensure that at 
least one plate has well-spaced colonies) of transformed cells were plated onto LB 
plates containing 50 µg/ml ampicillin, 40 µl of 40 mg/mL X-Gal and 40 mg/mL of 
IPTG and incubated overnight at 37°C. To perform blue-white screening for the insert, 
IPTG was added to plates to express LacZα as TOP10F´ does express the lac repressor 
(lacIq), which will repress transcription from the lac promoter. 
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3.2.3.3 Transformants analysis 
Blue-white screening 
The blue-white screening method was adapted from Sambrook and Russell (2001). Due 
to the light sensitivity of X-gal, plates were incubated overnight at 37°C wrapped in foil. 
Plates were then transferred to incubation at 4ºC for 2 h to allow proper colour 
development before white colonies were selected for analysis. Cloning into plasmid 
pCR
®
2.1 enabled this method of screening and IPTG was included for blue-white 
screening as TOP10F’ was used to express the lac repressor (Sambrook and Russell 
2001). 
 
Isolation of cloned topo pCR®2.1 
Ten white colonies were picked for plasmid isolation and restriction analysis. These 
colonies were grown overnight in 5 mL LB broth containing 50 µg/mL of ampicillin. 
Topo pCR
®
2.1 plasmid was purified using Isolate II Plasmid Mini Kit (Bioline) 
according to the manufacturer’s instructions. Briefly, to harvest the bacterial cells 5 ml 
of 10 F’ cells were pelleted for 30s at 11,000 x g and the supernatant was discarded. 
Cells were lysed by resuspending in 250 µl of Buffer p1 and vortexed until no cell 
clumps remained. 250 µl of buffer P2 was added to the mixture and cells were mixed 
gently by inverting the tube 6-8 times, then 300 µl of neutralisation buffer P3 was 
added to the mixture and mixed by inverting the tube 6-8 times followed by 
centrifugation for 5 min at 11,000 x g. To bind DNA, 750 µl of clear supernatant was 
pipetted into an Isolate Mini Spin Column and centrifuged for 1 min at 11,000 x g and 
the flowthrough was discarded. The silica membrane was washed with 500 µl using 
buffer PW1 followed by 600 µl of buffer PW2 provided by the kit and centrifuged for 1 
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min at 11,000 x g after each buffer was added and the flowthrough was discarded. To 
dry the silica membrane and remove residual ethanol, the column was centrifuged for 2 
min at 11,000 x g then the column was transferred to a new 1.5 Eppendorf tube. The 
resulting DNA was eluted in 50 µl of elution buffer after incubation at room 
temperature for 1 min and centrifugation for 1 min at 11,000 x g. 
 
 
Figure 3.1 pCR®2.1. 3.9 kbp PCR cloning plasmid, AmpR, KmR, lacZ, 3’ T-overhang 
PCR amplification 
 
A conventional PCR was performed to amplify ECE1 using the isolated cloned topo 
pCR®2.1 plasmid as DNA template. Forward and reverse primers designed for cloning 
in addition to M13 forward and M13 reverse primers provided with the kit were used to 
confirm that ECE1 had been cloned into the topo 2.1 vector. Conventional PCR (in 
duplicate) was performed in a PCR thermal cycler machine (G-Storm, Australia). The 
total reaction mixture volume of 50 µl consisted of 10 µl of 5 x MyTaq™ reaction 
buffer (Bioline), 1.0 µl (1.0 µM) of each primer and 1.0 µl (100 ng/µl) of cDNA and 
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0.2 µl (2 U) Taq DNA polymerase. The PCR parameters were as follows: initial 
denaturing at 95°C for 2 min to activate the Platinum Taq DNA polymerase followed 
by 40 cycles of 15 s at 95°C, 30 s at 57°C and 1 min at 72°C and a final extension of 7 
min at 72°C.  
 
Restriction enzyme digests 
The restriction enzymes selected were XhoI and NcoI which recognise (C▼TCGAG) 
and (C▼CATGG) sequences respectively. A junk nucleotide (A) (Figure 3.2) was 
added to the gene sequence of primer ECE1 forward after the XhoI sequence and before 
ECE1 sequence to keep a proper translation for rECE1 protein. These restriction 
enzymes were chosen because they both do not have recognition sites within the target 
gene but do have in pCR 2.1 and pRSET-B vectors. CCG and CATG nucleotides were 
added before XhoI sequence and after NcoI sequence respectively to increase the 
stability of the primers. Restriction enzyme reaction conditions were as specified by the 
manufacturer. In multi-enzyme reactions, the buffer was chosen based on maximum 
compatibility with both enzymes. About 1 µg of DNA was digested with 2 U of the 
enzyme in 1× buffer in a total volume of 20 µL at 37°C for 1-20 h. Reactions were 
incubated for over 4 h; acetylated BSA was added at a concentration of 100 µg/mL. 
Enzymes were heat inactivated at 80ºC for 20 min. 
 
 
Figure 3.2 Sequence of ECE1 cloned to pRSET-B the (a) nucleotide in red colour was 
added to sequence to keep a proper translation of rECE1 protein 
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Double digestion of Topo 2.1 and gel electrophoresis of DNA 
To confirm that the ECE1 insert had been cloned into topo pCR 2.1 vector, a double 
digestion with both XhoI and NcoI restriction enzymes was performed before running 
on a gel. The components shown in Table 3.5 were mixed in an Eppendorf tube and 
then incubated in a 37°C water bath for 4 h, afterwhich the restriction products were 
viewed by gel electrophoresis (Section 3.3.5). 
 
Table 3.5 Components of double digestion solution of ECE1 cloned into topo 2.1 vector 
Component Topo 2.1 vector 
Plasmid DNA 3.3 µl (300.3 ng/ µl) 
10x Buffer H 5 µl 
XhoI enzyme 1 µl 
NcoI enzyme 1 µl 
BSA 5 µl 
N F W 34.7 µl 
Total volume 50 µl 
 
3.2.4 Second cloning step 
3.2.4.1 Preparing electrocompetent DH5α E. coli  
Competent E. coli DH5α were prepared for electrotransformation according to the Gene 
Pulser apparatus user’s manual (BioRad) with minor alterations. All steps were 
performed aseptically. An overnight E. coli DH5α culture was used to inoculate 200 ml 
of LB broth at a 1/100 volume. The cells were incubated with shaking at 37°C until an 
OD 600 of about 0.6 (early to mid-log phase) was obtained. The culture was then 
placed on ice for 30 min before the bacteria were pelleted by centrifugation at 5,000 x g 
for 15 min at 4ºC. The supernatant was removed, and the pellet resuspended in 200 mL 
of ice-cold sterile Milli-Q water. The resuspension was placed on a flat shaker at slow 
speed until the pellet disappeared, then centrifuged at 3500 x g for 15 min at 4°C. This 
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centrifugation process was repeated twice, with the cells firstly resuspended in 100 mL 
of ice-cold sterile Milli-Q water followed by resuspension in 10 mL of ice-cold 10% 
glycerol. The cells were then finally pelleted by centrifugation at 4,000 x g for 15 min 
and resuspended in 400 µL of ice-cold 10% glycerol and immediately aliquoted into 40 
µL amounts in tubes and stored at -80ºC.  
 
3.2.4.2 Assessing the efficacy of the electrocompetent cells 
To measure the preparation effectiveness of electrocompetent cells, 0.5 µl of PUC19 
plasmid (0.1 ng/µl), which has been previously shown to be efficiently transformed into 
electrocompetent cells, was mixed with 50 µl of the prepared electrocompetent cells 
and then transferred to a cuvette tube. The transformation was done by placing the 
cuvette in a chamber attached to the BIORAD electroporation system set at 2.5 volts, 
25 µF, 200 ohms and then giving the cells an electrical shock. Following the addition of 
1 ml of LB broth to the cells, they were then transferred to a microcentrifuge tube and 
incubated at 37°C on a shaker at 225 rpm for one hour. The culture (100 µl) was plated 
on LB agar containing 50 µg/ml of ampicillin and incubated overnight at 37°C and 
afterwards the colony forming units (CFU) were counted and used in the transformation 
efficiency calculation. The calculation was done as follows: 
 
1) Total DNA transformed (ng)       = plasmid concentration x the added volume 
                                                             = 0.1 ng/µl x 0.5 µl =0.0001 ng.  
2) Transformation efficacy (CFU/µg) = 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐶𝐹𝑈
𝑇𝑜𝑡𝑎𝑙 𝐷𝑁𝐴 𝑡𝑟𝑎𝑛𝑠𝑓𝑜𝑟𝑚𝑒𝑑 (𝑛𝑔)
 x 103 x  
𝑇𝑜𝑡𝑎𝑙 𝑉𝑜𝑙𝑢𝑚𝑒 𝑡𝑟𝑎𝑛𝑠𝑓𝑜𝑟𝑚𝑒𝑑 
𝑇ℎ𝑒 𝑝𝑙𝑎𝑡𝑒 𝑣𝑜𝑙𝑢𝑚𝑒
 
                                                             = 
540 𝐶𝐹𝑈
0.0001 𝑛𝑔
 x 103 x  
(250+50)µ𝑙
100 µ𝑙
 
                                                            = 3.24 x 1010 CFU/µg 
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From this result of 3 x 1010 it was concluded that the prepared E. coli DH5α cells were 
suitable for further electroporation as the number of viable cells in a preparation for a 
transformation reaction may range from 2×108 to 1011 and most common methods of E. 
coli preparation yield around 1010 viable cells per reaction. 
 
3.2.4.3 Isolation of pRSET-B vector 
The vector pRSET-B was purified from DH5α E. coli using the Plasmid Mini Kit 
(Bioline) using the high copy plasmid DNA isolation protocol according to the 
manufacturer’s instructions. Briefly, the E. coli DH5α that included the pRSET-B 
plasmid was grown overnight in 5 mL LB broth containing 50 µg/mL of ampicillin. 
Cells were pelleted for 30 s at 11,000 x g and the supernatant was discarded. Cells were 
then lysed through resuspension in 250 µl of buffer P1 and vortexed until no cell 
clumps remained. 250 µl of buffer P2 was then added to the mixture, and the cells were 
mixed gently by inverting the tube 6-8 times. 300 µl of neutralisation buffer P3 was 
then added to the mixture and mixed by inverting the tube 6-8 times, then centrifuged 
for 5 min at 11,000 x g. To bind DNA, 750 µl of clear supernatant was pipetted into an 
Isolate Mini Spin Column and centrifuged for 1 min at 11,000 x g and the flowthrough 
was discarded. The silica membrane was then washed with 500 µl of buffer PW1 
followed by 600 µl of buffer PW2 and centrifuged for 1 min at 11,000 x g after each 
buffer was added and the flowthrough was discarded. To dry the silica membrane and 
remove residual ethanol the column was centrifuged for 2 min at 11,000 x g and the 
column was then transferred to a new 1.5 Eppendorf tube. The resulting DNA was 
eluted into 50 µl of elution buffer after incubation at room temperature for 1 min and 
then centrifuged for 1 min at 11,000 x g. The elution step was repeated to increase the 
DNA yield, and the DNA was stored at -20°C. 
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Figure 3.3 pRSET-B 2.9 kbp PCR cloning plasmid. A) shows the sequence 
sites of the start codon and the polyhistidine and restriction enzyme sites used in this 
study. B) shows the complete design of pRSET-B. 
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3.2.4.4 Digestion of pRSET-B vector DNA and ECE1 cloned into topo pCR 2.1 
vector DNA by restriction enzymes 
To clone ECE1 digested from the Topo pCR 2.1 vector into the pRSET-B vector, both 
the insert and the dedicated cloning site of the pRSET-B vector were digested with both 
XhoI and NcoI restriction enzymes before running on a gel. The components shown in 
Table 3.6 were mixed in a microfuge and then incubated in a 37°C water bath for 4 h. 
The restriction products were then viewed after separation in 1.5% gel electrophoresis. 
 
Table 3.6 Conditions for double digestion of ECE1 and pRSET-A vector 
Component  ECE1 cloned into topo 2.1 pRSETB 
Plasmid DNA 3.3 µl (300.3 ng/µl) 2 µl (500.3 ng/µl) 
10x Buffer H 5 µl 5 µl 
XhoI enzyme 1 µl 1 µl 
NcoI enzyme 1 µl 1 µl 
BSA 5 µl 5 µl 
N F W 34.7 µl 36 µl 
Total volume 50 µl 50 µl 
 
3.2.4.5 Gel extraction of DNA  
Both the insert (ECE1 cloned into topo pCR 2.1 vector) and the digested pRSET-B 
vector were isolated from the gel to clone ECE1 into the pRSET-B vector. 
Consequently, restriction reactions were prepared for both the clone pCR 2.1 and the 
pRSET-B in 50 µl total volume separately. The digested products were loaded (20 µl) 
into 1.5% agarose gel (1.5 g of agarose dissolved into 100 ml TAE buffer) and 
electrophoresed for all the reactions. The DNA products were visualised with a UV 
illuminator and photographed using a Biorad Geldoc imaging system running Quantity 
One software. The bands corresponding to the ECE1 insert and the pRSET-B backbone 
were excised from the gel using a sharp scalpel and weighed in 1.5 ml Eppendorf tubes. 
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The bands were purified using Isolate II PCR and Gel Kit (Bioline) according to the 
manufacturer’s instructions. Briefly, the excised gel slice was dissolved in 200 µl 
binding buffer and incubated at 50°C for 10 min. The sample was then vortexed briefly 
every 3 min until the gel slice was completely dissolved. To bind DNA, the dissolved 
mixture was loaded to a column provided in the kit and centrifuged for 30 s at 11,000 x 
g and the flow through was discarding. The silica membrane was then washed with 700 
µl CW buffer and centrifuged for 30 s at 11,000 x g. The centrifugation was repeated to 
dry the silica membrane and remove residual ethanol. The column was then transferred 
to a new 1.5 ml Eppendorf tube and the DNA eluted in 30 µl of elution buffer. To 
calculate the concentration of the purified DNA, 2 µl of each sample was tested using a 
NanoDrop spectrophotometer. The resulting DNA was stored at -20°C.   
 
3.2.4.6 Ligation of ECE1 into pRSET-B vector 
The ligation reaction was performed using 50 ng of pRSET-B vector and 40.34 ng of 
the purified ECE1 insert, by applying a 1:3 ratio of insert to vector and by using the 
calculations below. The ligation reactions were prepared according to the components 
listed in Table 3.7, and the tubes were incubated overnight at 14°C.   
 
                    ng of DNA insert = 
ng vector x size of insert (bp) 
size of the vector (bp)
  X molar ratio 
                    ng of DNA insert = 
50 ng x 781 (bp) 
2900 (bp)
  X 3  
                    ng of DNA insert =  40.4 ng  
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Table 3.7 pRSET-B vector and ECE1 ligation conditions 
Components Volume 
Gel extracted pRSET-B backbone 1.46 µl (50 ng) 
Gel extracted ECE1 insert 2 µl (40.4 ng) 
20 mM ATP 1 µl 
T4 DNA Ligase 1 µl 
10x T4 DNA Ligase Reaction Buffer 2 µl 
N F W 12.54 µl 
Total volume 20 µl 
 
3.2.4.7 DH5α electroporation protocol 
To confirm that ECE1 had been ligated into the pRSET-B vector, 2 µl of the ligation 
product was transformed into electrocompetent E. coli DH5-α using the method applied 
for the positive control plasmid (Section 3.2.4.2), and then the transformed cells were 
plated on LB agar containing 100µg/ml of ampicillin and incubated at 37°C. 
 
3.2.4.8 Analysis of transformants 
Conventional PCR and double digestion were performed as described in section 3.2.3.3, 
using the DNA of isolated pRSET-B vector from overnight E. coli DH5-α competent 
cells in order to confirm that ECE1 had been cloned into the pRSET-B vector. 
 
Sequencing and alignment of rECE1 
To confirm that ECE1 had been cloned into pRSET-B vector, the DNA of the pRSET-
B vector was isolated and purified from DH5α E. coli cells using the Plasmid Mini Kit 
(Bioline) protocol described in section 3.2.3.3 and sequenced using the forward and 
reverse primers used for cloning. The purified plasmid was sequenced at the Australian 
Genome Research Facility LTD (AGRF, La Trobe University, Bundoora, Victoria, 
Australia), which recommends sending 12 µl containing 600 to 1500 ng of double-
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stranded plasmid and 0.8 pmol/1 µl of primers. The purified DNA was measured using 
a Nanodrop spectrophotometer which determined a final concentration of 626.6 ng/µl 
of DNA. The calculation below was performed to determine the volume of 10 µM 
ECE1 primers to be added to the sample. This determined that 1 µl of the 10 µm ECE1 
forward primer was to be added to 2 µl of the purified plasmid and made up to a total of 
12 µl of nuclease free water. The same step was performed with the ECE1 reverse 
primer. The two 12 µl samples were then sent to AGRF for sequencing.  
𝐶1 × 𝑉1 = 𝐶2 × 𝑉2 
    10 𝑝𝑚𝑜𝑙/µ𝑙 ×  𝑉1 =  0.8 𝑝𝑚𝑜𝑙/µ𝑙 × 12 µ 
                                                                             𝑉1 = 1 µ𝑙 
     
3.2.5 Protein expression and purification  
3.2.5.1 Preparation of electrocompetent DH5α E. coli strain BL21 (DE3) pLysS 
Electrocompetent E. coli DH5-α strain BL21 (DE3) pLysS cells were prepared by the 
same method described previously (Section 3.2.4.1) using LB broth containing 35 
µg/ml chloramphenicol. To assess the efficiency of the prepared electrocompetent cells, 
0.5 µl of pUC19 plasmid (0.1 ng/µl) was transformed into the prepared cells using the 
method previously described (Section 3.2.4.2) and inoculated onto LB agar containing 
35 µg/ml chloramphenicol and 50 µg/ml ampicillin. After overnight incubation at 37°C, 
the DNA transformed was calculated and transformation efficiency determined:  
 
1) Total DNA transformed (ng)        = plasmid concentration x the added volume 
                                                             = 0.1 ng/µl x 0.5 µl =0.0001 ng.  
2) Transformation efficacy (CFU/µg) = 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐶𝐹𝑈
𝑇𝑜𝑡𝑎𝑙 𝐷𝑁𝐴 𝑡𝑟𝑎𝑛𝑠𝑓𝑜𝑟𝑚𝑒𝑑 (𝑛𝑔)
 x 103 x  
𝑇𝑜𝑡𝑎𝑙 𝑉𝑜𝑙𝑢𝑚𝑒 𝑡𝑟𝑎𝑛𝑠𝑓𝑜𝑟𝑚𝑒𝑑 
𝑇ℎ𝑒 𝑝𝑙𝑎𝑡𝑒 𝑣𝑜𝑙𝑢𝑚𝑒
 
                                                             =  
60 𝐶𝐹𝑈
0.0001 𝑛𝑔
  x 103 x  
(250+50)µ𝑙
100 µ𝑙
      = 1.8 x 109 CFU/µg 
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Hence, it was concluded that the prepared E. coli strain BL21 (DE3) pLysS were 
efficiently electrocompetent as the number of viable cells in the preparation for the 
transformation reaction were within the acceptable range of 2×108 to 1011 CFU. 
 
3.2.5.2 Pilot expression 
The purified pRSET-B with the cloned ECE1 was transformed into 50 µl of 
electrocompetent DH5α E. coli strain BL21 (DE3) pLysS cells and then plated on LB 
agar containing 35 µg/ml chloramphenicol and 50 µg/ml ampicillin. After overnight 
incubation at 37°C, one colony was inoculated into 5 ml LB broth containing the 
required antibiotics and incubated with vigorous shaking at 37°C until an OD 600 nm 
0.6 to 1.0 resulted. 0.5 ml of the culture was then stored in 40% glycerol at -80°C and 
0.5 ml was stored at 4°C to be used on the following day. The 0.5 ml culture was 
centrifuged for 30 seconds at maximum speed and the pellet resuspended in 250 µl 
fresh LB broth. This was then added to 25 ml LB broth containing 35 µg/ml 
chloramphenicol and 50 µg/ml ampicillin and incubated at 37°C until the OD 600 nm 
was between 0.4 to 0.6. 1 ml of this culture was removed (the time zero concentration) 
and stored at 4°C. 240 µl of 100 mM IPTG stock was then added to the remaining 
culture resulting in a final concentration of 1mM IPTG. Finally, the culture was 
incubated at 37°C with vigorous shaking and 1 ml aliquots were removed every hour 
and stored at 4°C. Whole cell lysate process was performed on each of the 6 collected 
aliquots by first centrifuging for 1 min at maximum speed and then performing two 
wash steps. The pellets were washed by being resuspended in 1 ml 10 mM Tris-HCL 
(ph 8.0) and centrifugation for 2 min at maximum speed. The cells were then lysed by 
resuspending the pellets in 500 µl of whole cell lysis buffer and boiling them in a 
heating block (100°C) for 5 min. The samples were centrifuged at maximum speed for 
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5 min, and the supernatants were collected and stored at -20°C for later analysis by 
SDS-PAGE. 
 
3.2.5.3 First protein expression approach (freezer and 37°C water bath) 
The BL21 (DE3) pLysS cells containing pRSET-B with the cloned ECE1 were plated 
onto agar containing 35 µg/ml chloramphenicol and 50 µg/ml ampicillin. After 
overnight incubation at 37°C, one colony was inoculated into 5 ml LB broth containing 
the required antibiotics and incubated with vigorous shaking at 37°C until an OD 600 
nm 0.6 to 1.0 resulted and then stored at 4°C. On the following day, 2 ml of culture was 
centrifuged for 30 seconds at maximum speed and the pellet resuspended in 1 ml of 
fresh LB broth. 200 ml of LB broth containing the required antibiotics was then added. 
The culture was grown at 37°C with vigorous shaking until OD 600 nm 0.3 to 0.6 
resulted (pre-induction), then 2 ml of 100 mM ITPG stock was added to the culture 
resulting in a final concentration of 1 mM IPTG. To induce protein production, the 
culture was incubated for 5 hours at 37°C with vigorous shaking (this was the time 
determined during the pilot expression experiment found to be optimal for protein 
production). The culture was then harvested by centrifugation at 4700 x g for 15 min at 
4°C and the pellet then resuspended in 8 ml lysis buffer containing 50 mM Tris-base 
(pH 8.0), 150 mM NaCl, 1 mg/ml lysozyme and 20 mM imidazole. The cells were then 
subjected to 4 freeze/thaw cycles using a -80°C freezer and a 37°C water bath. 30 units 
of DNAse was also added to the cells after the second freeze/thaw cycle. Following the 
fourth cycle, the sample was centrifuged at 4700 x g for 15 min at 4°C and the 
supernatant was filter sterilised using a 0.22 µm filter. 
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3.2.5.4 Second protein expression approach (sonication) 
Following analysis of the protein product from the previous protein expression 
approach, a second protocol was performed in an attempt to maximise lysis (which 
could have contributed to the failure of purifying the rECE1 protein by IMAC in the 
first protocol). The same procedure was repeated but for this second protocol, 
sonication was performed after treatment with the lysis buffer using a Branson Digital 
Sonifier at 35% setting (15 seconds on and 30 seconds off, for 3 cycles). Then the 
sample was centrifuged at 4700 x g for 15 min at 4°C to remove cell debris. The 
supernatant was transferred to a new tube and filter sterilised using a 0.22 µm filter and 
stored at -20°C.  
 
3.2.5.5 Preparation of immobilised metal affinity chromatography (IMAC) 
column 
A 1 ml polypropylene column (Qiagen) was prepared for IMAC purification of rECE1 
protein by washing with 10 ml Milli-Q water, using a steady stream of water to remove 
air bubbles. Chelating Sepharose TM fast flow through resin (stored in alcohol) was 
then added and left to settle to the pre-marked 1 ml column level. The column was then 
washed with 10 ml of MilliQ water to remove ethanol from the the resin. The column 
was then charged with 0.5 ml (0.5 CV) of 0.2 M NiSO4 and washed with 10 ml (10 CV) 
of MilliQ water to remove unbound metal ions. The flow through was collected in a 
disposable tube and discarded. Finally, the column was equilibrated with 5 ml (5 CV) 
of the equilibration wash buffer containing 50 mM Tris-base (pH 8.0), 150 mM NaCl 
and 20 mM imidazole. 
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3.2.5.6 Optimisation of IMAC protein purification 
Five ml of the samples from each of the protein expression preparations were each 
added to a column and then mixed with the resin by slowly flipping the column up and 
down. Subsequently columns were incubated for one hour at room temperature with 
horizontal shaking and then returned to the vertical position and left to settle for 15 min. 
2 ml crude eluent was then collected and each column washed with 10 ml (10 CV) post 
sample wash buffer and the flow through eluent containing unbound protein was 
collected. 1ml of elution buffer containing increasing concentrations (1 mM, 50 mM, 
100 mM, 150 mM, 200 mM and 300 mM) of imidazole was then added to the columns 
and eluates were collected in labelled tubes. SDS-PAGE was then performed, and 
protein bands stained with acquastain blue dye. The presence of the protein of interest 
was then confirmed by performing Western blot analysis (described in the next 
sections).  
 
3.2.6 Protein electrophoresis and analysis 
3.2.6.1 Tris-glycine sodium dodecyl sulphate- polyacrylamide gel electrophoresis 
(SDS-PAGE) 
SDS-PAGE is a common technique used to separate proteins based on their molecular 
weight. The negatively charged detergent, sodium dodecyl sulphate (SDS), with a 
reducing agent such as (mercaptoethanol), binds to the proteins, denatures and breaks 
down the disulfide bonds of the protein. The negatively charged SDS-protein complex 
is then applied to an assembled acrylamide gel with different concentrations and pH (a 
low acrylamide percentage-stacking gel segment with lower pH (6.8) and then a higher 
percentage section with a higher pH of 8.8). When this gel is placed in an electric field, 
the proteins move towards the anode with smaller proteins moving faster than the larger 
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ones (Smith, 2003). The Laemmli protocol was used to prepare all the stock solutions 
of stacking gel, resolving gel, running and loading buffer. According to the 
manufacturer’s instructions (BIORAD), two glass plates were assembled using 0.75 
mm spacer glass and checked for the absence of leakage with distilled water. The size 
of protein was predicted to be between 25 to 35 kDa, and thus, a resolving gel with 12% 
polyacrylamide was prepared (Table 3.8) just prior to the experiment. 
 
Table 3.8 Recipe for one resolving gel (12% polyacrylamide) 
Components Volume 
30% Acrylamide stock 3.13 ml 
1.5M Tris-HCL pH 8.8 1.88 ml 
10% SDS 0.08 ml 
mQ water 2.38 ml 
10% w/v APS 37.5 µl 
TEMED 2.5 µl 
 
The gel was then poured gently in between the glass sheets leaving a 1.5 cm space at 
the top of the stacking gel. To obtain a sharp surface and prevent the diffusion of 
oxygen, bubble formation and drying of the gel, a solution of saturated butanol was 
added. After one hour, the resolving gel had become polymerised and the surface liquid 
poured off and washed several times with running buffer and dried with blotting paper. 
1 ml of 4% stacking gel was then prepared (Table 3.9) and layered over the top. 
Immediately a plastic Teflon comb was inserted into the stacking gel between the plates 
to form 10 or 15 wells (depending on the choice of comb) and the gel allowed to 
polymerise for 40 min. 
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Table 3.9 Recipe for one stacking gel (4% polyacrylamide) 
Components Volume 
30% Acrylamide stock 0.33 ml 
0.5 M Tris-HCL pH 8.8 0.63 ml 
10% SDS 0.03 ml 
MG water 1.50 ml 
10% w/v APS 12.5 µl 
TEMED 1.25 µl 
The gel was then removed from the casting stand and clamped to the electrode 
assembly and placed in the tank of a Mini-PROTEIN Tetra Cell electrophoresis system 
(Bio-Rad, Gladesville, NSW, Australia) and filled with a 1x electrophoresis running 
buffer.   
 
3.2.6.2 Sample preparation for SDS-PAGE 
Dilutions of protein extracts were prepared in PBS. 20 µl of each dilution had 5 µl of 
5x sample buffer added and all heated in a water bath or heater at 100°C for 5 min. 
These preparations were then loaded into the prepared gel (as described in the previous 
section). 7 µl of a molecular protein marker (Perfect Protein™ Markers, 15-150 kDa, 
Merck Millipore, Bayswater, VIC, Australia) was loaded into the first well of the gel. 
 
3.2.6.3 SDS-PAGE: Running conditions and staining 
The electrophoresis apparatus was connected to the power supply and electropheses in 
two stages: the first at 60 volts for 30 min (until the protein reached the top of the 
resolving gel) and the second stage at 180 volts for 45 min (until the dye front reached 
the bottom of the gel). 
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3.2.6.4 AcquaStain Blue dye 
When the electrophoresis was complete, the stacking gel region was cut away using a 
scalpel blade and the gel was removed from the glass plates. The gel was stained with 
50 ml of AcquaStain blue dye (GeneWorks, Hindmarsh SA, Australia) for 2 hours on a 
rotating shaker at room temperature. The stain was then removed, and the gel washed 
with distilled water. To visualise the protein bands, the gel was placed on transparency 
paper and scanned using a Gel Doc EQ system (Bio-Rad). 
 
3.2.7 Western blotting 
The SDS-PAGE electrophoresis was repeated but this time a Kaleidoscope prestained 
marker (Biorad) was used. The electrophoresed proteins were then transferred from the 
SDS-PAGE gel to a nitrocellulose membrane using the iBlot® Transfer Stack, 
nitrocellulose, regular size (Thermo Fisher). Briefly this procedure involved firstly 
placing the anode stack on the tray and then the SDS-PAGE gel was overlaid on the top. 
Next a pre-soaked iBlot filter paper in deionized water was placed on top and air 
bubbles were removed using a blotting roller. Then the cathode was placed with the 
electrode side facing up and a disposable sponge was positioned on the top with the 
metal contact on the upper side. The lid was then closed on the assembled stacks and 
the blotting process was run for 7 min. The nitrocellulose membrane was now ready for 
further Western immunoblotting analysis.  
 
3.2.7.1 Immunoblotting with anti-polyhistidine polyclonal antibody 
After blotting the nitrocellulose membrane was placed in a plastic bag and blocked with 
50 ml of 5% (w/v) skim milk in Tris Buffered Saline (TBS) for 1 h. on a shaker at room 
temperature, this was followed by three washes with TBS each for 5 min. The 
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membrane was then placed in a plastic container and incubated at 4°C overnight with 
10 ml of the primary antibody, rabbit anti-polyhistidine polyclonal antibody (VWR 
International, Murarrie, QLD, Australia) diluted 1: 10,000 with 1% (w/v) skim milk in 
TBS 0.5 Tween20. The membrane was then placed in a plastic bag and washed three 
times with 20 ml TBS-Tween20 for 5 min each time, then incubated for 2 hours at 
room temperature with 10 ml of the secondary antibody, rabbit anti-mouse IgG alkaline 
phosphatase (AP) antibody (Sigma Aldrich) and diluted 1: 10,000 with 1% (w/v) skim 
milk in TBS 0.5 Tween. The membrane was then washed 3 times with TBS containing 
0.05% Tween20 and then immersed in detection buffer for 10 min. The colour was 
developed by adding 3 ml of Western Blue® Stabilized Substrate for Alkaline 
Phosphatase (Promega, Madison, WI, USA) and rinsing it with distilled water after a 
few min. 
 
3.2.7.2 Immunoblotting with anti-ECE1 polyclonal antibody   
To confirm that the rECE1 protein has been expressed and purified properly as in 
section 3.2.5 and to choose the best concentration of polyclonal anti-ECE1 antibody 
produced in rabbit (Abmart, Shanghai, China) for immune-blotting and 
immunofluorescence techniques, a whole protein extract was prepared from C. albicans 
ATCC 14053. To prepare this, the organisms was inoculated into yeast extract peptone 
dextrose (YEPD) broth and incubated at 37°C for 24 hours with shaking at 220 rpm. 
The broth culture was then centrifuged at 10000 rpm for 20 min at 4°C, then the 
supernatant was discarded and the pellet then lysed with RIPA buffer (20 mM Tris-HCl 
(pH 7.5), 150 mM NaCl, 1 mM Na2 EDTA, 1 mM EGTA, 1% NP-40, 1% sodium 
deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM 
Na3VO4 and 1 µg/ml leupeptin, 1mM PMSF) and sonicated for 15 min (15 s on and 15 
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s off). The lysate was then filtered using a 0.22 mm filter and 20 µl of extracted protein 
was run in each of 8 wells of an SDS-PAGE electrophoresis gel, 4 of these were 
subjected to anti-polyhistidine polyclonal antibody and the other four were subjected to 
4 different concentrations of polyclonal anti-ECE1 antibody. The purified rECE1 band 
was confirmed with anti-polyhistidine antibody and was also used as a positive control 
to compare its band size and position with the ECE1 protein extracted from the C. 
albicans ATCC 14053. After removing the nitrocellulose membrane from the device, it 
was cut into 5 pieces, the first one included 2 wells (protein marker and rECE1), and 
the other four pieces each had one well (2 wells of rECE1 and ATCC 14053 protein). 
These were then each placed in 50 ml Falcon tubes and blocked with 50 ml of 5% (w/v) 
skim milk in TBS for 1 h. on the shaker at room temperature, followed by washing 
three times with TBS for 5 min each time. The membrane pieces were then incubated at 
4°C overnight with 10 ml of rabbit anti-histidine polyclonal antibody for the first 
membrane piece and with 10 ml of the rabbit polyclonal anti-ECE1 antibody for the 
other four pieces diluted 1:50 1:100 1:200 and 1:200 respectively with 1% (w/v) skim 
milk in TBS 0.5 Tween 20 (primary antibody). Subsequently, each membrane was 
washed three times with 20 ml TBS-T for 5 min each time, then incubated for 2 h. at 
room temperature with 10 ml of goat anti-rabbit IgG AP conjugate polyclonal antibody 
(Thermo Fisher) and diluted 1: 10,000 with 1% (w/v) skim milk in TBS 0.5 Tween20 
(secondary antibody). The membranes were washed 3 times with TBS containing 0.05% 
Tween20, and then immersed in detection buffer for 10 min. The colour was developed 
by adding 3 ml of Western Blue® Stabilized Substrate for Alkaline Phosphatase 
(Promega) and rinsing it with distilled water after a few minutes. 
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3.2.8 Immunoblotting with anti-ECE1 polyclonal antibody to investigate the 
expression of ECE1 protein in tissue culture assay (J774 infected with C. 
albicans and treated with different concentrations of fresh garlic extract) 
For the immunoblotting assay, 5 x 104 cells/ml per sample of macrophage cell line J774 
were cultured in 9 small flasks and incubated overnight at 37°C and 5% CO2. Then 4 × 
105 cells/ml of C. albicans was added to each flask. For immunoblotting, RPMI 1640 
medium containing 10% inactivated fetal bovine serum was used. Prior to infection of 
the macrophage J774 cell line, C. albicans was subcultured for 4 h in YPD at 30°C to 
induce yeast-form (blastospore) cells. After addition of C. albicans ATCC 14053, two 
different concentrations of fresh garlic extract (20, and 100 µg/ml) were added to flasks 
with untreated samples and flasks were incubated at 37°C and 5% CO2. Incubation time 
points were 30 min, 2 hours and 8 hours for each three different treatments. The cells 
were lysed as described in the last section then the cell suspension was frozen 
immediately in liquid nitrogen and stored at -80°C for Western blotting. 
 
3.2.8.1 SDS-PAGE 
The protein sample was prepared for SDS-PAGE analysis as previously described 
(Section 3.2.6.2). Run conditions and staining procedure were as previously described 
(Section 3.2.6.3). Western blotting was run using iBlot® Transfer Stack, nitrocellulose 
following manufacturer’s instructions, as previously described (Section 3.2.7). 
 
3.2.8.2 Immunoblotting analysis 
After removing the nitrocellulose membrane from the device, it was placed in a plastic 
bag and blocked with 50 ml 5% (w/v) skim milk in TBS for 1 hr on a shaker at room 
temperature, followed by washing three times with TBS for 5 min each time. The 
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membrane was then placed in a plastic container and incubated at 4°C overnight with 
10 ml of rabbit polyclonal anti-ECE1 antibody solution diluted 1:10,000 with 1% (w/v) 
skim milk in TBS 0.5 Tween20 (primary antibody). Subsequently, the membrane was 
placed in a plastic container and washed three times with 20 ml TBS-T for 5 min each 
time, then incubated for 2 h. at room temperature with 10 ml of the anti-rabbit IgG 
(whole molecule) alkaline phosphatase antibody produced in goat (Santa Cruze 
Biotechnology, Dallas, Texas, USA) and diluted 1:10,000 with 1% (w/v) skim milk in 
TBS 0.5 Tween (secondary antibody). The membrane was washed 3 times with TBS 
containing 0.05% Tween20 and then immersed in the detection buffer for 10 min. The 
colour was developed by adding 3 ml of Western Blue® stabilized substrate for 
alkaline phosphatase and rinsing it with distilled water after a few minutes. 
 
3.2.9 Generation of polyclonal anti-ECE1 antibody for immunofluorescence 
technique 
In order to investigate the expression time and the role of ECE1 protein in the 
morphological changes of C. albicans cell wall, the protein sequence  of the ECE1 
protein sequence was submitted into TMHMM Server v. 2.0.and Immunomedicine 
Group tools in order to detect transmembrane domain regions and for antigenic peptide 
prediction. The aim was to select one putative peptide of 12 amino acids for polyclonal 
ECE1-antibody generation. 
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3.3 Results 
3.3.1 Signal peptide and transmembrane domain prediction for ECE1 protein 
The complete amino acid sequence of the ECE1 protein of C. albicans ATCC 14053 
was submitted to the SignalP 4.1 server. Figure 3.4 shows the result that a signal 
peptide is present. This result indicates that ECE1 is likely to be a secreted protein.  
 
 
Figure 3.4 Signal peptide prediction for the ECE1 protein of C. albicans ATCC 14053 
using the SignalP 4.1 server. 
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3.3.2 Double stranded cDNA synthesized from messenger RNA (mRNA) from C. 
albicans 
12 µl of ECE1 PCR product produced in section 3.2.2.6 was electrophoresed in a 1.5% 
agarose gel and visualised by ethidium bromide staining (Figure 3.5). The cDNA 
sequence obtained was estimated to be around 782 bp in length.   
 
 
Figure 3.5 Amplification of ECE1 782 bp product by conventional PCR using 
forward and reverse primers designed for cloning. Lane 1 is DNA marker VI (154-2176 
bp); lanes 2 and 3 are empty wells; lane 4 is ECE1, lanes 5 is a no template control 
 
 
    1        2        3         4        5 
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3.3.3 Blue-white screening 
The numbers of white colonies obtained after transformation (Figure 3.6) were within 
the expected range of 5–25 colonies from the 50 μL plated. Because TOP 10 F´ was 
used for this transformation, IPTG was added to plates to express the LacZα gene. 
 
 
Figure 3.6 Blue and white colonies after transformation of the ligation product into 
TOP 10 F competent cells. 
 
3.3.4 Amplification of ECE1 of C. albicans ATCC 14053 by specific designed 
primers. 
DNA was extracted from white colonies and conventional PCR was run to confirm that 
ECE1 was cloned into the pCR2.1 vector using two sets of primers (Figure 3.7). M13 
forward and reverse primers were used to amplify the sequence of ECE1 including the 
extra sequences of pCR2.1 vector and the ECE1 forward and reverse primers were used 
to amplify only the ECE1 sequence. 
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Figure 3.7 Two sets of primers were used to amplify ECE1 to confirm that ECE1 
had been cloned into pCR2.1 vector. M13 forward and reverse primers (orange colour) 
were used to amplify the sequence of ECE1 with extra sequences of pCR2.1 vector and 
ECE1 forward and reverse primers blue colour) used to amplify only ECE1 sequen 
 
 
The strong single band in lane 4 Figure 3.8 represents ECE1 as it was at the predicted 
size (782 bp). The other two strong bands in lane 5, 983 bp and 202 bp represent the 
sequence including ECE1 and the sequence without ECE1 respectively amplified using 
M13 primers.  
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Figure 3.8 Amplification of ECE1 782 bp product and two other sequences 
by conventional PCR using DNA from white colonies. Lanes 1, 2 and 3 are DNA 
marker; lane 4 represents the ECE1; Lane 5 represents the sequences amplified by M13 
primers; lane 6 is a no template control. 
 
3.3.5 Digestion of pCR2.1 including ECE1 and pRSET-B by both XhoI and NcoI 
restriction enzyme respectively.  
One white colony of Top 10 F’ competent cells that had been transformed was selected 
and subcultured in LB media with ampicillin 50 mg/ml for DNA extraction. The vector 
pCR 2.1 DNA was isolated, and then digested to confirm the presence and the correct 
orientation of ECE1. Agarose gel electrophoresis (1.5%) was used to visualise the 
positive recombinant pCR 2.1/ECE1 clones. Both the positive recombinant pCR 
2.1/ECE1 and pREST-B vector were double digested with the restriction enzymes XhoI 
and NcoI which produced three bands of different sizes in pCR 2.1/ECE1 dependent on 
the site of digestion (Figure 3.9). The ECE1 band from pCR 2.1 vector was confirmed 
in lane 3, at size 773 bp, while the other two bands seen in lane 3 are from the pCR 2.1 
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vector. Lane 6 represents the pREST-B vector digested by both restriction enzymes. 
Lane 1 represents the marker ladder (Promega; 1kb DNA Ladder). The process of 
digestion was performed in order to ligate ECE1 with the pREST-B vector.  
 
 
Figure 3.9 Digestion of pCR2.1 including ECE1 (Lane 3) and pREST-B vector 
(Lane 6) by restriction enzymes XhoI and NcoI. Lane 1 represents DNA ladder, lanes 2, 
4 and 5 are empty wells. 
 
Once the digestion of pCR 2.1/ECE1 and pREST-B vector was confirmed (Figure 3.9) 
the gel was examined to visualise bands under UV, and both ECE1 band (773 bp) and 
pREST-B band (2900 bp) were excised in order to perform DNA extraction and 
complete the ligation process (Figure 3.10).   
 
 
 1     2    3    4    5    6 
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Figure 3.10 Digestion of pCR 2.1 including ECE1 (Lane 3), and pREST-B vector 
(Lane 6) by restriction enzymes XhoI and NcoI. Lane 1 represent DNA ladder, lanes 2, 
4 and 5 are empty wells. 
 
3.3.6 Amplification of ECE1 of C. albicans ATCC 14053 strain in pRSET-B after 
successful cloning 
Growing of E. coli DH5α colonies on LB media containing ampicillin indicated 
successful ligation of ECE1 into the pRSET-B vector. 12 colonies were randomly 
selected, and DNA was extracted from these 12 colonies to confirm that pRSET-B 
including ECE1 had been cloned into the E. coli DH5α cells. The DNA from 9 colonies 
of 12 colonies examined is represented by lanes 2, 5, 6, 7, 8, 9, 10, 11 and 13 and 
indicates the presence of ECE1 of expected size (773 bp) (Figure 3.11), while the DNA 
from three colonies represented by lanes 3, 4 and 12 did not show any amplified 
products. 
 1     2     3     4     5     6 
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Figure 3.11 Amplification of ECE1 769 bp product by conventional PCR using 
DNA from LB media containing 50 mg/ml ampicillin. Lanes 1 is DNA marker VI; 
lanes 2, 5-11 and 13 representing a colony with pRSETB including ECE1; lanes3, 4 
and 12 representing colonies with pRSET-B vector not including ECE1; lane 14 is no 
template control (NTC). 
 
3.3.7 Digestion of pRSET-B including ECE1 by both XhoI and NcoI restriction 
enzymes, respectively. 
The presence of ECE1 excised from pCR 2.1 vector and which was subcloned into 
pRSET-B plasmid was also confirmed in pRSET-B as described for pRC 2.1. In the 
case of pRSET-B, two bands were obtained from this digestion. The presence of the 
ECE1 fragment from the pRSET-B vector was observed at size 773 bp while the other 
band was the rest of the pRSET-B vector (Figure 3.12). 
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Figure 3.12 Digestion of pRSET-B including ECE1 (Lane 3, 5-8) by 
restriction enzymes XhoI and NcoI; and pREST-B vector as a positive control (Lane 2); 
lane 1 represents DNA ladder 
 
3.3.8 Nucleic acid sequence and protein sequence of recombinant ECE1 in C. 
albicans ATCC 14053 
Since the digestion of pRSET-B including ECE1 showed a clear band of expected size, 
sequencing was used to confirm that ECE1 has been successfully cloned into pRSET-B. 
Sequencing was performed using ECE1 forward and reverse primers designed for 
cloning purposes (Figure 3.13). This alignment showed single nucleotide 
polymorphisms between SC5314 sequence and ATCC strain sequence as seen in Figure 
3.13. 
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Figure 3.13 Nucleic acid sequence of C. albicans ATCC 14053 represented 
by ECE1-F and ECE1-R compared to reference strain SC5314 represented by ECE1-
REF. The red line under the nucleotides refers to start codon (atg) and stop codon (taa), 
while the green line refers to his-tag amino acids. 
 
Alignment of the ECE1 sequence from C. albicans ATCC 14053 (Figure 3.13) with the 
reference strain C. albicans SC5314 using the basic local alignment sequence tool 
(BLAST) revealed that the identity reached 93% (Figure 3.14). Alignment with 13 
different C. albicans strains showed that the identity ranged from 82% to 97% (Figure 
3.14). 
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Figure 3.14 Alignment of ECE1 sequences from 11 different C. albicans isolates and 
two C. dubliniensis isolates 
 
The estimated molecular mass of C. albicans ATCC 14053 rECE1 protein is 32.58 
KDa. Figure 3.15 shows the amino acid alignment of C. albicans ATCC 14053 with 
reference strain SC5314. The initiation codon atg is translated as the amino acid M 
(methionine) and finishes with an in-frame stop codon (S). Alignment also showed that 
there are 2 extra amino acids in the rECE1 protein sequence of the ATCC strain 
compared to the SC5314 strain with the different amino acid sequences are coloured 
red as shown in Figure 3.15.  
 
Sequencing of rECE1 protein showed that this protein consists of seven lysine and 
arginine motifs (KR) coloured blue in Figure 3.15 resulting in eight peptides. 
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Alignment of peptide number three sequences (Candidalysin) of SC5314 strain to 
ATCC strain 14053 showed differences in three amino acids (Figure 3.15). 
 
 
Figure 3.15 Amino acid alignment of C. albicans ATCC 14053 and with SC5314 strain. 
Differing amino acids in red and KR in blue represents the cleavage sites that reduce 
ECE1 into 8 peptides 
 
3.3.9 Amplification of ECE1 from DNA of pRSET-B after successful cloning into 
BL21 (DE3) pLysS 
Growing of BL21 (DE3) pLysS colonies on LB media containing ampicillin indicated 
the successful ligation of ECE1 into the pRSET-B vector. Four colonies were randomly 
selected and subcultured and DNA was extracted from these colonies to confirm that 
pRSET-B including ECE1 had been cloned into BL21 (DE3) pLysS cells. The DNA 
from all colonies were used to amplify ECE1 and showed the presence of ECE1 of 
expected size (Figure 3.16)  
  
  
 
 
                    10        20        30          40        50        60        70     
 SC5314     MKFSKIACATVFALSSQAAIIHHAPEFNMKRDVAPAAPA--APADQAPTVPAPQEFNTAITKRSIIGIIMGILGNIPQVI 
            :::::::::::::::::::::::::::::::.:.::. .  ::. .   .::::. ::::::::::.:::::: :::::: 
ATCC 14053  MKFSKIACATVFALSSQAAIIHHAPEFNMKREVVPAGQGDPAPGPEPQLAPAPQDVNTAITKRSIISIIMGILTNIPQVI 
                    10        20        30        40        50        60        70        80 
 
            80        90       100       110       120       130       140       150         
SC5314      QIIMSIVKAFKGNKREDIDSVVAGIIADMPFVVRAVDTAMTSVASTKRDGANDDVANAVVRLPEIVARVATGVQQSIENA 
            :::::::.::::::::::::::::::::::::.:::::::::::::::::.:::::::::::::::::::::::::.::: 
ATCC 14053  QIIMSIVRAFKGNKREDIDSVVAGIIADMPFVARAVDTAMTSVASTKRDGVNDDVANAVVRLPEIVARVATGVQQSVENA 
                    90       100       110       120       130       140       150       160 
 
            160       170       180       190       200       210       220       230         
SC5314      KRDGVPDVGLNLVANAPRLISNVFDGVLETVQQAKRDGLEDFLDELLQRLPQLITRSAESALKDSQPVKRDAGSVALSNL 
            :::::::.:::::::::::.:.::::::::::::::::::: :..::..:::::.::::::::::::::::::::::::: 
ATCC 14053  KRDGVPDIGLNLVANAPRLFSDVFDGVLETVQQAKRDGLEDVLQQLLDQLPQLIARSAESALKDSQPVKRDAGSVALSNL 
                   170       180       190       200       210       220       230       240 
 
            240       250       260       270   
SC5314      IKKSIETVGIENAAQIVSERDISSLIEEYFGKAS 
            :::::::::::::::::::::::::::::::.:: 
ATCC 14053  IKKSIETVGIENAAQIVSERDISSLIEEYFGNAS 
                   250       260       270     
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Figure 3.16 Amplification of ECE1 773 bp product by conventional PCR using DNA 
from BL21 (DE3) plysS grown in LB media containing 50 mg/ml ampicillin. Lanes 1 
DNA marker VI; lane 2 positive control; lanes 3, 4, 5 and 6 represent colonies with 
pRSET-B vector including ECE1; lane 7 is an NTC. 
 
3.3.10 Extraction of raw protein from BL21 (DE3) plysS  
Different incubation times were used to find an optimal time for the induction of cloned 
ECE1. Figure 3.17 shows the difference in the expression of the rECE1 protein after 
induction by IPTG. The best expression was found after 5 hours of induction with IPTG. 
Chapter 3 – Cloning, expression and processing 
 
118 
 
 
Figure 3.17 Identification of the presence of rECE1 protein from BL21 (DE3) pLysS, 
using SDS-PAGE gel stained with AcquaStain Blue dye. Lane 1 is a protein marker 
(15-150 KDa). Lane 2 zero-time protein expression, lanes 3-7 represent protein 
expression after induction with IPTG with one-hour differences, lane 8 protein 
expression after 24 hours. 
 
3.3.11 Identification of the size of rECE1 protein from BL21 (DE3) pLysS cloned 
into pRSET-B 
Confirmation of the presence of rECE1 protein from BL21 (DE3) pLysS using SDS-
PAGE gel stained with acquastain blue dye was the first stage of the protein expression 
experiment (Figure 3.18). 
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Figure 3.18 SDS-PAGE electrophoresis of the rECE1 protein, lane 1 protein prestained 
standards marker, lane 4, the purified rECE1 protein from BL21 (DE3) pLysS at 
32.51kDa, lanes 2 and 3 are empty wells 
 
3.3.12 Immunoblotting profile 
3.3.12.1 Immunoblotting profile using anti-histidine polyclonal antibody to 
confirm the rECE1 
Immunoblotting using anti-histidine polyclonal antibody showed blots that developed 
represented the rECE1 band (32.51kDa) within 5 min of exposure (Figure 3.19).  
   1      2      3      4 
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Figure 3.19 Immunoblotting profile using anti-polyhistidine polyclonal antibody, 
lane 1 protein prestained standards marker, lane 4, the purified rECE1 protein from 
BL21 (DE3) pLysS at 32.51kDa, lanes 2 and 3 are empty wells 
 
To confirm that rECE1 protein was extracted and purified and was of the correct size 
(32.51KDa), two SDS-PAGE were run to compare the purified rECE1 protein by 
IMAC with a whole protein extracted from BL21 (DE3) plysS contain pRSET-B 
cloned with ECE1 as a positive control and a whole protein extracted from BL21 (DE3) 
plysS containing pRSET-B (not including ECE1 and BL21 (DE3) plysS not containing 
pRSET-B as a negative control). One gel was stained with AquaStain dye (Figure 3.20 
A) and the second were used for immunoblotting profile using anti-histidine polyclonal 
antibody (Figure 3.20 B). This shows reactivity with another tiny band, with the 
strongest activity at a band of 32.51kDa. The other band may be either prematurely 
terminated protein or degradation products. 
   1      2      3      4 
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Figure 3.20 SDS-PAGE electrophoresis (A) and immunoblotting profile (B) using 
anti-histidine polyclonal antibody of the rECE1 protein, lane1 protein prestained 
standards marker, lane 2, the purified rECE1 protein from BL21 (DE3) pLysS at 32.51 
kDa, lane 4 a whole protein extracted from BL21 (DE3) plysS contain pRSET-B cloned 
with ECE1, lane 7 a whole protein extracted from BL21 (DE3) plysS contain pRSET-B 
and not including ECE1, lane 8 BL21 (DE3) plysS not containing pRSET-B as a 
negative control, lanes 3, 5 and 6 are empty wells  
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3.3.12.2 Immunoblotting with anti-ECE1 polyclonal antibody 
The immunoblotting profile using anti-histidine polyclonal antibody and rabbit 
polyclonal anti-ECE1 antibody showed that the blots developed represented rECE1 
protein from BL21 (DE3) pLysS at 32.51 kDa (Figure 3.21). This showed reactivity of 
rECE1 protein with anti-polyhistidine in lane 2 Figure 3.21, with the strongest activity a 
band of 32.51 kDa. The other bands may be either prematurely terminated protein or 
degradation products at 17 kDa.  
 
 
Figure 3.21 Immunoblotting profile using anti-polyhistidine polyclonal antibody and 
rabbit polyclonal anti-ECE1 antibody, lane 1 protein standards marker, lanes 2, 4, 6, 8 
and 10 the purified rECE1 protein from BL21 (DE3) pLysS at 32.51 kDa, lanes 3, 5, 7 
and 9 a native protein extracted from C. albicans ATCC 14053, lane 2 confirmed with 
anti-polyhistidine polyclonal antibody, while lanes 3-10 confirmed with rabbit 
polyclonal anti-ECE1 antibody in different concentrations 
 
The reactivity of rECE1 protein and the native protein extracted from C. albicans 
ATCC 14053 with rabbit polyclonal anti-ECE1 antibody in lanes 3-10 in Figure 3.21 
were very clear,  lanes (3,4), (5,6), (7,8) and (9, 10) showed detection with different 
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concentrations of rabbit polyclonal anti-ECE1 antibody at 1:50, 1:100, 1:200 and 1:300 
respectively, with the strongest activity at a concentration of 1:100. The other 17 kDa 
bands may be either prematurely terminated protein or degradation products. 
 
3.3.13 Immunoblotting with anti-ECE1 polyclonal antibody to investigate the 
expression of native ECE1 in tissue culture assay (J774 infected with C. 
albicans and treated with different concentrations of fresh garlic extract 
(FGE)) 
Immunoblotting with rabbit polyclonal anti-ECE1 antibody was used to investigate the 
expression of native ECE1 protein in a tissue culture assay infected with C. albicans 
ATCC 14053 and treated with different concentrations of FGE. This assay showed 
blots developed for a native ECE1 protein band at 32.51kDa after 30 min but within 2 
hours (Figure 3.22). This shows reactivity of native ECE1 protein band with rabbit 
polyclonal anti-ECE1 antibody in lanes 3 and 4 which represents the untreated samples 
at point of time 2 hours and 8 hours respectively, and lanes 6 and 7 which represents 
the samples treated with 20 µg/ml of FGE at point of time 2 hours and 8 hours, 
respectively (Figure 3.22), with the strongest activity a band of 32.51 kDa in the 
untreated sample at 8 hours period. The other bands may be either prematurely 
terminated protein or degradation products at 17 kDa.  
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Figure 3.22 Immunoblotting profile using rabbit polyclonal anti-ECE1 antibody, 
lane1 protein prestained standards marker, lanes 2, 3 and 4 represent untreated samples 
at 30 min, 2 hours and 8 hours, lanes 5, 6 and 7 represent the samples treated with 20 
µg/ml of FGE at 30 min, 2 hours and 8 hours, while lanes 8, 9 and 10 represent those 
samples treated with 100 µg/ml of FGE at 30 min, 2 hours and 8 hours 
 
 
3.3.14 Production of rabbit anti-ECE1 polyclonal antibody  
The amino acid sequence of our rECE1 protein was checked in the TMHMM Server v. 
2.0 to detect transmembrane domains because amino acids included in the 
transmembrane domain are embedded in the cell wall of C. albicans and unlikely to be 
useful for anti-ECE1 polyclonal antibody generation. This report indicated that part of 
this protein was embedded in the cell wall of C. albicans ATCC 14053, while another 
part was secreted outside the cell (Figure 3.23) and this was confirmed by the presence 
of a signal peptide (Figure 3.4). The analysis indicated the presence of one 
transmembrane domain in a region beginning at amino acid number 65 and ending at 
amino acid number 87 (Figure 3.23). The amino acids chosen for antibody production 
were thus selected to be before this region.  
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Figure 3.23 TMHMM result for transmembrane domain of rECE1 protein of C. 
albicans strain ATCC 14053 
 
Figure 3.24 shows the sequence of rECE1 protein and the position of peptides selected 
for the antibody generation (in red) and the position of transmembrane domain 
sequence (in blue) as confirmed by TMHMM Server v. 2.0.  
 
 
Figure 3.24 Position of polyclonal ECE1-antibody sequence represented by red 
colour and transmembrane domain sequence represented by blue colour 
 
The complete amino acids sequence of the rECE1 protein (256 a.a.) was also submitted 
to the Immunomedicine Group tools for predicting antigenic peptides. The average 
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antigenic propensity for this protein is 1.0396, and there are 13 antigenic determinants 
in this sequence (Table 3.10). One of these antigenic determinants coloured in red in 
Table 3.10 was selected for antibody generation purposes. In addition, the 
hydrophobicity of this peptide was tested for antibody production and confirmed as a 
good antigen peptide according to the analysis of the manufacturing company. This 
peptide was manufactured and used to create polyclonal antibodies (rabbit IgG 
polyclonal anti-ECE1 antibody solution) by an external provider (Abmart, Shanghai, 
China). 
 
Table 3.10 The Antigenic peptide prediction for the rECE1 protein of C. albicans 
using the Immunomedicine Group tools. Selected peptides sequence for antibody 
production in red. 
 
 
This antibody was used in Western blotting for detection of native ECE1 protein 
expression as seen in section 3.3.13 and Figures 3.21 and 3.22 and was used to 
investigate the expression time and participation of native ECE1 protein in 
morphological changes of C. albicans in the next chapter. 
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3.4 Discussion  
The work presented in this chapter aimed to clone, sequence, express and purify the 
rECE1 protein from C. albicans ATCC 14053 to be used in the next chapter for 
investigating if the rECE1 protein affects host cells through evidence of pro-
inflammatory effects and if there are any compounds used in complementary medicine 
that down-regulate this activity. 
 
In the present work, total RNA was initially extracted from the overnight culture of C. 
albicans ATCC 14053 using RNA Extraction Mini Kit then cDNA synthesis of the 
selected poly (A)+ mRNA using a cDNA Synthesis Kit. Amplification of ECE1 (size 
782 bp) was confirmed by 1.5% agarose gel electrophoresis. During our progress in 
this study, Moyes et al. (2016) also reported the isolation of RNA for ECE1 
expression. In this chapter, we describe the steps that have led to the efficient and 
reliable production of rECE1 that will enable us to perform further studies. In 
summary, these steps follow. 
 
The sequences of the ECE1 of C. albicans SC5314 were downloaded from the 
database of GenBank/NCBI and primers were designed. Optimal annealing 
temperature was determined at 57°C which yielded a product length of 782 bp.  The 
amplified PCR product was seen as a bright band confirming excellent primer 
selection for the ATCC strain used in our study. Moyes et al. (2006), had also 
successfully previously amplified ECE1 including upstream and downstream 
intergenic regions with primers ECE1-RecF3k and ECE1-RecR and cloned into 
plasmid CIp10 at MluI and SalI sites. 
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A conventional PCR was used with generated cDNA encoding ECE1 protein to 
amplify the ECE1. The purified PCR products (insert) of ECE1 were efficiently 
ligated into the pCR2.1 TOPO vector as an intermediate vector and then transformed 
into the E. coli Top 10F’strain. The recombinant plasmid pCR2.1 TOPO DNA 
containing the C. albicans ECE1 (812 bp) was also confirmed by amplification using 
specific forward and reverse primers. Sequencing of ECE1 in the recombinant plasmid 
DNA was done using specific primers, and its right orientation was confirmed. In a 
similar study by Elguezabal et al. (2005), ECE1 was expressed in E. coli and used in 
both immunoblotting and ELISA assays to detect antibodies in patients with invasive 
candidiasis (Elguezabal, et al. 2005).  
 
Recombinant plasmid (pCR2.1 TOPO) was isolated and purified from E. coli Top 
10F’strain then digested by XhoI and NcoI restriction enzymes to establish the positive 
clones. After success ligation of the ECE1 into the intermediate vector, the insert was 
ligated into the pRSET-B expression vector and transformed into E. coli DH5α. The 
resulting plasmids were digested by XhoI and NcoI to establish the identity of the 
positive clones. The purified pRSET-B (plasmid producing a protein with a histidine 
N-terminal tag) expression vector containing ECE1 was sequenced using designed 
primers, and its right orientation was confirmed then transformed into E. coli BL21 
(DE3) pLysS, specific for expression of the target protein (rECE1 protein). 
Purification of rECE1 protein was completed using an IMAC purification system for a 
6 × His-tag. This is not the first description of rECE1 detection. Birse et al. (1993) 
showed ECE1 expression detectable by using an ECE1 cDNA clone pECEC41 as a 
hybridisation probe. Our method, however, is described in full and the production of 
rECE1 has only been reported previously in a conference abstract (Elguezabal, et al. 
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2005), thus enabling other workers also to use our methodology to investigate 
recombinant ECE1 and the specifically developed polyclonal antibody for specific use 
in immunoblotting.  
 
Expression of the rECE1 protein (CaECE1p) in the pRSET-B plasmid was confirmed 
by Western blot using an anti-his antibody and by rabbit polyclonal anti-ECE1 
antibody. When analysed by SDS-polyacrylamide gel electrophoresis, the purified C. 
albicans rECE1 protein showed a molecular mass of 32.51kDa.  Birse et al. (1993) 
isolated genomic DNA from strain SC5314, partially digested with Sau3A, and then 
ligated it into the XbaI site of the vector XGEM12 following a partial fill-in reaction. 
The library was initially plated on E. coli KW251 and subsequently plated on strain 
LE392. 
 
The present study revealed that the plasmid DNA encoding ECE1 expressed the ECE1 
in the fully functional form in E. coli BL21 (DE3) pLysS. The idea to use this system 
was developed from previous successful work on the expression of eukaryotic proteins 
in bacteria. Alsharif in his PhD study (2015) used an E. coli expression system (E. coli 
BL21 (DE3) pLysS) for the cloning of tropomyosin protein into a pRSET-A plasmid 
that was then confirmed by Western blot using anti-polyhis antibody.  
 
In order to pilot whether native ECE1 protein expression could be efficiently 
visualised in a cell culture system, the developed polyclonal antibody was used to 
detect expression and repression by FGE. The macrophage cell line J774 was infected 
with ATCC strain 14053 and treated with two different concentrations of FGE (20, 
and 100 µg/ml). The experiment showed that at a concentration of 100 µg/ml, FGE 
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has a potent effect on the native ECE1 protein expression of C. albicans ATCC 14053 
with the cessation of detectable native ECE1 by Western blot at 100 µg/ml at 30 min. 
Cells treated with 20 µg/ml and analysed by Western blot indicated a reduced band of 
the native ECE1 protein indicating that 20 µg/ml of FGE was unable to stop C. 
albicans producing ECE1 protein. The untreated infected macrophages showed visible 
bands by SDS-PAGE, especially after eight hours of incubation which may be due to 
the ability of C. albicans to grow even when attacked by macrophage cells. This 
finding is the first report revealing the efficacy of FGE against C. albicans when 
infecting macrophage cells.    
 
Alignment of the ECE1 sequence with ECE1 from other published C. albicans strains 
showed an apparent variation in these sequences; this variation might be responsible 
for the varying response of isolates to treatment with garlic extract. Further work 
should be performed on isolates to determine whether this observation is aligned with 
clinical responsiveness. Also, alignment of the protein sequence of ATCC 14053 with 
SC5314 showed that ATCC strain has an extra two amino acids compared to SC5314 
with variation in many amino acids which may be related to the virulence of these 
strains especially in the sequence of peptide number three which is one of the 8 
peptides forming ECE1 protein. This peptide was recently identified as the first C. 
albicans cytotoxin and named Candidalysin. 
 
Interestingly the antibody raised for our work is not directed towards the part of ECE1 
that produces Candidalysin. The sequence for Candidalysin is predicted to be a 
transmembrane domain. This raises the question of how this peptide is cytotoxic to 
mammalian cells. It is possible that ECE1 is natively released after an attack by 
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macrophages and this allows Candida the ability to survive the immune response. Our 
finding of ECE1 production even after 8 hours of co-incubation with macrophages 
would seem to support this hypothesis. 
 
In conclusion, we have cloned and purified a secretory protein of C. albicans that can 
efficiently be expressed in E. coli. The developed polyclonal antibody was able to 
show then the effect of FGE in preventing ECE1 production in an infected 
macrophage cell line. 
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Investigation of the pro-inflammatory 
effects of rECE1 protein and effects of 
garlic in cell culture 
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4.1 Introduction 
The main reasons given for the inflammation that arises from mucosal infection with C. 
albicans are adhesion to the epithelial and subsequent secretion of hydrolases and the 
effects of morphogenesis from yeast to hyphal or pseudohyphal forms (Calcagno, et al. 
2003). This inflammation is believed to be the source of discomfort for women 
suffering from vulvovaginal candidiasis (Watson, et al. 2014). Since inflammation is 
the main problem in VVC, it may be possible to dampen this response using alternative 
medications. Investigations using a model of cellular inflammation are thus required to 
investigate this possibility. 
 
Activation of a macrophage cell line by stimulus leads to the production and release of 
pro-inflammatory cytokines; however, the extreme activation of these immune cells 
may cause severe damage to the tissues of the host's body. Cytokines are essential 
mediators of inflammatory responses. During the early stages of infection, cytokines 
play a central role in the innate immune response, by direct action against the invading 
agent or through immune-modulatory mechanisms which activate natural killer cells, 
monocytes and macrophages which then induce the release of other cytokines.  
Macrophages are primary producers of pro-inflammatory tumour necrosis factor-α 
(TNF-α) (Jouault, et al. 1994), interleukin 6 (IL-6) (Fernando, et al. 2014), and 
interleukin 1 beta (IL-1β) (Devillers, et al. 2013). Measurement of cytokines can 
indicate activation and amplification of the immune response and may help measure the 
effects of molecules that may regulate such a response. 
 
It is important to note that it has recently been shown that ece1Δ/Δ null mutant C. 
albicans strains still retain the ability to form hyphae but do not stimulate the immune 
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response of host cells (Moyes et al., 2016). A recent study that investigated the role of 
Candidalysin (a cytolytic peptide derived from the cytoplasmic processing of ECE1) on 
the cells lining the vagina has documented that Candidalysin is responsible for the 
inflammatory response and the resulting vaginal epithelial cellular damage 
(Richardson, et al. 2017). This discovery paves the way for investigations into 
alternative treatments that may help to alleviate the symptoms of VVC.  
 
The ECE1 protein contains seven KR-processing sites (lysine-arginine motifs), 
suggesting it has the potential to produce eight secreted peptides from C. albicans 
(Bader, et al. 2008). In an investigation to determine which peptide was responsible for 
epithelial activation and cellular damage, Moyes et al. (2016) synthetically produced 
these eight peptides and incubated each separately with oral epithelial cells. They found 
that only Ece1-III62–93 induced p-MKP1, c-Fos, cytokines and damage. In this study 
we will investigate the effect of purified rECE1 protein on the macrophage cell line 
J774 to determine whether rECE1 protein can induce these cells to produce pro-
inflammatory cytokines such as TNF-α, IL-6 and IL1β. 
  
It is believed that many of the genes associated with the virulence of C. albicans are 
mainly expressed during switching (Sudbery 2011; Jacobsen, et al. 2012). ECE1 is one 
of those genes that encode a membrane protein necessary for the adhesion to host cells, 
for the hyphal elongation process and biofilm formation (Fan, et al. 2013), but the 
actual timing of the secretion of the protein (exponential or post-exponential) has not 
been reported. 
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Allium sativum (garlic) has been used for medical purposes for thousands of years in 
many different cultures as mentioned in Chapter One section 1.5.5. One of the aims of 
this study was to investigate the role of garlic as a complementary medicine on the 
expression timing of ECE1 in C. albicans ATCC 14053. Through strain treatment with 
different concentrations of fresh garlic extracts in tissue culture assay (aimed to 
simulate the human body), the timing expression of native ECE1 protein will be 
described though the use of confocal microscopy and the use of the anti-ECE1 
polyclonal antibody developed in Chapter Three. 
 
The aims of this chapter are: 
1- To check that purification of rECE1 is sufficient to remove any contaminating 
endotoxin that may produce confounding inflammatory effects  
2- To investigate if the rECE1 protein can produce pro-inflammatory effects in a 
cell culture assay by inducing the production and release of inflammatory 
mediators (cytokines TNF-α, IL-1β and IL-6). 
3- By using laser scanning confocal microscopy (LSCM), investigate if ECE1 
protein participates in the morphological switch of yeast to hyphal form using 
our polyclonal ECE1-antibody. 
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4.2 Materials and Methods 
4.2.1 Protein preparation 
ECE1 was cloned into an E. coli cloning system and the rECE1 purified using an 
IMAC column and purification was confirmed by Western blotting using rabbit anti-
histidine polyclonal antibody (Chapter Three). 
 
4.2.1.1  Lipopolysaccharide (LPS) removal from rECE1 protein preparation 
The presence of residual LPS mixed with purified rECE1 protein was one possible 
confounding factor for planned experiments measuring inflammatory effects of 
recombinant proteins. This contamination is due to the presence of endotoxin in the 
outer membrane of gram-negative bacteria and the breakdown of the outer membrane 
of E. coli that occurs during the expression and production of rECE1 protein. Endotoxin 
is known to be a potent mediator of inflammation and thus might be the cause of any 
immune response when rECE1 protein is investigated. Contaminating LPS was 
removed from the protein preparation by phase separation using Triton X-114 (Aida 
and Pabst 1990). For Triton X-114 extractions, 1/20 volume of Triton X-114 (Sigma 
Aldrich) was added to the rECE1 protein solution. Samples were placed in an ice bath 
for 5 min to ensure a homogenous solution. After vortexing the chilled samples, the 
tubes were warmed at 37°C for 5 min to allow two phases to form. The solution was 
centrifuged for 10 min (8000 × g) at room temperature. After centrifugation, the 
detergent phase was found as an oily droplet at the bottom of the tube. The upper 
aqueous phase was removed with care so as not to aspirate the detergent phase. This 
cycle was repeated three times to ensure the complete removal of endotoxin. It has been 
reported that proteins treated by this procedure retain standard functions (Aida and 
Pabst 1990). The LPS content in the treated rECE1 protein was measured by the 
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Chromogenic Limulus Amebocyte Lysate assay (LAL) according to the manufacturer's 
instructions (Bio Whittaker, Walkersville, MD, USA). 
 
4.2.1.2  Measurement of endotoxin (LPS) by Limulus amebocyte lysate 
assay (LAL) 
To determine the amount of the remaining endotoxin, ToxinSensor™ chromogenic LAL 
Endotoxin Assay Kit (GenScript, Piscataway, NJ, USA) was used. An endotoxin 
standard (100 μl) and samples (100 μl) were added into endotoxin-free vials. The pH of 
standard and samples were adjusted to pH 7.0. Limulus amebocyte lysate reagent was 
added to each vial and mixed thoroughly. The bottles were incubated at 37°C for 
45 min. After incubation, 100 μl of chromogenic substrate solution was added to each 
vial and incubated at 37°C for 6 min. Five hundred microliters of stop solution and 
500 μl of colour-stabiliser (#2 and #3) were added to each vial and mixed well. The 
absorbance of each reaction at 545 nm was analysed by spectrophotometer. After 
examining the absorbance, endotoxin units were calculated using a standard curve 
obtained using a standard solution provided with the kit. 
 
4.2.1.3 Dialysis  
Dialysis was used to reduce the salt concentration and to concentrate the target protein. 
A dialysis bag (Sigma Aldrich) of defined porosity (a pore size was selected to be less 
than the molecular weight of the target by at least half). Dialysis tubing with a cut-off 
of 12 kDa was prepared according to Sambrook et al. (1989) and always handled with 
gloves. The tube was cut to 20 centimetres in length and boiled for 10 min in 500 ml of 
2% (w/v) sodium bicarbonate containing 1 mM EDTA at pH 8.0. The tube was rinsed 
with MQ water and then boiled for 10 min in 500 ml of 1 mM EDTA pH 8.0. The tube 
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was stored in 500 ml of 1 mM EDTA, pH 8.0 at 4°C. Before dialysis, the tube was 
washed inside and out with MQ water. After IMAC purification of the rECE1 protein, it 
was dialysed in exchange buffer in order to remove any components that might 
interfere with the binding of the protein in a tissue culture assay. 10 ml of the IMAC 
purified protein was placed in the dialysis tube, and the tube ends were sealed with 
clamps. The tube was then submerged in 1 litre of dialysis buffer (100 mM NaCl 
(BDH) pH 7.6) and incubated with stirring at 4oC. The dialysis buffer was changed at 
least four times, at a minimum of 12 h apart. Once equilibration was completed, the 
dialysis tube was placed in a plastic bag and covered with polyethylene glycol 6000 
(BDH Chemicals, Kilsyth, Victoria. Australia) in order to concentrate the rECE1 
protein. The final volume of the concentrated solution in the bag was less than the 
starting volume due to osmotic effects. After 6 hours, the dialysis tube was washed with 
MQ water, and the container was ruptured, and the solution poured off into a collection 
vessel for protein measurement by the Bradford method. 
 
4.2.1.4 Estimation of protein by the Bradford method 
The Bradford assay was used to determine the concentration of rECE1 protein resulting 
after dialysis. Briefly, the Bradford protein assay kit (Bio-Rad) was used to quantify the 
purified rECE1 protein. Two-fold dilutions of BSA (16, 8, 4, 2, 1 and 0.5 mg/ml) were 
used as standards. Five samples of rECE1 protein purified by IMAC and concentrated 
by dialysis were prepared using PBS buffer, which was also used as a blank. 20 µl of 
the six concentrations of BSA diluted samples and PBS were pipetted into a 96 well 
microplate in triplicate and then 200 µl of Bradford reagent was added to these wells 
using a multichannel pipette. A Thermo Scientific Multiskan Ascent Microplate 
Photometer (Bio-Rad) was used to read the absorbance values at 595 nm. 
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4.2.1.5 Media and reagents 
Phosphate buffered saline was prepared by either dissolving one tablet of commercial 
dehydrated PBS (Thermo Fisher) in 100 ml distilled water or prepared from 8 g of 
NaCl, 0.2 g of KCl, 1.44 g of Na2HPO4 and 0.24 g of KH2PO4 dissolved in 1 litre of 
distilled water and the pH adjusted to 7.3. All PBS solutions were sterilised by 
autoclaving. Fetal bovine serum (FBS) (Thermo Fisher) was heat inactivated by 
incubating in a water bath at 37oC for 30 min then raising the temperature to 56oC for a 
further 30 min. FBS was then cooled at room temperature and stored at -20oC. 
Penicillin-streptomycin was purchased from Invitrogen (Gibco®, USA) and added as 
0.1% to Dulbecco’s modified Eagle medium (DMEM) (Thermo Fisher) for the tissue 
culture assay. Trypsin (10x) (Thermo Fisher) was diluted and used at 1x concentration 
with EDTA 0.5 mM for cell trypsination. Trypan Blue Solution 1% (w/v) (Sigma 
Aldrich) was dissolved in sterile PBS. To prepare 500 ml volume of culture medium, 
50 ml of heat-inactivated FBS was filtered using a 0.22 µm filter and 0.5 ml of 
penicillin and streptomycin then added to 450 ml of DMEM. This was liquated into 50 
ml portions in Falcon tubes and stored at -4oC until use.  
 
4.2.1.6 Tissue culture cell lines 
The mouse macrophage-like J774 cell line (ECAC 85011428), derived from a tumour 
of a female BALB/c mouse, originates from the European Collection of Cell Cultures 
(ECAC) and was commercially sourced from Sigma Aldrich. Adherent cells were 
cultured at 37°C in an atmosphere containing 5% CO2 in DMEM supplemented with 
10% heat-inactivated fetal calf serum (FCS) (Valbiotech, Paris, France), five mM L-
glutamine, 100 μg/ml streptomycin, and 50 μg/ml penicillin. Cultures were split by 
removing the media and washing twice in PBS. Trypsin solution and five mM EDTA 
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were added to an appropriate volume in a ratio of 1:1, and the flask was incubated at 
37oC for 5-10 min in 5% CO2. The dissociated cells were removed from the flask and 
washed twice in RPMI medium. An appropriate volume of cells was used to seed a new 
flask or flasks. 
 
4.2.1.7 Storage and maintenance of cell lines 
Tissue culture cells were stored in liquid nitrogen in complete DMEM supplemented 
with 5% DMSO as a cryo-protectant. Cells were dissociated by adding trypsin and 
incubated for 10 min in a tissue culture incubator (37°C, 5% CO2). They were 
transferred to a centrifuge tube, washed twice and centrifuged at 1000 x g for 5 min. 
The cells were stored at -70oC for 2-3 days before transferring them to liquid nitrogen 
for more permanent storage. 
 
4.2.2 Determination of pro-inflammatory response of J774 against rECE1 protein 
J774 macrophage cells were maintained in complete HEPES (25 mM) buffered media 
(DMEM) supplemented with 10% heat-inactivated fetal calf serum, glutamine (2 mM), 
penicillin (100 U/ml) streptomycin (100 U/ml) in stirring flasks and used in the log 
phase of growth. 
 
4.2.2.1 Activation of J774 cells 
Cells were grown as in section 4.2.1.6 in complete DMEM supplemented with 10% 
heat-inactivated fetal calf serum in preparation for treatment with rECE1 protein and 
lipopolysaccharides (LPS). 
 
 
 Chapter 4 – Investigation of the pro-inflammatory 
 
141 
 
4.2.2.2 Cell counts  
Cell counting was performed using a Countess™ Automated Cell Counter (Thermo 
Fisher) according to the manufacturer’s protocol. In brief, ten µl of 0.4% Trypan Blue 
and 10 µl of cell suspension were mixed and then placed into a cell counting chamber 
slide. 
 
4.2.2.3 Treatment of macrophage cell line J774 with rECE1 protein 
Cells growing in suspension were centrifuged at 1000 x g for 5 min, then resuspended 
at 3 x 106 cell/ml in complete DMEM media and 3 X 105 cell/ml were pipetted into 15 
well plates (2 X 104 per well) (Figure 4.1). Three plates of 6 well plates were used to 
prepare cells treated with different concentrations of rECE1 protein (5, 10 and 15 
µg/ml). Powdered LPS was purchased from Sigma-Aldrich (O127:B8) and disolved in 
water to obtain a final concentration of 10 µg/ml, and then kept at -20°C until use. LPS 
was used as a positive control, while untreated cells were used as a negative control in 
this experiment. After incubation of these three plates for three different periods (2, 4, 
and 8 hours) in the tissue culture incubator, the culture supernatants were removed and 
stored at -20°C for cytokine measurements. Untreated cells were used as a negative 
control. 
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Figure 4.1 Flow chart of ELISA assay or for determination of pro-inflammatory 
response of J774 against rECE1 protein 
 
4.2.2.4 Cytokine ELISA 
A TNF-α, IL-6 and IL-1β ELISA Ready-SET-Go! ® KIT (eBioscince, San Diego, CA, 
USA) was used to measure the three target cytokines following the manufacturer’s 
instructions. In brief, an Ultra Cruz® ELISA high binding, 96 well flat bottom plates 
(VWR International, Murarrie, QLD, Australia) was coated with 100 µL/well of 
capture antibody (Chapter Three) in 1x coating buffer (diluted from 10 x coating buffer 
included with the reagent set). The plate was sealed and incubated overnight at 2-8°C. 
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The wells were then aspirated and washed three times with 300 µL/well wash buffer 
(PBS; Tween 20, 0.02%). Wells were soaked (~ 1 min) with wash buffer during each 
wash step to increase the effectiveness of the washes. The plate was then blotted on 
absorbent paper to remove any residual buffer. One part 5 x ELISA/ELISPOT diluent 
was diluted with four parts DI water. Wells were blocked with 200 µL/well of 1 x 
ELISA/ELISPOT diluent, and the plate was incubated at room temperature for 1 hour. 
Wells were aspirated and washed once with wash buffer. 10 ml DI water was used to 
reconstitute the lyophilised standards (10 mg). The mixture could sit for 15 min with 
gentle agitation before diluting further. One x ELISA/ELISPOT diluent was used to 
dilute the reconstituted standard to prepare 2-fold serial dilutions of the top standards to 
make the standard curve for a total of 8 dilutions. 100 µL/well of samples and standard 
were added to the appropriate wells and two wells with 100 µL/well of 1 x 
ELISA/ELISPOT diluent were included to serve as plate blanks. The plate was sealed 
and incubated overnight at 2-8°C to ensure maximal sensitivity. The plate was aspirated 
and washed for a total of 5 washes with wash buffer (PBS; Tween 20, 0.02%) and 
soaked (~ 1 min) during each wash step to increase the effectiveness of the washes. 
Then 100 µL/well of detection antibody was diluted in 1 x ELISA/ELISPOT diluent 
and added to each well. The plate was sealed and incubated at room temperature for 1 
hour then aspirated and washed as the last step for a total of 5 washes. 100 µL/well of 
the kit supplied Avidin-HRP diluted in 1 x ELISA/ELISPOT diluent was added, and 
the plate was sealed and incubated at room temperature for 30 min. The plate was 
aspirated and washed as in the last step. In this wash step, wells were soaked in wash 
buffer for 2 min before aspiration and repeated for a total of 6 washes. 100 µL/well of 
kit supplied 1 x TMB Solution were added to each well and the plate was incubated at 
room temperature for around 5 min until the colour was developed, then 50 µL of kit 
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supplied stop solution (H2SO4) was added to each well. The plate was read at 450 nm in 
a spectrophotometer (Eppendorf UK Limited). In this assay, the intensity of the colour 
reaction was directly proportional to the concentration of bound labelled TNF-α or IL-6 
or IL-1β antibodies, which in turn, was equivalent to the quantity of TNF-α or IL-6 or 
IL-1β in the samples. TNF-α or IL-6 or IL-1β concentrations in the cultures were 
determined by interpolation from the standard curves. 
 
4.2.3 Investigation of the role of native ECE1 protein in the morphological switch 
of yeast to hyphal form 
It has been reported that ECE1 expression is involved in cell regulation and cell shape 
(Sharkey, et al. 1999), but its exact time of expression in the cell cycle is still unknown. 
In this experiment, the expression timing of native ECE1 protein will be investigated 
using the polyclonal ECE1-antibody generated against 12 amino acids of ECE1 protein 
of ATCC strain 14053 (Chapter 3, section 3.3.14).  
 
4.2.3.1 Strains and media 
C. albicans ATCC 14053 was used and stored in 20% (v/v) sterile glycerol as a stock at 
-80°C. For all experiments, the strain was subcultured in yeast peptone dextrose broth 
(YPD) at 37°C to induce the yeast form for 24 hrs, or RPMI containing 2% glucose at 
37°C to induce the hyphal form according to the protocol of Urban et al. (2006) with 
slight modifications. In brief, the yeast strain was grown on SDA at 37°C for 24 hrs, 
and then ten colonies were inoculated into 5 ml of YPD and incubated at 37°C for 24 
hrs. A suspension containing 1x106 cells/ml of the strain was prepared in standard 
RPMI 1640 medium (with 0.2% glucose and buffered to pH 7.0 and with MOPS (0.165 
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M)) and then incubated at 37°C. One ml of broth was collected in Eppendorf tubes 
every 30 min, 2, 4 and 8 h and kept at -80°C. 
4.2.3.2 Immunofluorescence staining and laser scanning confocal microscopy 
For the immunofluorescence staining procedure, samples were centrifuged at 7000 x g 
for 10 min and washed with sterile PBS three times. 200 µl of paraformaldehyde was 
then added for fixation and cells were washed with PBS and centrifuged three times as 
before. 200 µl of blocking buffer (1% BSA) was then added to each sample and 
incubated for 1 hour at room temperature. During that time, primary and secondary 
antibodies were prepared and diluted in blocking buffer and placed on ice until 
required. For the labelling step, 200 µl of rabbit IgG polyclonal anti-ECE1 antibody 
solution (primary antibody, section 3.3.14) was added directly to the cells and 
incubated at 4°C overnight. The samples were then washed with PBS and centrifuged 
for three times as before. Subsequently, 200 µl of HRP mouse anti-rabbit IgG 
secondary antibody conjugated to FITC was added directly to the sample, then 
incubated at room temperature for 30 min and washed with PBS and centrifuged three 
times. The sample was then stained with DAPI for 1-3 min and washed with PBS and 
centrifuged three times. 1 ml of PBS buffer was added to each sample and transferred 
from the Eppendorf tubes to 24 well plates. Cells were viewed and analysed by laser 
scanning confocal microscopy (LSCM; Eclipse Ti Confocal Microscope, Nikon 
Instruments Inc., Melville, NY). 
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4.2.4 Investigation of the role of native ECE1 protein in the morphological switch 
of yeast to hyphal form in tissue culture assay (J774 infected with C. albicans and 
treated with different concentrations of fresh garlic extract) 
To test the effect of different levels of fresh garlic extract on the adhesion and 
morphogenesis processes of C. albicans in cell culture assay, the expression of native 
ECE1 protein was investigated following infection with C. albicans of the macrophage 
cell line J774 and subsequent treatment with different concentrations of fresh garlic 
extract and viewed over different time periods.  
 
4.2.4.1 Strains and media 
Strains and media were prepared as in section 4.2.3.1 with the additional step that cells 
were counted and reconstituted to a concentration of 2 x 108 cell/ml in RPMI media 
without antibiotics or FBS and stored at 4°C until needed. 
 
4.2.4.2 Scanning electron and confocal immunofluorescence microscopy 
For microscopic assays, 1 ml of a suspension solution containing 4 × 105 cells/ml of 
macrophage cell line J774 were added to each well (12 well plates) and incubated 
overnight in a tissue culture incubator. One ml of complete DMEM medium containing 
5 x 104 cells/ml of C. albicans ATCC 14053 was then added to each well. For 
immunostaining, DMEM supplemented with 10% heat-inactivated fetal calf serum was 
used. Before infection of cells, the ATCC strain 14053 was subcultured for four hours 
in YPD broth at 37°C to induce blastospores. After addition of the yeast, different 
concentrations of fresh garlic extract (20 and 100 µg/ml) were added to wells and plates 
were incubated in a tissue culture incubator. Incubation time points were 30 min, 2 
hours, 8 hours and 24 hours for three dishes. After incubation, the supernatant was 
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decanted, and the co-cultures washed with warm DMEM and fixed with 3.7% 
formaldehyde, then permeabilised with 0.2% Triton X-100 in phosphate buffer at 20°C 
for 20 min. The co-cultures were then blocked overnight (1% bovine serum albumin, 
0.05% Tween-20 in PBS) and incubated with primary antibody (polyclonal ECE1-
antibody). For double labelling, the sample was incubated with FITC-conjugated 
secondary antibodies (1:1000) and tetramethylrhodamine isothiocyanate (TRITC)-
conjugated phalloidin (1:200) for 1 hour at room temperature, followed by washing 
three times with wash buffer for 10 min each. The cell nuclei were then counterstained 
by DAPI (1:2000) for 5 min. Finally, the sample was again washed three times with 
buffer solution for 10 min each time prior to analysis using LSCM. 
 
4.2.5 Statistical analysis  
Statistical analysis was performed using Microsoft Excel 2010 (Microsoft Co-
operation, USA) and GraphPad Prism Version 7. All data were analysed with one-way 
ANOVA. Each experiment was repeated three times and in triplicate. All values were 
expressed as mean ± standard deviations, and results were considered significant at P < 
0.05. 
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4.3 Results 
4.3.1 Purification of rECE1 and removal of the contaminanting LPS  
Purification of rECE1 protein was performed by an IMAC purification system as it has 
high affinity for his-tagged protein. Further purification of rECE1 removed endotoxins 
was determined through measurements using the Toxin-Sensor™ chromogenic LAL 
Endotoxin Assay Kit. Figure 4.2 shows the concentration of LPS in the rECE1 protein 
sample was less than 0.01 EU/ml (0.0003 EU/ml) which is considered endotoxin free 
(Ma, et al. 2012). 
 
 
Figure 4.2 Detection the amount of LPS in protein sample by Limulus assay 
 
4.3.2 Determination of pro-inflammatory response of J774 against rECE1 protein 
The rECE1 protein from C. albicans ATCC 14053 was used to check its pro-
inflammatory effects in cell culture assay. The roles of the cytokines examined in this 
study are summarised in Table 4.1. 
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Table 4.1 Characteristics of cytokines implicated in the innate response 
Cytokine Structure Producing C. Function 
TNFα Homotrimer 
(17KD) 
Macrophages, 
Lymphocytes, 
N cells and 
Monocytes 
Local inflammation  
Permeability 
Heat changes 
IL6 Monomer 
(26KD) 
Lymphocytes 
Macrophages 
T and B Lymphocytes activation 
IL-1β Monomer 
(20KD) 
Macrophages Elevation of the temperature  
T Lymphocytes and Macrophages 
activation 
 
4.3.2.1 TNF-α  
Figure 4.3 shows a significant increase in TNF-levels after treatment with rECE1 of 
J774 macrophages in comparison to untreated cells (P < 0.005). At two hours of 
treatment with three different concentrations of rECE1 protein (Figure 4.3 A), the level 
of production of TNF-α in J774 increased dramatically and this was also seen with 
increasing strength of rECE1 protein. The highest concentration (15 µg/ml) induced a 
TNF-α response similar to the effect of 10 µg/ml LPS at the same time point (Figure 
4.3 A). The four-hour treatment showed the highest concentration of TNF-α. 
Significant increases in TNF-α level were seen with the different protein concentrations 
(5, 10 and 15 µg/ml) of rECE1 protein (P < 0.005). Importantly, the highest 
concentration of TNF-α was seen with protein at 15 µg/ml (4-hour treatment) (Figure 
4.3 B) and was higher than that caused by LPS.  
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In contrast, the increase in TNF-α production was almost the same after eight hours of 
treatment of J774 cells with different concentrations of rECE1 protein (Figure 4.3 C). 
Production of this cytokine showed a significant increase compared to the untreated 
samples at the same time. The levels of cytokine measured were all significantly 
different from the control at P < 0.005. 
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Figure 4.3 TNF-α cytokine response of J774 macrophage to 3 different concentrations 
of rECE1 protein and one concentration of LPS. J774 macrophage was challenged with 
varying doses of rECE1 protein for 2 hours Figure A, 4 hours Figure B and 8 hours 
Figure C. The bars represent one SD of the mean of triplicate TNF-α measurement. 
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Overall the results indicated that rECE1 has similar properties to LPS in stimulating 
macrophages to produce TNF-α cytokine (Figure 4.4). 
 
Figure 4.4 TNF-α cytokine response of J774 macrophage to 3 different concentrations
of rECE1 protein and one concentration of LPS. J774 macrophage was challenged with 
different doses of rECE1 protein for 2, 4 and 8 hrs. The bars represent one SD of the 
mean of triplicate TNF-α measurement. 
  
4.3.2.2 IL-6  
Both the positive control (LPS) and the rECE1 protein significantly induced the 
macrophage J774 cell line to produce IL-6 cytokine in comparison to untreated cells (P 
<0.005). The IL-6 levels dramatically increased with time of incubation and protein 
concentrations (Figure 4.5). 
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Figure 4.5 IL-6 cytokine responses of J774 macrophage to 3 different concentrations
of rECE1 protein and one concentration of LPS. J774 macrophage was challenged with 
different doses of rECE1 protein for 2 hours Figure A, 4 hours Figure B and 8 hours 
Figure C.  The bars represent one SD of the mean of triplicate IL-6 measurements. 
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Figure 4.6 shows that the stimulation of IL-6 in macrophage J774 was strongly related 
to the change in the time of incubation rather than the change in the concentration of 
the protein of interest (rECE1) or the positive control (LPS). 
 
 
Figure 4.6 IL-6 cytokine responses of J774 macrophage to 3 different concentrations
of rECE1 protein and one concentration of LPS. J774 macrophage was challenged with 
different doses of rECE1 protein for 2, 4 and 8 hrs. The bars represent one SD of the 
mean of triplicate IL-6 measurement 
 
The levels of IL-6 cytokine measured were all significantly different from the control at 
P < 0.005. 
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Levels of IL-1β were at their highest at 8-hour of treatment (Figure 4.7 C). The results 
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Figure 4.7 IL-1β responses of J774 macrophage to 3 different concentrations
of rECE1 protein and one concentration of LPS. J774 macrophage was challenged with 
different doses of rECE1 protein for 2 hours Figure A, 4 hours Figure B and 8 hours 
Figure C. The bars represent one SD of the mean of triplicate IL-1β measurements 
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Figure 4.8 shows that the stimulation of IL-1β in macrophage J774 was strongly related 
to the change in the time of incubation rather than the change in the concentration of 
the protein of interest (rECE1) or the positive control (LPS). 
 
 
Figure 4.8 IL-1β responses of J774 macrophage to 3 different concentrations
of rECE1 protein and one concentration of LPS. J774 macrophage was challenged with 
different doses of rECE1 protein for 2, 4 and 8 hrs. The bars represent one SD of the 
mean of triplicate IL-1β measurements.  
 
The levels of IL-1β cytokine measured were all significantly different from the control 
at P < 0.005. 
 
 
IL -1   le v e l
I
L
-
1

(
n
g
/m
l)
2
 h
4
 h
8
 h
5
 µ
g
/m
l
1
0
 µ
g
/m
l
1
5
 µ
g
/m
l
5
 µ
g
/m
l
1
0
 µ
g
/m
l
1
5
 µ
g
/m
l
5
 µ
g
/m
l
1
0
 µ
g
/m
l
1
5
 µ
g
/m
l
2
 h
 L
P
S
4
 h
 L
P
S
8
 h
 L
P
S
0 .0
0 .1
0 .2
0 .3
0 .4
0 .5
U n - t r e a t e d 2  h  r E C E 1 4  h  r E C E 1 8  h  r E C E 1 1 0  µ g / m l
 Chapter 4 – Investigation of the pro-inflammatory 
 
157 
 
4.3.3 Investigation of the role of native ECE1 protein in participating in the 
morphological switch of yeast to hyphal form 
The expression time of native ECE1 protein and its time of production were examined 
by confocal microscopy using the developed polyclonal ECE1-antibody.  
 
Gram staining of C. albicans was used to confirm transformation from the yeast to 
hyphal form. The beginning of hyphae formation was seen at 30 minutes (Figure 4.9A). 
Hyphae were prominent after 2 hours of incubation, while after 8 hours of incubation, 
the hyphae had become more elongated and branching and at 24 hours, this resulted in 
a net-like structure (Figure 4.9).  
 
 
Figure 4.9 Representative light microscopy images revealing the growth stages
of C. albicans stained with Gram stain at four different times 30 min (A), two hours (B), 
eight hours (C), and 24 hours (D) 
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In order to detect the localisation of the native ECE1 protein during growth, fixed yeast 
and hyphae were treated with polyclonal ECE1-antibody and then incubated with 
FITC-conjugated secondary antibodies (1:1000) and counterstained by DAPI. 
 
Figure 4.10 shows that native ECE1 protein (FITC, bright green fluorescence) was 
produced by some yeast cells at 30 min. It was not possible to see hyphae at this stage.  
 
 
Figure 4.10 Confocal images of J774 macrophage cells after 30 min of
infection with C. albicans ATCC 14053. Native ECE1 protein is stained brightly green 
with secondary antibody conjugated FITC. DNA is stained blue by DAPI. The scale 
bars represent 50 μm in length. 
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After two hours the hyphal form was apparent (Figure 4.11). A similar staining pattern 
was seen for the DNA stain and the presence of anti-ECE1 (Figure 4.11).  
 
 
Figure 4.11 Confocal images of J774 macrophage cells after 2 hours of
infection with C. albicans ATCC 14053. Native ECE1 protein is stained green with 
secondary antibody conjugated FITC. DNA is stained blue by DAPI. The scale bars 
represent 50 μm in length. 
 
Figure 4.12 shows the growth at 8 hours. There seems to be two populations of cells, 
one staining equally strong with DAPI and the anti-ECE1 stain and the second 
population of cells staining less intense in most cells. Only the round yeast forms 
(blastospores) are brightly stained, rather than the hyphal elements. 
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Figure 4.12 Confocal images of J774 macrophage cells after 8 hours of
infection with C. albicans ATCC 14053. Native ECE1 protein is stained green with 
secondary antibody conjugated FITC. DNA is stained blue by DAPI. The scale bars 
represent 50 μm in length. 
 
At twenty-four hours of growth, DAPI staining seems to be restricted to the center of 
cells possibly indicating less mitochondrial activity. The intensity of native ECE1 
staining seems to be at its greatest, indicating that native ECE1 production may be at its 
greatest at post exponential growth (Figure 4.13). Some hyphae seem to be staining but 
this may due to excess ECE1 protein production from nearby yeast cells. 
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Figure 4.13 Confocal images of J774 macrophage cells after 24 hours of
infection with C. albicans ATCC 14053. Native ECE1 protein is stained green with 
secondary antibody conjugated FITC. DNA is stained blue by DAPI. The scale bars 
represent 50 μm in length. 
 
 
4.3.4 Investigation of the role of native ECE1 protein in the morphological switch 
of yeast to hyphal form in tissue culture assay in the presence of FGE 
The treatment with different concentrations of FGE (20 µg/ml and 100 µg/ml) was used 
to determine the effect of FGE on production of native ECE1 protein of C. albicans 
ATCC 14053 in cell culture assay using J744 macrophages as a model of human 
infection and visualised by LSCM. 
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No expression of ECE1 was seen in treated cells (Figures 4.16, 4.17, 4.18 and 4.19) at 
30 min or 2 hours compared to control untreated cells (Figures 4.14 and 4.15).  
 
 
Figure 4.14 Confocal images of untreated J774 macrophage cells infected with
C. albicans ATCC 14053 after 30 minutes of incubation. Green colour refers to the 
stain of native ECE1 protein or cross-reactivation with the J774 nucleus. Nuclei are 
stained blue by DAPI. The scale bars represent 10 μm in length. 
 
 
Figure 4.15 Confocal images of untreated J774 macrophage cells infected with
C. albicans ATCC 14053 after 2 hours of incubation. Green colour refers to the stain of 
native ECE1 protein or cross-reactivation with the J774 nucleus. The scale bars 
represent 20 μm in length.  
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Figure 4.16 Confocal images of J774 macrophage cells infected with C. albicans 
ATCC 14053 and treated with different concentrations of FGE and incubated for 30 
min. (Top panel A, control) that of 30 min with no treatment, (middle panel B) is 30 
min treatment with 20 µg/ml of FGE and (bottom panel C) is 30 min treatment with 
100 µg/ml of FGE. Green colour refers to the stain of ECE1 protein or cross-
reactivation with the J774 nucleus. Nuclei were stained blue by DAPI, and F-actin was 
stained red by conjugated phalloidin. Images were overlaid in the first column. The 
scale bars represent 50 μm in length. 
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Figure 4.17 Confocal images of J774 macrophage cells infected with C. albicans 
ATCC 14053 and treated with different concentrations of FGE and incubated for 2 
hours. (Top panel A, control) That of 2 hours with no treatment, (middle panel B) is 2 
hours treatment with 20 µg/ml of FGE and (bottom panel C) is 2 hours treatment with 
100 µg/ml of FGE. Green colour refers to the stain of ECE1 protein or cross-
reactivation with the J774 nucleus. Nuclei were stained blue by DAPI, and F-actin was 
stained red by conjugated phalloidin. Images were overlaid in the first column. The 
scale bars represent 50 μm in length. 
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Figure 4.18 Confocal images of J774 macrophage cells infected with C. albicans 
ATCC 14053 and treated with different concentrations of FGE and incubated for 8 
hours. (Top panel A, control) that of 8 hours with no treatment, (middle panel B) is 8 
hours treatment with 20 µg/ml of FGE and (bottom panel C) is 8 hours treatment with 
100 µg/ml of FGE. Green colour refers to the stain of ECE1 protein or cross-
reactivation with the J774 nucleus. Nuclei were stained blue by DAPI, and F-actin was 
stained red by conjugated phalloidin. Images were overlaid in the first column. The 
scale bars represent 50 μm in length 
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Figure 4.19 Confocal images of J774 macrophage cells infected with C. albicans 
ATCC 14053 and treated with different concentrations of FGE and incubated for 24 
hours. (Top panel A, control) that of 24 hours with no treatment, (middle panel B) is 24 
hours treatment with 20 µg/ml of FGE and (bottom panel C) is 24 hours treatment with 
100 µg/ml of FGE. Green colour refers to the stain of ECE1 protein or cross-
reactivation with the J774 nucleus. Nuclei were stained blue by DAPI, and F-actin was 
stained red by conjugated phalloidin. Images were overlaid in the first column. The 
scale bars represent 50 μm in length 
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4.4 Discussion 
In this study, incubation of macrophage J774 cells with rECE1 protein and LPS 
stimulated the macrophages to produce TNF-α, IL-6 and IL-1β as pro-inflammatory 
mediators. TNF-α is one of the first and the most potent pro-inflammatory cytokines 
produced by stimulated macrophage cells and plays an essential role in immunity, 
although it also plays a role as a cause of inflammation (Beutler 1999).  
 
Blasi et al. stated in their publication (1992) that the hyphal form of C. albicans can 
work as a stimulating agent but not the yeast form when cells are incubated for a short 
time (1-3 hours). However two years later they reported that the yeast form also was 
able to induce macrophage cells to produce TNF-α after 3-24 hours of incubation (Blasi, 
et al. 1992; Blasi, et al. 1994). In vitro, peripheral blood mononuclear cells are 
stimulated extensively by C. albicans blastospores to secrete the TNF-α while the 
stimulation by hyphae to secrete TNF-α was found to be much less (Filler 2006).  
 
Several proteins produced during the transformation of C. albicans from the yeast form 
to the hyphal form have been identified that stimulate macrophages to produce TNF-α 
(Matuschak and Lechner 1997). In a study conducted by Rohm (2013) looking at the 
role of ECE1 in the damage of the mucosal epithelia, found that only hyphae producing 
strains were able to induce MKP1 phosphorylation, cytokines and damage in oral 
epithelial cells. It is important to note that the ece1Δ/Δ null mutant C. albicans strains 
still retains the ability to form the hyphal form (Birse, et al. 1993) but cannot stimulate 
the immune response of host cells (Moyes, et al. 2016).  
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In this study, rECE1 stimulated J774 macrophage to produce IL-6; however, this 
stimulus was gradually reaching its highest level after eight hours of stimulation. IL-1β 
was also studied in this experiment, since IL-1β cytokine is an essential mediator of the 
inflammatory response, and is involved in a variety of cellular activities, including cell 
proliferation, differentiation, and apoptosis production. This study found that the levels 
of IL-1β from macrophage cells stimulated by rECE1 protein were not significant at 
two and four hours of incubation, but these levels were elevated at eight hours. This 
difference might be due to the way that IL-1β produced. The IL-1β precursor is cleaved 
by cytosolic caspase 1 (interleukin 1 beta convertase) to form mature IL-1β, and this 
process takes time (Dinarello 2009). 
 
In a recent study investigating the toxicity of ECE1 protein using synthetic peptides 
derived from the ECE1 protein  (Moyes, et al. 2016), it was reported that only the 
Ece1-III 62–93 peptide (Candidalysin) induced p-MKP1, c-Fos, cytokines production, 
and damage to oral epithelial cells. They also reported that low concentrations of 
Candidalysin (1.5–15 μM) were able to produce c-Fos DNA binding, G-CSF and GM-
CSF, while only a high concentration of Ece1-III 62–93 (70 μM) induced damage and 
elicited the damage-associated cytokine IL-6  (Moyes, et al. 2016). It is interesting to 
speculate whether this observation is specific to strain SC5314 as we were able to 
observe inflammation with our rECE1 which a whole protein was rather than the 
cleaved peptide. 
 
A stated aim of this chapter was to see if ECE1 participated in the morphological 
switch of yeast to hyphae. There was no evidence that our antibody was able to localise 
to the area where new protrusions occurred in yeast cells. DNA (stained blue by DAPI) 
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appeared at the edges of the cells rather centrally. This may be due to intense 
mitochondrial activity. Interestingly, it was difficult to see any ECE1 associated 
fluorescence with 20 µg/ml of FGE, yet in chapter 3 the Western blot analysis to 
demonstrate a small amount of ECE1 production even in the presence of 20 µg/ml of 
FGE (Figure 3.22). This variation may indicate that CLSM may not be sufficiently 
sensitive to detect ECE1 production at low levels compared to immunoblotting. 
  
In conclusion, purification of rECE1 protein and remove of the endotoxin from the 
protein solution by IMAC and separation phase was efficient. Also, rECE1 can produce 
pro-inflammatory effects in a cell culture assay by inducing the production and release 
of inflammatory mediators (cytokines TNF-α, IL-1β and IL-6). Finally, the polyclonal 
ECE-antibody was able to detect the expression of ECE protein expression in the 
different stages of C. albicans with a different effect of FGE on this expression depend 
on the concentration of FGE and the time of incubations. 
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The chapter will summarise the overall findings of the thesis, discuss the limitations of 
the studies and also provide future directions for approaches to anti-Candida therapy. 
 
Antifungal therapy continues to be challenging from the point of view of side-effects 
and rising resistance. New anti-fungal agents and new treatment modalities will be 
required to meet these challenges going forward.  
 
Garlic has been used in the medical field for thousands of years in the treatment and 
control of many diseases (Kelly, et al. 2005; Zhang, et al. 2008). Garlic extract has 
been reported to contain antifungal compounds such as Allicin and ajoene. Allicin is 
one of the main bioactive components of garlic and has been shown to be effective in 
the treatment of cryptococcosis when used intravenously (Davis, et al. 1990; Davis, et 
al. 2003). In addition, allicin has been shown to reduce serum levels of cholesterol and 
lipid and also lower intraocular pressure, in addition to putative anti-cancer and other 
antimicrobial properties (Miron, et al. 2000; Rabinkov, et al. 2000). 
 
VVC has significant impact on patients and treatment of Candida infections is possibly 
leading to rising resistance and the need for new treatment modalities. Current 
treatment aims to kill the yeast. We wished to explore whether the behaviour of yeast 
could be modified to open alternative treatment strategies. We were able to show that 
garlic could down-regulate an essential virulence gene of Candida. 
 
In order to study the effect of proteins produced by genes associated with virulence, it 
is necessary to isolate these proteins. It can be difficult to purify and analyse these 
proteins in vitro. New expression systems can amplify the production of these proteins, 
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allowing easier visualisation of their effects in culture. We were able to adapt a vector 
and host described for studies in allergy (Alsharif 2015) to use for expression of this 
putative inflammatory protein, ECE1. Not only were we successful in this approach we 
also were able to produce large quantities of the protein for study.  
 
Today’s technologies enable us to predict epitopes of proteins through computer 
analysis of protein sequence. The current project was able to use this to great effect to 
design an antibody and have it manufactured to enable visualisation of protein 
production in cell culture, and through confocal microscopy. Interestingly we showed 
through Western blotting the inhibitory effect of garlic on protein production at sub-
inhibitory levels to that seen by confocal microscopy. 
 
This opens the way for new models to test other candidate anti-expression compounds. 
This study is a proof of concept that garlic can down-regulate a key virulence gene that 
produces the newly described toxin, Candidalysin. Candidalysin has recently been 
shown to be a potent inflammatory agent and an essential fungal toxin. We hypothesis 
through our work that the domain for Candidalysin is actually a transmembrane domain, 
that in practice antifungal treatment could lead to release of Candidalysin, much like 
what is seen through the release of endotoxins in the treatment of gram-negative sepsis. 
This may be a contributing reason for the reported high death rate in candidaemia 
patients who have been treated with an antifungal agent and the down-regulation of the 
expression of this gene may improve patient survival. The description of Candidalysin 
is perhaps one of the most significant reports in our understanding of Candida virulence 
that has emerged in the last few years (Moyes, et al. 2016). 
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Going forward our pilot shows the promising potential for using transcriptional analysis 
and predictive antibody production to further study essential virulence proteins. Future 
work should examine a much larger collection of clinical isolates to show whether 
response to garlic is indeed linked to strain and whether particular sequence types can 
be predicted to respond to alternative therapies. 
 
This study looked at two isolates from VVC patients differing in their response to garlic 
treatment. It would be important to also look at blood isolates to see if there is also 
varying transcriptional expression of virulence proteins in these isolates. Treatment of 
severe infections may be improved through combining therapies that may include 
dietary supplantation such as garlic. Going forward we can consider the measurement 
of synergism of garlic with other conventional treatments. 
 
The synergistic combinations of two antifungal agents to treat fungal infections has 
proved effective in the treatment of fungal infection (Cui, et al. 2015). The 
development of resistance by different strains of C. albicans against traditional 
antifungals means that new combinations of drugs may need to be used in future. This 
makes it important to discover new drugs from natural sources that have similar 
effectiveness to traditional antifungals and are characterised by a lack of side effects 
and low toxicity.  
 
Naturally occurring fungal medicines such as beauvericin, a natural product of marine 
microbes, as well as berberine, have shown strong synergy with azole derivatives in the 
elimination of C. albicans in vitro as well as in systemic infections as seen in a 
candidiasis in vivo infection mouse model study (Zhang, et al. 2007). Garlic in 
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combination with other fungicidal agents may be synergistic but as the present study 
shows, consideration of strain variation may be important. 
 
In conclusion, this study shows that response of Candida albicans to a complementary 
medicine such as garlic is strain dependent. These strain dependent characteristics can 
be identified in vitro but may be dependent on the testing milieu. We provide a method 
for high-level recombinant protein production in an E. coli expression system. This 
study reported for the first time the ability of the rECE1 as a whole protein to produce 
pro-inflammatory effects in cell culture assay when tested in vitro. This thesis provides 
a model of prokaryotic expression of eukaryotic proteins that may help other 
researchers investigate essential virulence genes. The high level of protein expression 
was able to demonstrate subtle antimicrobial effects by immunoblotting that could not 
be seen through immunofluorescence. Finally, the investigation into published ECE1 
shows that there is considerable variation in the sequence of this gene in isolates 
examined. This finding supports the hypothesis that the efficacy of complementary 
medicine may be strain dependent and thus a personalised medicine approach may be 
needed to determine when garlic can efficiently be used in the management of VVC. 
This finding has broader implications as antibodies to ECE1 have previously been 
demonstrated in the serum of patients with invasive candidiasis (Elguezabal, et al. 
2005), and thus complementary medicine such as garlic may have usefulness beyond 
the treatment of mucosal candidiasis. 
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Appendix A: RT-PCR efficiency results 
 
Figure A.1 (A) Amplification of β-actin for C. albicans ATCC 14053 and clinical 
isolates (0861 and 1358) by monoplex real-time PCR. Different colour curves refer to 
different FGE and pure allicin concentrations, while the aqua lines were NTC. (B) Melt 
curve analysis of C. albicans ATCC 14053 and clinical isolates (0861 and 1358) 
showing the melting point of β-actin and the identity of primers used for amplification. 
(C) Real-Time PCR standard curve representing 97% PCR efficiency  
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Figure A.2 (A) Amplification of SIR2 gene for C. albicans ATCC 14053 and clinical 
isolates (0861 and 1358) by monoplex real-time PCR. Different colours curves 
referring to different FGE and pure allicin concentrations, while the aqua lines were 
NTC. (B) Melt curve analysis of C. albicans ATCC 14053 and clinical isolates (0861 
and 1358) showing the melting point of SIR2 gene and the identity of primers used for 
amplification. (C) Real-Time PCR standard curve representing 100% PCR efficiency 
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Figure A.3 (A) Amplification of ECE1 for C. albicans ATCC 14053 and clinical 
isolates (0861 and 1358) by monoplex real-time PCR. Different colours curves 
referring to different FGE and pure allicin concentrations, while the aqua lines were 
NTC. (B) Melt curve analysis of C. albicans ATCC 14053 and clinical isolates (0861 
and 1358) showing the melting point of ECE1 and the identity of primers used for 
amplification. (C) Real-Time PCR standard curve representing 100% PCR efficiency
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Table A.1 Concentration of reverse transcription-polymerase chain reaction (RT-PCR) products of SIR2 and β-actin for each strain in the 
Comparative CT Method (ΔΔCT Method) results in Figure 2.8 (A, B and C) 
Antifu. agent Conce. GOI  ATCC 14053   strain  C. isolate   0861  C. isolate   135.8 
   
 Normalised 
ratio (SIR2/ β-
actin) 
Fold change 
relative to 
control 
 Normalised 
ratio (SIR2⁄ β-
actin) 
Fold change 
relative to 
control 
 Normalised 
ratio (SIR2⁄ β-
actin) 
Fold change 
Relative to 
control 
FGE (µg/ml) 0 SIR2  1 1  1 1  1 1 
FGE (µg/ml) 20 SIR2  0.69 -1.45  0.2 -5  0.57 -1.75 
FGE (µg/ml) 60 SIR2  0.36 -2.7  0.16 -6.25  0.25 -4 
FGE (µg/ml) 100 SIR2  0.87 -1.5  0.49 -2.04  0.38 -2.63 
Pure allicin (µg/ml) 10 SIR2  0.29 -3.45  0.19 -5.26  0.28 -3.57 
Pure allicin (µg/ml) 60 SIR2  0.06 -16.67  0.1 -10  0.05 -20 
 
 
Table A.2 Concentration of reverse transcription-polymerase chain reaction (RT-PCR) products of ECE1 and β-actin for each sample in the 
omparative CT Method (ΔΔCT Method) results in Figure 2.10 (A, B and C) 
Antifu. agent Conce. GOI  ATCC 14053   strain  C. isolate   0861  C. isolate   135.8 
   
 Normalised 
ratio (ECE1/ 
β-actin) 
Fold change 
relative to 
control 
 Normalised 
ratio (ECE1⁄ 
β-actin) 
Fold change 
relative to 
control 
 Normalised 
ratio (ECE1⁄ 
β-actin) 
Fold change 
Relative to 
control 
FGE (µg/ml) 0 ECE1  1 1  1 1  1 1 
FGE (µg/ml) 20 ECE1  3.6 3.6  0.50 -2  3.31 3.31 
FGE (µg/ml) 60 ECE1  1.57 1.57  0.47 -2.13  1.91 1.91 
FGE (µg/ml) 100 ECE1  2.31 2.31  1.66 1.66  5.01 5.01 
Pure allicin (µg/ml) 10 ECE1  0.0004 -2500  0.05 -20  0.041 -24.4 
Pure allicin (µg/ml) 60 ECE1  0.0009 -1111  0.005 -200  0.01 -100 
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Table A.3 Concentration of reverse transcription-polymerase chain reaction (RT-PCR) 
products of ECE1 and β-actin for each strain in the comparative CT method (ΔΔCT 
method) 
Sample GOI 
 ATCC 
14053  
 strain 
 
C. isolate   0861 
 
C. isolate   135.8 
  
 Normalised 
ratio    
(ECE1/  
β-actin) 
Fold 
change 
relative  
to control 
 Normalised 
ratio 
(ECE1/ 
β-actin) 
Fold 
change 
relative  
to control 
 Normalised 
ratio 
(ECE1/  
  β-actin) 
Fold 
change 
Relative 
to control 
Untreated ECE1  1 1  0.65 *1.53  0.195 *5.13 
3% FBS ECE1  0.875 *1.14  1.58 1.58  0.43 *2.33 
*mean down-regulation in ECE1 expression by fold 
 
Table A.4 Concentration of reverse transcription-polymerase chain reaction (RT-PCR) 
products of ECE1 and β-actin for each sample in the Comparative CT Method (ΔΔCT 
Method) results in Fig. 2.15 (A, B and C) 
Sample GOI  ATCC14053  strain  C. isolate   0861  C. isolate   135.8 
  
 
Normalised 
ratio (ECE1/ 
β-actin) 
Fold 
change 
relative  
to control 
 
Normalised 
ratio (ECE1/ 
β-actin) 
Fold 
change 
relative  
to control 
 
Normalised 
ratio (ECE1/ 
β-actin) 
Fold 
change 
Relative 
to control 
No FBS ECE1  1 1  1 1  1 1 
3% FBS ECE1  0.875 *1.14  2.755 2.775  2.44 2.44 
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Figure A.4 (A) Amplification of β-actin for C. albicans ATCC 14053 and clinical 
isolates (0861 and 1358) by monoplex real-time PCR, different colours curves referring 
to different strains, while the aqua lines were NTC. (B) Melt curve analysis of C. 
albicans ATCC 14053 and clinical isolates (0861 and 1358) showing the melting point 
of β-actin and the identity of primers used for amplification. (C) Real-Time PCR 
standard curve representing 92% PCR efficiency  
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Figure A.5 (A) Amplification of ECE1 for C. albicans ATCC 14053 and clinical 
isolates (0861 and 1358) by monoplex real-time PCR, different colours curves referring 
to different strains, while the turquoise lines were NTC. (B) Melt curve analysis of C. 
albicans ATCC 14053 and clinical isolates (0861 and 1358) showing the melting point 
of ECE1 and the identity of primers used for amplification. (C) Real-Time PCR 
standard curve representing 98% PCR efficiency  
 
